US20070160984A1 - Multiple-property composite beads and preparation and use thereof - Google Patents
Multiple-property composite beads and preparation and use thereof Download PDFInfo
- Publication number
- US20070160984A1 US20070160984A1 US11/714,954 US71495407A US2007160984A1 US 20070160984 A1 US20070160984 A1 US 20070160984A1 US 71495407 A US71495407 A US 71495407A US 2007160984 A1 US2007160984 A1 US 2007160984A1
- Authority
- US
- United States
- Prior art keywords
- moiety
- bead
- beads
- substance
- binding partner
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000011324 bead Substances 0.000 title claims abstract description 377
- 239000002131 composite material Substances 0.000 title description 5
- 238000002360 preparation method Methods 0.000 title description 5
- 239000000126 substance Substances 0.000 claims abstract description 202
- 238000000034 method Methods 0.000 claims abstract description 181
- 230000003287 optical effect Effects 0.000 claims abstract description 99
- 238000002372 labelling Methods 0.000 claims abstract description 85
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 25
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 25
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 15
- 238000002955 isolation Methods 0.000 claims abstract description 14
- 230000027455 binding Effects 0.000 claims description 168
- 238000009739 binding Methods 0.000 claims description 168
- 230000005291 magnetic effect Effects 0.000 claims description 91
- 210000004027 cell Anatomy 0.000 claims description 55
- 239000002096 quantum dot Substances 0.000 claims description 53
- 238000004720 dielectrophoresis Methods 0.000 claims description 40
- 210000000056 organ Anatomy 0.000 claims description 37
- 241000700605 Viruses Species 0.000 claims description 35
- 239000007788 liquid Substances 0.000 claims description 32
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 108020004414 DNA Proteins 0.000 claims description 21
- 239000012530 fluid Substances 0.000 claims description 20
- 238000004458 analytical method Methods 0.000 claims description 18
- 230000001413 cellular effect Effects 0.000 claims description 17
- 210000003463 organelle Anatomy 0.000 claims description 17
- 238000000926 separation method Methods 0.000 claims description 12
- 239000011859 microparticle Substances 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 238000005119 centrifugation Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 7
- 230000033001 locomotion Effects 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 102000007079 Peptide Fragments Human genes 0.000 claims description 5
- 108010033276 Peptide Fragments Proteins 0.000 claims description 5
- 230000002776 aggregation Effects 0.000 claims description 5
- 238000004220 aggregation Methods 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 238000005194 fractionation Methods 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 238000005339 levitation Methods 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- 230000008827 biological function Effects 0.000 claims description 2
- 230000008236 biological pathway Effects 0.000 claims description 2
- 230000022131 cell cycle Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000002823 phage display Methods 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 11
- 239000002245 particle Substances 0.000 description 65
- 239000000523 sample Substances 0.000 description 40
- 239000011325 microbead Substances 0.000 description 38
- 239000000203 mixture Substances 0.000 description 28
- 239000000758 substrate Substances 0.000 description 27
- 241000894006 Bacteria Species 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 230000005298 paramagnetic effect Effects 0.000 description 19
- 238000000576 coating method Methods 0.000 description 18
- 239000011248 coating agent Substances 0.000 description 17
- 230000005684 electric field Effects 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000011521 glass Substances 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- -1 antibodies Proteins 0.000 description 13
- 229910044991 metal oxide Inorganic materials 0.000 description 13
- 150000004706 metal oxides Chemical class 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 239000004793 Polystyrene Substances 0.000 description 12
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 12
- 239000006249 magnetic particle Substances 0.000 description 12
- 229920002223 polystyrene Polymers 0.000 description 12
- 239000000872 buffer Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 239000000178 monomer Substances 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000000018 DNA microarray Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 239000004033 plastic Substances 0.000 description 8
- 229920003023 plastic Polymers 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 230000005294 ferromagnetic effect Effects 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 241000233866 Fungi Species 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000005389 magnetism Effects 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 241000203069 Archaea Species 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000005293 ferrimagnetic effect Effects 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 230000005415 magnetization Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 229910052710 silicon Inorganic materials 0.000 description 5
- 239000010703 silicon Substances 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 229910045601 alloy Inorganic materials 0.000 description 4
- 239000000956 alloy Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 229910017052 cobalt Inorganic materials 0.000 description 4
- 239000010941 cobalt Substances 0.000 description 4
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 4
- 229910052759 nickel Inorganic materials 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 239000005060 rubber Substances 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 238000005842 biochemical reaction Methods 0.000 description 3
- 239000013060 biological fluid Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- HDFRDWFLWVCOGP-UHFFFAOYSA-N carbonothioic O,S-acid Chemical compound OC(S)=O HDFRDWFLWVCOGP-UHFFFAOYSA-N 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 210000003763 chloroplast Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 229920001940 conductive polymer Polymers 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 238000010908 decantation Methods 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 239000002159 nanocrystal Substances 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- 239000007987 MES buffer Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000003851 biochemical process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229910052793 cadmium Inorganic materials 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 210000001752 female genitalia Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000011810 insulating material Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 2
- 235000013980 iron oxide Nutrition 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000000696 magnetic material Substances 0.000 description 2
- 210000000260 male genitalia Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000002985 organ of corti Anatomy 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 229920000767 polyaniline Polymers 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000001209 resonance light scattering Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000004054 semiconductor nanocrystal Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000004544 sputter deposition Methods 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229910052715 tantalum Inorganic materials 0.000 description 2
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 2
- 229910052714 tellurium Inorganic materials 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 210000000605 viral structure Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 210000001121 vomeronasal organ Anatomy 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- NCMVOABPESMRCP-SHYZEUOFSA-N 2'-deoxycytosine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 NCMVOABPESMRCP-SHYZEUOFSA-N 0.000 description 1
- LTFMZDNNPPEQNG-KVQBGUIXSA-N 2'-deoxyguanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 LTFMZDNNPPEQNG-KVQBGUIXSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000157882 Acrasida Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000223782 Ciliophora Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-CBPJZXOFSA-N D-Gulose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-CBPJZXOFSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 1
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- HAIWUXASLYEWLM-UHFFFAOYSA-N D-manno-Heptulose Natural products OCC1OC(O)(CO)C(O)C(O)C1O HAIWUXASLYEWLM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 206010056474 Erythrosis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- HSNZZMHEPUFJNZ-UHFFFAOYSA-N L-galacto-2-Heptulose Natural products OCC(O)C(O)C(O)C(O)C(=O)CO HSNZZMHEPUFJNZ-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- YEJCDKJIEMIWRQ-UHFFFAOYSA-N Linopirdine Chemical compound O=C1N(C=2C=CC=CC=2)C2=CC=CC=C2C1(CC=1C=CN=CC=1)CC1=CC=NC=C1 YEJCDKJIEMIWRQ-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000243190 Microsporidia Species 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- HAIWUXASLYEWLM-AZEWMMITSA-N Sedoheptulose Natural products OC[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@](O)(CO)O1 HAIWUXASLYEWLM-AZEWMMITSA-N 0.000 description 1
- 229910052581 Si3N4 Inorganic materials 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 108020005172 Z-Form DNA Proteins 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- ZGWQKLYPIPNASE-UHFFFAOYSA-N [Co].[Zr].[Ta] Chemical compound [Co].[Zr].[Ta] ZGWQKLYPIPNASE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- QXJJQWWVWRCVQT-UHFFFAOYSA-K calcium;sodium;phosphate Chemical compound [Na+].[Ca+2].[O-]P([O-])([O-])=O QXJJQWWVWRCVQT-UHFFFAOYSA-K 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000003575 carbonaceous material Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002801 charged material Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- DAEAPNUQQAICNR-RRKCRQDMSA-K dADP(3-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP([O-])(=O)OP([O-])([O-])=O)O1 DAEAPNUQQAICNR-RRKCRQDMSA-K 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- FTDHDKPUHBLBTL-SHYZEUOFSA-K dCDP(3-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 FTDHDKPUHBLBTL-SHYZEUOFSA-K 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- CIKGWCTVFSRMJU-KVQBGUIXSA-N dGDP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O1 CIKGWCTVFSRMJU-KVQBGUIXSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- UJLXYODCHAELLY-XLPZGREQSA-N dTDP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 UJLXYODCHAELLY-XLPZGREQSA-N 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- KHWCHTKSEGGWEX-UHFFFAOYSA-N deoxyadenylic acid Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(O)=O)O1 KHWCHTKSEGGWEX-UHFFFAOYSA-N 0.000 description 1
- LTFMZDNNPPEQNG-UHFFFAOYSA-N deoxyguanylic acid Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(COP(O)(O)=O)O1 LTFMZDNNPPEQNG-UHFFFAOYSA-N 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000009713 electroplating Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000001080 enamel organ Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- IWBOPFCKHIJFMS-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl) ether Chemical compound NCCOCCOCCN IWBOPFCKHIJFMS-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000005308 ferrimagnetism Effects 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 230000005307 ferromagnetism Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960000587 glutaral Drugs 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000001339 gustatory effect Effects 0.000 description 1
- 241001148029 halophilic archaeon Species 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229910052595 hematite Inorganic materials 0.000 description 1
- 239000011019 hematite Substances 0.000 description 1
- 150000002386 heptoses Chemical class 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 150000002454 idoses Chemical class 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002032 lab-on-a-chip Methods 0.000 description 1
- 239000002346 layers by function Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000005381 magnetic domain Effects 0.000 description 1
- 239000006148 magnetic separator Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000000412 mechanoreceptor Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000005459 micromachining Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000002707 nanocrystalline material Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000002842 otolith Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 210000004174 para-aortic body Anatomy 0.000 description 1
- 230000005408 paramagnetism Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 229920002120 photoresistant polymer Polymers 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920000548 poly(silane) polymer Polymers 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- ODGAOXROABLFNM-UHFFFAOYSA-N polynoxylin Chemical compound O=C.NC(N)=O ODGAOXROABLFNM-UHFFFAOYSA-N 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000128 polypyrrole Polymers 0.000 description 1
- 229920000123 polythiophene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004094 preconcentration Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000001528 ptotic effect Effects 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- HSNZZMHEPUFJNZ-SHUUEZRQSA-N sedoheptulose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO HSNZZMHEPUFJNZ-SHUUEZRQSA-N 0.000 description 1
- VSZWPYCFIRKVQL-UHFFFAOYSA-N selanylidenegallium;selenium Chemical compound [Se].[Se]=[Ga].[Se]=[Ga] VSZWPYCFIRKVQL-UHFFFAOYSA-N 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000000714 subcommissural organ Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 150000003538 tetroses Chemical class 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910000314 transition metal oxide Inorganic materials 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- 150000003641 trioses Chemical class 0.000 description 1
- 229960001947 tripalmitin Drugs 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical group 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B70/00—Tags or labels specially adapted for combinatorial chemistry or libraries, e.g. fluorescent tags or bar codes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C1/00—Magnetic separation
- B03C1/02—Magnetic separation acting directly on the substance being separated
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C5/00—Separating dispersed particles from liquids by electrostatic effect
- B03C5/02—Separators
- B03C5/022—Non-uniform field separators
- B03C5/026—Non-uniform field separators using open-gradient differential dielectric separation, i.e. using electrodes of special shapes for non-uniform field creation, e.g. Fluid Integrated Circuit [FIC]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C5/00—Separating dispersed particles from liquids by electrostatic effect
- B03C5/02—Separators
- B03C5/022—Non-uniform field separators
- B03C5/028—Non-uniform field separators using travelling electric fields, i.e. travelling wave dielectrophoresis [TWD]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
- C40B50/16—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support involving encoding steps
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00457—Dispensing or evacuation of the solid phase support
- B01J2219/00459—Beads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/005—Beads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/0054—Means for coding or tagging the apparatus or the reagents
- B01J2219/00545—Colours
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/0054—Means for coding or tagging the apparatus or the reagents
- B01J2219/00547—Bar codes
- B01J2219/00551—3-dimensional
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00585—Parallel processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00596—Solid-phase processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00655—Making arrays on substantially continuous surfaces the compounds being bound to magnets embedded in or on the solid supports
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/0074—Biological products
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S428/00—Stock material or miscellaneous articles
- Y10S428/90—Magnetic feature
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2991—Coated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/32—Composite [nonstructural laminate] of inorganic material having metal-compound-containing layer and having defined magnetic layer
Definitions
- This invention relates generally to the field of moiety or molecule isolation, detection and manipulation and library synthesis.
- the invention provides a bead, which bead comprises: a) a magnetizable substance; and b) an electrically conductive substance or an optical labeling substance.
- Methods and kits for isolating, detecting and manipulating moieties and synthesizing libraries using the beads are also provided.
- Quantum dots have found their applications in bioanalysis just recently. Quantum dot nanocrystals are nanometer scale particles that are neither small molecules nor bulk solids. Their composition and small size (a few hundred to a few thousand atoms) give these dots extraordinary optical properties, which can be readily customized by changing the size or composition of the dots. This property is the basis for encoding using quantum dots.
- Biochips have experienced rapid progress during last several years.
- biochips There are two types of biochips: passive and active biochips.
- Passive biochips refer to those on which chemical or biochemical reactions are dependent on passive diffusion of sample molecules.
- Active biochips allow versatile functions of molecular manipulation, interaction, hybridization reaction and separation by external forces through means such as microfluidic manipulation and electrical manipulation of molecules.
- functional beads When functional beads are used as molecular carrier, the beads are manipulated on the active chips.
- beads technology has found wide applications in separation and analysis, there is a limited supply of various beads, especially those suitable to be used with active biochips, e.g., multiple-forces chips.
- the present invention addresses this and other related needs in the art.
- the present invention is directed to a bead, which bead comprises: a) a magnetizable substance; and b) an electrically conductive substance or an optical labeling substance.
- the present invention is directed to a method for isolating a moiety, which method comprises: a) providing a bead comprising 1) a magnetizable substance, 2) an optical labeling substance, and preferably 3) a binding partner that is capable of binding to a moiety to be isolated; b) contacting a sample containing or suspected of containing of said moiety with said bead provided in step a) under conditions allowing binding between said moiety and said bead and/or binding partner; and c) recovering said bead from said sample, whereby the identity of said isolated moiety is assessed by analyzing said optical labeling substance comprised in said bead.
- the present invention is directed to a method for manipulating a moiety, which method comprises: a) providing a bead comprising 1) a magnetizable substance, 2) an electrically conductive substance, and preferably 3) a binding partner that is capable of binding to a moiety to be manipulated; b) coupling said moiety to said bead provided in step a) via binding between said moiety and said binding partner to form a moiety-bead complex; and c) manipulating said moiety-bead complex with a dielectrophoresis, a traveling-wave dielectrophoresis and/or a magnetic force, preferably in a chip format, thereby said moiety is manipulated.
- the above method for manipulating a moiety can be readily extended to manipulating multiple moieties by using multiple types of beads, each type of which is targeted to one type of moieties to be manipulated.
- the present invention is directed to a kit for manipulating a moiety, which kit comprises: a) a bead comprising 1) a magnetizable substance, 2) an electrically conductive substance or an optical labeling substance, and preferably 3) a binding partner that is capable of binding, or capable of specifically binding, to a moiety to be manipulated; and b) a means for generating a physical force for manipulating said moiety-bead complex.
- the present invention is directed to a kit for manipulating a moiety in a chip format, which kit comprises: a) a bead comprising 1) a magnetizable substance, 2) an electrically conductive substance or an optical labeling substance, and preferably 3) a binding partner that is capable of binding, or capable of specifically binding, to a moiety to be manipulated; and b) a chip on which a moiety-bead complex can be manipulated.
- the present invention is directed to a method for detecting a moiety, which method comprises: a) providing a bead comprising 1) a magnetizable substance, 2) an optical labeling substance, and preferably 3) a binding partner that is capable of binding to a moiety to be detected; b) contacting a sample containing or suspected of containing of said moiety with said bead provided in step a) under conditions allowing binding between said moiety and said bead and/or said binding partner; and c) detecting binding between said moiety and said bead and/or said binding partner, whereby the presence or amount of said moiety is assessed by analysis of binding between said moiety and said bead and/or said binding partner and the identity of said moiety is assessed by analyzing the optical labeling substance comprised in the bead.
- the above method for detecting a moiety can be readily extended to detecting multiple moieties by using multiple types of beads, each type of which is targeted to one type of moieties to be detected and each of which has
- the present invention is directed to a method for synthesizing a library, which method comprises: a) providing a plurality of beads of the present invention, each of said beads comprising a magnetizable substance and an optical labeling substance that corresponds to an entity to be synthesized on said bead; and b) synthesizing said entities on said beads, wherein said beads are sorted after each synthesis cycle according to said optical labeling substances and the sorted beads are then subjected to appropriate synthesis reaction in the next synthesis cycle according to said entities to be synthesized on said beads, whereby a library is synthesized, wherein each of said beads contains an entity that corresponds to an optical labeling substance on said bead and the sum of said beads collectively contains a plurality of entities that is predetermined before the library synthesis.
- a library that is synthesized according to the above method is also provided.
- the present invention is directed to a method for synthesizing a library, which method comprises: a) providing a plurality of beads, each of said beads comprising a magnetizable substance, an electrically conductive substance and a unique optical labeling substance, wherein said unique optical labeling substance on each of said beads corresponds to an entity to be synthesized on each of said beads; and b) synthesizing said entities on said beads, wherein said beads are identified after each synthesis cycle according to said unique optical labeling substances, whereby a library is synthesized, wherein each of said beads contains an entity that corresponds to said unique optical labeling substance on each of said beads.
- the present invention is directed to a method for generating an antibody library, which method comprises: a) contacting a library synthesized according to the above method with a plurality of antibodies; and b) selecting and/or recovering the antibodies that specifically bind to the entities of the above library.
- FIG. 1 shows the random distribution of exemplary beads (or microbeads) of the present invention on a microelectrode array. These microbeads can exhibit magnetic field induced effects, and positive and negative dielectrophoresis effects. The microbeads are seen as black dots, the microelectrodes are seen as the light structure and the grey area represents the inter-microelectrode space.
- FIG. 2 shows the collection and aggregation of the microbeads at the interspaces between the neighboring electrodes under an electric voltage of 5 V peak-peak (pk-to-pk) at frequency of 50 kHz.
- the microbeads are seen as black dots, the microelectrodes are seen as the light structure and the grey area represents the inter-microelectrode space.
- FIG. 3 shows the collection and aggregation of the microbeads at the electrode edges between the neighboring electrodes under an electric voltage of 5 V pk-to-pk at frequency of 500 kHz.
- the microbeads are seen as black dots, the microelectrodes are seen as the light structure and the grey area represents the inter-microelectrode space.
- FIG. 4 shows the random distribution of the microbeads on an electromagnetic chip.
- the microbeads are seen as black dots
- the dielectrophoretic force generating structures are seen as the light structures
- the electromagnetic coil is seen as the dark structure underneath the dielectrophoretic force generating structures.
- FIG. 5 shows that the microbeads were attracted towards the poles of the electromagnetic units when a DC current of 200 mA was applied to an electromagnetic unit on the chip.
- the microbeads are seen as black dots
- the dielectrophoretic force generating structures are seen as the light structures
- the electromagnetic coil is seen as the dark structure underneath the dielectrophoretic force generating structures.
- FIG. 6 shows that the collection of the microbeads at the poles of the electromagnetic units after the DC current has been applied for over 2 minutes.
- the microbeads are seen as black dots
- the dielectrophoretic force generating structures are seen as the light structures
- the electromagnetic coil is seen as the dark structure underneath the dielectrophoretic force generating structures.
- magnetic substance refers to any substance that has the properties of a magnet, pertaining to a magnet or to magnetism, producing, caused by, or operating by means of, magnetism.
- magnetizable substance refers to any substance that has the property of being interacted with the field of a magnet, and hence, when suspended or placed freely in a magnetic field, of inducing magnetization and producing a magnetic moment.
- magnetizable substances include, but are not limited to, paramagnetic, ferromagnetic and ferrimagnetic substances.
- magnetization substance refers to the substances where the individual atoms, ions or molecules possess a permanent magnetic dipole moment.
- the atomic dipoles point in random directions and there is no resultant magnetization of the substances as a whole in any direction. This random orientation is the result of thermal agitation within the substance.
- the atomic dipoles tend to orient themselves parallel to the field, since this is the state of lower energy than antiparallel position. This gives a net magnetization parallel to the field and a positive contribution to the susceptibility.
- ferromagnetic substance refers to the substances that are distinguished by very large (positive) values of susceptibility, and are dependent on the applied magnetic field strength. In addition, ferromagnetic substances may possess a magnetic moment even in the absence of the applied magnetic field, and the retention of magnetization in zero field is known as “remanence”. Further details on “ferromagnetic substance” or “ferromagnetism” can be found in various literatures, e.g., at Page 171-page 174, Chapter 6, in “Electricity and Magnetism” by B. I Bleaney and B. Bleaney, Oxford, 1975.
- ferrimagnetic substance refers to the substances that show spontaneous magnetization, remanence, and other properties similar to ordinary ferromagnetic materials, but the spontaneous moment does not correspond to the value expected for full parallel alignment of the (magnetic) dipoles in the substance. Further details on “ferrimagnetic substance” or “ferrimagnetism” can be found in various literatures, e.g., at Page 519-524, Chapter 16, in “Electricity and Magnetism” by B. I Bleaney and B. Bleaney, Oxford, 1975.
- metal oxide particle refers to any oxide of a metal in a particle form. Certain metal oxide particles have paramagnetic or super-paramagnetic properties. “Paramagnetic particle” is defined as a particle which is susceptible to the application of external magnetic fields, yet is unable to maintain a permanent magnetic domain. In other words, “paramagnetic particle” may also be defined as a particle that is made from or made of “paramagnetic substances”. Non-limiting examples of paramagnetic particles include certain metal oxide particles, e.g., Fe 3 O 4 particles, metal alloy particles, e.g., CoTaZr particles.
- electrically conductive substance refers to any substance that is not electrically-insulating and can exhibit positive dielectrophoresis force under appropriate conditions. Under such conditions, “electrically conductive substance” has higher electrical conductivity and/or higher dielectric permittivity than those of the suspending media in which the “electrically conductive substance” is suspended, placed, or introduced.
- optical labeling substance refers to any optically detectable substance that can be used to label the beads of the present invention to facilitate and/or enable detection and/or identification of the beads.
- Quantum-dot is an example of an optical labeling substance.
- sintered-light detectable particle refers to any particle that can emit unique and identifiable scattered-light upon illumination with light under appropriate conditions.
- the nano-sized particles with certain “resonance light scattering (RLS)” properties are examples of one type of “scattered-light detectable particle.”
- quantum dot refers to a fluorescent label comprising water-soluble semiconductor nanocrystal(s).
- One unique feature of a quantum dot is that its fluorescent spectrum is related to or determined by the diameter of its nanocrystals(s).
- Water-soluble is used herein to mean sufficiently soluble or suspendable in a aqueous-based solution, such as in water or water-based solutions or physiological solutions, including those used in the various fluorescence detection systems as known by those skilled in the art.
- quantum dots can be prepared which result in relative monodispersity; e.g., the diameter of the core varying approximately less than 10% between quantum dots in the preparation.
- quantum dots Details of quantum dots and how they can be incorporated into microbeads may be found in the literatures, for example, in the articles by Chan and Nie, Science, 281:2016 (1998) and by Han et al., Nature Biotechnology, 19:631-635 (2001).
- chip refers to a solid substrate with a plurality of one-, two- or three-dimensional micro structures or micro-scale structures on which certain processes, such as physical, chemical, biological, biophysical or biochemical processes, etc., can be carried out.
- the micro structures or micro-scale structures such as, channels and wells, electrode elements, electromagnetic elements, are incorporated into, fabricated on or otherwise attached to the substrate for facilitating physical, biophysical, biological, biochemical, chemical reactions or processes on the chip.
- the chip may be thin in one dimension and may have various shapes in other dimensions, for example, a rectangle, a circle, an ellipse, or other irregular shapes.
- the size of the major surface of chips of the present invention can vary considerably, e.g., from about 1 mm 2 to about 0.25 m 2 .
- the size of the chips is from about 4 mm 2 to about 25 cm 2 with a characteristic dimension from about 1 mm to about 5 cm.
- the chip surfaces may be flat, or not flat.
- the chips with non-flat surfaces may include channels or wells fabricated on the surfaces.
- a “chamber” refers to a structure that comprises a chip and that is capable of containing a fluid sample.
- the chamber may have various dimensions and its volume may vary between 0.001 microliter and 50 milliliter. More detailed description of a chamber is given in Section C.
- a means for generating a physical force on said chip refers to any substance, structure or a combination thereof that is capable of generating, in conjunction with an internal structure on a chip, to generate a desirable physical force on the chip.
- “physical field,” e.g., used itself or used as “physical field in a region of space” or “physical field is generated in a region of space” means that the region of space has following characteristics.
- a moiety, alone or bound to a bead via a binding partner, of appropriate properties is introduced into the region of space (i.e. into the physical field)
- forces are produced on the moiety, the bead or both, as a result of the interaction between the moiety and/or bead and the field.
- a moiety can be manipulated within a field via the physical forces exerted on the moiety by the field.
- Exemplary fields include electric, magnetic, acoustic, optical and velocity fields.
- an electric field may produce electrophoretic forces on charged moieties, or may produce conventional dielectrophoretic forces and/or traveling wave dielectrophoretic forces on charged and/or neutral moieties.
- Magnetic field may produce magnetic forces on magnetic moieties.
- Acoustic field may produce acoustic radiation forces on moieties.
- Optical field may produce optical radiation forces on moieties.
- Velocity field in the medium in a region of space refers to a velocity distribution of the medium that moves in the region of the space.
- Various mechanisms may be responsible for causing the medium to move and the medium at different positions may exhibit different velocities, thus generating a velocity field.
- Velocity field may exert mechanical forces on moieties in the medium.
- medium refers to a fluidic carrier, e.g., liquid or gas, wherein a moiety, alone or bound to a bead via a binding partner, is dissolved, suspended or contained.
- microfluidic application refers to the use of microscale devices, e.g., the characteristic dimension of basic structural elements is in the range between less than 1 micron to 1 cm scale, for manipulations and processes in a fluidic setting, typically for performing specific biological, biochemical or chemical reactions and procedures.
- the specific areas include, but are not limited to, biochips, i.e., chips for biologically related reactions and processes, chemchips, i.e., chips for chemical reactions, or a combination thereof.
- the characteristic dimensions of the basic elements refer to the single dimension sizes. For example, for the microscale devices having circular shape structures (e.g. round electrode pads), the characteristic dimension refers to the diameter of the round electrodes. For the devices having thin, rectangular lines as basic structures, the characteristic dimensions may refer to the width or length of these lines.
- built-in structures on said substrate of a chip means that the structures are built into the substrate or the structures are located on the substrate or the structures are structurally linked to the substrate of the chip.
- the built-in structures may be fabricated on the substrate. For example, as described in “Dielectrophoretic manipulation of cells using spiral electrodes by Wang et al., Biophys. J, 72:1887-1899 (1997)”, spiral electrodes are fabricated on a glass substrate. Here the spiral electrodes are “built-in” structures on the glass substrate.
- the “built-in” structures may be first fabricated on one substrate and the structure-containing first substrate may then be attached or bound to a second substrate.
- Such structures are “built-in” structures not only on the first substrate but also on the second substrate.
- the built-in structures may be attached or bound to the substrate.
- thin, electrically-conductive wires may be used as electrodes for producing electric field. These electric wires may be bound or attached to a glass substrate.
- the electrically-conductive wires are “built-in” structures on the glass substrate.
- structures internal to said apparatus means that the structures are integral parts of and structurally linked to other parts of the apparatus, or the structures are not separated or separable from other structural elements of the apparatus.
- such internal structures can be microfabricated or otherwise attached to the substrate or other structural element(s) of the apparatus.
- Any “built-in structures on said substrates” described above are “structures internal to said apparatus” as long as the said apparatus comprise the substrates.
- Any built-in structures on a chip are “structures internal to said apparatus” as long as the said apparatus comprise the chip.
- “internal” structures of apparatus are capable of generating physical forces and/or physical fields or these structures generate physical forces and/or physical fields, these structures are used in combination with external signal sources or external energy sources.
- micro-scale structures means that the scale of the internal structures of the apparatus for exerting desired physical forces must be compatible with and useable in microfluidic applications and have characteristic dimension of basic structural elements in the range from about 1 micron to about 20 mm scale.
- moiety refers to any substance whose isolation, manipulation, measurement, quantification or detection using the present bead is desirable. Normally, the dimension (or the characteristic dimensions) of the moiety should not exceed 1 cm. For example, if the moiety is spherical or approximately spherical, the dimension of the moiety refers to the diameter of the sphere or an approximated sphere for the moiety. If the moiety is cubical or approximately cubical, then the dimension of the moiety refers to the side width of the cube or an approximated cube for the moiety. If the moiety has an irregular shape, the dimension of the moiety may refer to the average between its largest axis and smallest axis.
- moieties include cells, cellular organelles, viruses, particles, molecules, e.g., proteins, DNAs and RNAs, or an aggregate or complex thereof.
- Moiety to be isolated, manipulated, measured, quantified or detected includes many types of particles—solid (e.g., glass beads, latex particles, magnetic beads), liquid (e.g., liquid droplets) or gaseous particles (e.g., gas bubble), dissolved particles (e.g., molecules, proteins, antibodies, antigens, lipids, DNAs, RNAs, molecule-complexes), suspended particles (e.g., glass beads, latex particles, polystyrene beads).
- Particles can be organic (e.g., mammalian cells or other cells, bacteria, virus, or other microorganisms) or inorganic (e.g., metal particles).
- Particles can be of different shapes (e.g., sphere, elliptical sphere, cubic, discoid, needle-type) and can be of different sizes (e.g., nano-meter-size gold sphere, to micrometer-size cells, to millimeter-size particle-aggregate).
- particles include, but not limited to, biomolecules such as DNA, RNA, chromosomes, protein molecules (e.g., antibodies), cells, colloid particles (e.g., polystyrene beads, magnetic beads), any biomolecules (e.g., enzyme, antigen, hormone etc).
- One specific type of particle refers to complexes formed between moieties and their binding partners, as described in a co-pending U.S.
- Such complexes include particle-particle complexes, particle-molecule complexes (e.g., cell-magnetic bead complexes formed by binding of the cells onto antibody-coated beads through the interaction between the antigens or protein molecules on cell surfaces and the antibody molecules immobilized on the magnetic bead surfaces; DNA molecule-magnetic bead complexes formed by immobilizing DNA molecules on magnetic bead surfaces, or protein molecule-polystyrene bead complexes formed by covering polystyrene bead surfaces with protein molecules).
- particle-particle complexes e.g., cell-magnetic bead complexes formed by binding of the cells onto antibody-coated beads through the interaction between the antigens or protein molecules on cell surfaces and the antibody molecules immobilized on the magnetic bead surfaces
- DNA molecule-magnetic bead complexes formed by immobilizing DNA molecules on magnetic bead surfaces or protein molecule-polystyrene bead complexes formed by covering
- plant refers to any of various photosynthetic, eucaryotic multi-cellular organisms of the kingdom Plantae, characteristically producing embryos, containing chloroplasts, having cellulose cell walls and lacking locomotion.
- animal refers to a multi-cellular organism of the kingdom of Animalia, characterized by a capacity for locomotion, nonphotosynthetic metabolism, pronounced response to stimuli, restricted growth and fixed bodily structure.
- animals include birds such as chickens, vertebrates such fish and mammals such as mice, rats, rabbits, cats, dogs, pigs, cows, ox, sheep, goats, horses, monkeys and other non-human primates.
- bacteria refers to small prokaryotic organisms (linear dimensions of around 1 micron) with non-compartmentalized circular DNA and ribosomes of about 70 S. Bacteria protein synthesis differs from that of eukaryotes. Many anti-bacterial antibiotics interfere with bacteria proteins synthesis but do not affect the infected host.
- eubacteria refers to a major subdivision of the bacteria except the archaebacteria. Most Gram-positive bacteria, cyanobacteria, mycoplasmas, enterobacteria, pseudomonas and chloroplasts are eubacteria. The cytoplasmic membrane of eubacteria contains ester-linked lipids; there is peptidoglycan in the cell wall (if present); and no introns have been discovered in eubacteria.
- archaebacteria refers to a major subdivision of the bacteria except the eubacteria. There are three main orders of archaebacteria: extreme halophiles, methanogens and sulphur-dependent extreme thermophiles. Archaebacteria differs from eubacteria in ribosomal structure, the possession (in some case) of introns, and other features including membrane composition.
- virus refers to an obligate intracellular parasite of living but non-cellular nature, consisting of DNA or RNA and a protein coat. Viruses range in diameter from about 20 to about 300 nm. Class I viruses (Baltimore classification) have a double-stranded DNA as their genome; Class II viruses have a single-stranded DNA as their genome; Class III viruses have a double-stranded RNA as their genome; Class IV viruses have a positive single-stranded RNA as their genome, the genome itself acting as mRNA; Class V viruses have a negative single-stranded RNA as their genome used as a template for mRNA synthesis; and Class VI viruses have a positive single-stranded RNA genome but with a DNA intermediate not only in replication but also in mRNA synthesis. The majority of viruses are recognized by the diseases they cause in plants, animals and prokaryotes. Viruses of prokaryotes are known as bacteriophages.
- fungus refers to a division of eucaryotic organisms that grow in irregular masses, without roots, stems, or leaves, and are devoid of chlorophyll or other pigments capable of photosynthesis.
- Each organism thallus
- branched somatic structures hypertension
- cell walls containing glucan or chitin or both, and containing true nuclei.
- binding partners refers to any substances that bind to the moieties with desired affinity or specificity.
- Non-limiting examples of the binding partners include cells, cellular organelles, viruses, particles, microparticles or an aggregate or complex thereof, or an aggregate or complex of molecules, or specific molecules such as antibodies, single stranded DNAs.
- the binding partner can be a substance that is coated on the surface of a bead.
- the binding partner can be a substance that is incorporated, e.g., microfabricated, into the material composition of a bead.
- the material composition of a bead may possess binding affinity to certain moiety, and thus functioning a binding partner itself.
- an element that facilitates and/or enables manipulation of the bead and/or a moiety/bead complex refers to any substance that is itself manipulatable or makes the moiety/bead complex manipulatable with the desired physical force(s).
- Non-limiting examples of the elements include cells, cellular organelles, viruses, particles, microparticles or an aggregate or complex thereof, or an aggregate or complex of molecules.
- Non-limiting examples of the elements may further include deposited or other-procedure-produced materials with specific physical or chemical properties.
- Various metal compositions such as Au, Cr, Ti, Pt etc are examples of the elements that can be incorporated into the beads and increase electrical conductivity of the beads.
- conductive materials such as carbon and/or conductive polymers can also be incorporated into the beads to increase electrical conductivity of the beads.
- Insulating materials such as polystyrene, paralene, or other plastic polymers are also examples of the elements that may be incorporated into the beads and reduce electrical conductivity of the beads.
- microparticles refers to particles of any shape, any composition, any complex structures that are manipulatable by desired physical force(s) in microfluidic settings or applications.
- One example of microparticles is magnetic beads that are manipulatable by magnetic forces.
- Another example of microparticles is a cell that is manipulatable by an electric force such as a traveling-wave dielectrophoretic force.
- the microparticles used in the methods can have a dimension from about 0.01 micron to about ten centimeters.
- the microparticles used in the methods have a dimension from about 0.01 micron to about several thousand microns.
- microparticles examples include, but are not limited to, plastic particles, polystyrene microbeads, glass beads, magnetic beads, hollow glass spheres, particles of complex compositions, microfabricated free-standing microstructures, etc.
- Other particles include cells, cell organelles, large biomolecules such as DNA, RNA and proteins etc.
- “manipulation” refers to moving or processing of the moieties and the beads disclosed in the present invention, which results in one-, two- or three-dimensional movement of the moiety (and the beads), in a chip format, whether within a single chip or between or among multiple chips, or on a substrate or among substrates of an apparatus. “Manipulation” of moieties and the beads can also be performed in a non-chip format, e.g., in liquid containers. Non-limiting examples of the manipulations include transportation, focusing, enrichment, concentration, aggregation, trapping, repulsion, levitation, separation, sorting, fractionation, isolation or linear or other directed motion of the moieties.
- the characteristics of the moiety (and the beads) to be manipulated and the physical force used for manipulation must be compatible.
- the beads with certain magnetic properties can be used with magnetic force.
- the beads with electric charge(s) can be used with electrostatic (i.e. electrophoretic) force.
- the characteristics of the moiety, or its binding partner or the beads, and the physical force used for manipulation must be compatible.
- moiety or its binding partner or the beads with certain dielectric properties to induce dielectric polarization in the moiety or its binding partner or the beads can be used with dielectrophoresis force.
- the moiety is not directly manipulatable” by a particular physical force means that no observable movement of the moiety can be detected when the moiety itself not coupled to a binding partner is acted upon by the particular physical force.
- “physical force” refers to any force that moves the moieties or their binding partners or the corresponding beads without chemically or biologically reacting with the moieties and the binding partners, or with minimal chemical or biological reactions with the binding partners and the moieties so that the biological/chemical functions/properties of the binding partners and the moieties are not substantially altered as a result of such reactions.
- the term of “forces” or “physical forces” always means the “forces” or “physical forces” exerted on a moiety or moieties, the binding partner(s) and/or the bead(s).
- the “forces” or “physical forces” are always generated through “fields” or “physical fields”.
- the forces exerted on moieties, the binding partner(s) and/or the bead(s) by the fields depend on the properties of the moieties, the binding partner(s) and/or the bead(s). Thus, for a given field or physical field to exert physical forces on a moiety, it is necessary for the moiety to have certain properties. While certain types of fields may be able to exert forces on different types of moieties having different properties, other types of fields may be able to exert forces on only limited type of moieties. For example, magnetic field can exert forces or magnetic forces only on magnetic particles or moieties having certain magnetic properties, but not on other particles, e.g., polystyrene beads.
- a non-uniform electric field can exert physical forces on many types of moieties such as polystyrene beads, cells, and also magnetic particles. It is not necessary for the physical field to be able to exert forces on different types of moieties or different moieties. But it is necessary for the physical field to be able to exert forces on at least one type of moiety or at least one moiety, the binding partner(s) and/or the bead(s).
- electrical forces are the forces exerted on moieties, the binding partner(s) and/or the bead(s) by an electric (or electrical) field.
- magnetic forces are the forces exerted on moieties, the binding partner(s) and/or the bead(s) by a magnetic field.
- acoustic forces are the forces exerted on moieties, the binding partner(s) and/or the bead(s) by an acoustic field.
- optical (or optical radiation) forces are the forces exerted on moieties, the binding partner(s) and/or the bead(s) by an optical field.
- mechanical forces are the forces exerted on moieties, the binding partner(s) and/or the bead(s) by a velocity field.
- the percentage of the coupled moiety includes the percentage of the moiety coupled onto surface of a particular type of binding partner or a plurality of binding partners. When a plurality of binding partners is used, the moiety can be coupled onto surface of the plurality of binding partners simultaneously or sequentially.
- the percentage of the coupled moiety includes the percentage of the moiety coupled onto surface of a particular type of binding partner or a plurality of binding partners. When a plurality of binding partners is used, the moiety can be coupled onto surface of the plurality of binding partners simultaneously or sequentially.
- a means for generating a physical force for manipulating a moiety-bead complex refers to any substance, structure or a combination thereof that is capable of generating a desirable physical force for manipulating moiety-bead complex that is introduced or placed or suspended or dissolved in a fluid or otherwise existed in a fluid.
- the fluid containing the moiety-bead complex is introduced or placed or is generally contained in a fluid container (e.g. a liquid container such as a beaker, an eppendorf tube, any plastic or glass tube).
- intracellular moiety refers to any moiety that resides or is otherwise located within a cell, i.e., located in the cytoplasm or matrix of cellular organelle, attached to any intracellular membrane, resides or is otherwise located within periplasma, if there is one, or resides or is otherwise located on cell surface, i.e., attached on the outer surface of cytoplasm membrane or cell wall, if there is one.
- an optical labeling substance that corresponds to an entity to be synthesized on said bead means that the entity to be synthesized on a particular bead is predetermined according to the optical labeling substance on that bead.
- wherein said beads are sorted after each synthesis cycle according to said optical labeling substances means that the synthetic steps or orders for making an entity on a particular bead are predetermined according to the optical labeling substance on that bead and after each synthesis cycle, the optical labeling substance on the bead is assessed for directing the next synthetic step or order.
- sample refers to anything which may contain a moiety to be isolated, manipulated, measured, quantified or detected by the present beads and/or methods.
- the sample may be a biological sample, such as a biological fluid or a biological tissue.
- biological fluids include urine, blood, plasma, serum, saliva, semen, stool, sputum, cerebral spinal fluid, tears, mucus, amniotic fluid or the like.
- Biological tissues are aggregates of cells, usually of a particular kind together with their intercellular substance that form one of the structural materials of a human, animal, plant, bacterial, fungal or viral structure, including connective, epithelium, muscle and nerve tissues. Examples of biological tissues also include organs, tumors, lymph nodes, arteries and individual cell(s).
- the sample may also be a mixture of target analyte or enzyme containing molecules prepared in vitro.
- a “liquid (fluid) sample” refers to a sample that naturally exists as a liquid or fluid, e.g., a biological fluid.
- a “liquid sample” also refers to a sample that naturally exists in a non-liquid status, e.g., solid or gas, but is prepared as a liquid, fluid, solution or suspension containing the solid or gas sample material.
- a liquid sample can encompass a liquid, fluid, solution or suspension containing a biological tissue.
- assessing is intended to include quantitative and qualitative determination of the identity and/or amount of a moiety, e.g., a protein or nucleic acid, present in the sample or one bound to the beads or in whatever form or state. Assessment would involve obtaining an index, ratio, percentage, visual or other value indicative of the identity of a moiety in the sample and may further involve obtaining a number, an index, or other value indicative of the amount or quantity or the concentration of a moiety present in the sample or on the microdevice or in whatever form or state. Assessment may be direct or indirect and may be qualitative or quantitative.
- a moiety e.g., a protein or nucleic acid
- the present invention is directed to a bead, which bead comprises: a) a magnetizable substance; and b) an electrically conductive substance or an optical labeling substance.
- the present bead comprises a paramagnetic substance, e.g., a paramagnetic metal oxide composition.
- the paramagnetic metal oxide composition is a transition metal oxide or an alloy thereof. Any suitable transition metals can be used, such as iron, nickel, copper, cobalt, manganese, tantalum (Ta), zinc and zirconium (Zr).
- the metal oxide composition is Fe3O4 or Fe2O3.
- the magnetizable substance used in the beads of the present invention comprises a metal composition.
- the metal composition is a transition metal composition or an alloy thereof such as iron, nickel, copper, cobalt, manganese, tantalum, zirconium and cobalt-tantalum-zirconium (CoTaZr) alloy.
- the beads of this invention may be prepared from the available primary beads, from raw materials or from metal oxides that are encapsulated by monomers which when crosslinked form rigid, polymeric coatings as disclosed in U.S. Pat. No. 5,834,121.
- rigid refers to a polymeric coating that cross linked to the extent that the polymeric coating stabilizes the metal oxide particle within the coating (i.e. the coating essentially does not swell or dissolve) so that the particle remains enclosed therein.
- microporous refers to a resinous polymeric matrix that swells or expands in polar organic solvent.
- load is used to mean the capacity of the bead for attachment sites useful for functionalization or derivatization.
- Suitable substances which may be incorporated as magnetizable materials include iron oxides such as magnetite, ferrites of manganese, cobalt, and nickel, hematite and various alloys. Magnetite is the preferred metal oxide.
- metal salts are taught to be converted to metal oxides then either coated with a polymer or adsorbed into a bead comprising a thermoplastic polymer resin having reducing groups thereon.
- a thermoplastic polymer derived from vinyl monomers preferably a cross-linked polystyrene that is capable of binding or being bound by a microporous matrix.
- Magnetic particles may be formed by methods known in the art, e.g., procedures shown in Vandenberge et al., J. of Magnetism and Magnetic Materials, 15-18:1117-18 (1980); Matijevic, Acc. Chem. Res., 14:22-29 (1981); and U.S. Pat. Nos. 5,091,206; 4,774,265; 4,554,088; and 4,421,660. Examples of primary beads that may be used in this invention are shown in U.S. Pat. Nos.
- primary beads may be obtained commercially from available hydrophobic or hydrophilic beads that meet the starting requirements of size, sufficient stability of the polymeric coating to swelling in solvents to retain the paramagnetic particle, and ability to adsorb or absorb the vinyl monomer used to form the enmeshing matrix network.
- the primary bead is a hydrophobic, polystyrene encapsulated, paramagnetic bead.
- Such polystyrene paramagnetic beads are available from Dynal, Inc. (Lake Success, N.Y.), Rhone Poulonc (France), and SINTEF (Trondheim, Norway).
- toner particles or of magnetic particles having a first coating of an unstable polymer which are further encapsulated to produce an exterior rigid polymeric coating is also contemplated.
- the electrically conductive substance used in the present beads is gold, silver or other metal compositions, carbon material or a conductive polymer, e.g., a polyaniline, a polypyrrole, or a polythiophene.
- the electrically conductive substance allows the bead to exhibit positive dielectrophoresis force.
- Metal materials or compositions may be incorporated into the beads by, for example, sputtering or evaporating onto the beads.
- Conductive polymers may be incorporated onto the bead surfaces via chemical binding or polymerization. Carbon can be claded onto the surface of metal oxide to make it conductive.
- the optical labeling substance used in the present beads is a fluorescent substance, a scattered-light detectable particle (See e.g., U.S. Pat. No. 6,214,560) and a quantum dot (See e.g., U.S. Pat. No. 6,252,664).
- the quantum dot used in the present beads comprises a Cd—X core, X being Se, S or Te.
- the quantum dot can be passivated with an inorganic coating shell, e.g., a coating shell comprising Y-Z, Y being Cd or Zn, and Z being S or Se.
- the quantum dot can comprise a Cd—X core, X being Se, S or Te, a Y-Z shell, Y being Cd or Zn, and Z being S or Se, and the bead can further be overcoated with a trialkylphosphine oxide.
- any suitable methods can be used to make the CdX core/YZ shell quantum dots water-soluble (See e.g., U.S. Pat. No. 6,252,664).
- One method to make the CdX core/YZ shell quantum dots water-soluble is to exchange this overcoating layer with a coating which will make the quantum dots water-soluble.
- a mercaptocarboxylic acid may be used to exchange with the trialkylphosphine oxide coat. Exchange of the coating group is accomplished by treating the water-insoluble quantum dots with a large excess of neat mercaptocarboxylic acid.
- exchange of the coating group is accomplished by treating the water-insoluble quantum dots with a large excess of mercaptocarboxylic acid in CHCl3 solution (Chan and Nie, Science, 281:2016-2018 (1998)).
- the thiol group of the new coating molecule forms Cd (or Zn)—S bonds, creating a coating which is not easily displaced in solution.
- Another method to make the CdX core/YZ shell quantum dots water-soluble is by the formation of a coating of silica around the dots (Bruchez et al., Science, 281:2013-2015 (1998)).
- An extensively polymerized polysilane shell imparts water solubility to nanocrystalline materials, as well as allowing further chemical modifications of the silica surface.
- these “water-soluble” quantum dots require further functionalization to make them sufficiently stable in an aqueous solution for practical use in a fluorescence detection system (See e.g., U.S. Pat. No. 6,114,038), particularly when exposed to air (oxygen) and/or light.
- Water-soluble functionalized nanocrystals are extremely sensitive in terms of detection, because of their fluorescent properties (e.g., including, but not limited to, high quantum efficiency, resistance to photobleaching, and stability in complex aqueous environments); and comprise a class of semiconductor nanocrystals that may be excited with a single peak wavelength of light resulting in detectable fluorescence emissions of high quantum yield and with discrete fluorescence peaks (e.g., having a narrow spectral band ranging between about 10 nm to about 60 nm).
- fluorescent properties e.g., including, but not limited to, high quantum efficiency, resistance to photobleaching, and stability in complex aqueous environments
- discrete fluorescence peaks e.g., having a narrow spectral band ranging between about 10 nm to about 60 nm.
- the quantum dot used in the present bead can have any suitable size.
- the quantum dot can have a size ranging from about 1 nm to about 100 nm.
- the bead of the present invention can comprise a single quantum dot.
- the bead of the present invention can comprise a plurality of quantum dots.
- the bead of the present invention comprises at least two quantum dots that have different sizes and/or different colors. Details of quantum dots and how they can be incorporated into microbeads may be found in the literatures, for example, in the articles by Chan and Nie, Science, 281:2016 (1998) and by Han et al., Nature Biotechnology, 19:631-635 (2001).
- the bead of the present invention can comprise a single optical labeling substance.
- the bead of the present invention can comprise a plurality of optical labeling substances.
- the bead of the present invention comprises at least two different types of optical labeling substances.
- the bead of the present invention comprises a magnetizable substance and an electrically conductive substance. In another specific embodiment, the bead of the present invention comprises a magnetizable substance and an optical labeling substance.
- the bead of the present invention can further comprise a binding partner that is capable of binding to a moiety to be isolated, manipulated or detected.
- the binding partner specifically binds to the moiety.
- Any suitable binding partner can be used in the present bead, e.g., a cell, a cellular organelle, a virus, a molecule and an aggregate or complex thereof.
- the bead of the present invention comprises a magnetizable substance, an electrically conductive substance and an optical labeling substance.
- the magnetizable substance in this preferred embodiment may be selected from groups of ferrimagnetic, ferromagnetic and paramagnetic substances.
- the bead of the present invention comprises a ferrimagentic, ferromagnetic or paramagnetic substance, an electrically conductive substance and a quantum dot.
- This preferred bead can further comprise a binding partner that is capable of binding to a moiety to be isolated, manipulated or detected.
- the binding partner specifically binds to the moiety.
- the bead of the present invention comprises a magnetic or paramagnetic core coated with an electrically conductive substance, a quantum dot and binding partner that is capable of binding to a moiety to be isolated, manipulated or detected.
- bead of the present invention can have any suitable size.
- bead of the present invention has a size ranging from about 0.02 ⁇ m to about 500 ⁇ m.
- bead of the present invention has a size ranging from 0.1 ⁇ m to about 100 ⁇ m.
- bead of the present invention has a size ranging from 0.3 ⁇ m to about 20 ⁇ m.
- the bead of the present invention can have any suitable shape.
- the bead of the present invention has a spherical, a elliptical-sphere, cubical or other regular or irregular shape.
- the present invention is directed to a method for isolating a moiety, which method comprises: a) providing a bead comprising 1) a magnetizable substance, 2) an optical labeling substance, and preferably 3) a binding partner that is capable of binding to a moiety to be isolated; b) contacting a sample containing or suspected of containing of said moiety with said bead provided in step a) under conditions allowing binding between said moiety and said bead or binding partner; and c) recovering said bead from said sample, whereby the identity of said isolated moiety is assessed by analyzing said optical labeling substance comprised in said bead.
- the binding partner specifically binds to the moiety.
- the present method can further comprise a step of assessing or confirming whether a moiety has been isolated and bound to the bead by analyzing a property of the moiety.
- the step of assessing or confirming whether a cell has been isolated and bound to the bead may comprise examining the presence of a cell on the bead with various methods, for example, optical microscopy analysis.
- the moiety to be isolated is a molecule that may be labeled, for example, by a fluorescent molecule.
- the step of assessing or confirming whether a molecule has been isolated and bound to the bead may comprise examining the presence of certain fluorescent signals on the bead with various methods, for example, by fluorescent microscopy analysis.
- the above isolation methods may further comprise a step of recovering said isolated moiety from said bead by certain cleavage methods.
- certain cleavage methods For example, depending on the nature of binding between said moiety and said beads or binding partner, optical or chemical, or thermal cleavage methods may be utilized.
- any suitable optical labeling substance can be used in the present method.
- the optical labeling substance used in the present method is a fluorescent substance, a scattered-light detectable particle (See e.g., U.S. Pat. No. 6,214,560) and a quantum dot (See e.g., U.S. Pat. No. 6,252,664).
- the optical labeling substance used in the present method is a quantum dot. Any suitable quantum dot, including the quantum dot described in the above Section B can be used.
- any moiety can be isolated by the present method.
- the moiety to be isolated can be a cell, a cellular organelle, a virus, a molecule and an aggregate or complex there of.
- the bead can be recovered from the sample by any suitable methods, e.g., by a magnetic field/force using, for example, a permanent magnet or an electromagnetic chip centrifugation, dielectrophoresis collection on a dielectrophoresis chip or filtration.
- the present method can be used to isolate a single type of moiety, it is preferably to be used in high throughput analysis and preferably a plurality of types of moieties are isolated by using a plurality of types of beads, each type of the beads is capable of binding to a member of said plurality of types of the moieties or each type of the beads contains a binding partner that is capable of binding to a member of said plurality of types of the moieties.
- a moiety in any suitable sample can be isolated.
- the moiety to be isolated is contained in a fluid sample.
- the isolation can be conducted in any suitable apparatus or device.
- the isolation can be conducted in a liquid container such as a beaker, a flask, a cylinder, a test tube, a microcentrifuge tube, a centrifugation tube, a culture dish, a multiwell plate and a filter device or membrane.
- a liquid container such as a beaker, a flask, a cylinder, a test tube, a microcentrifuge tube, a centrifugation tube, a culture dish, a multiwell plate and a filter device or membrane.
- magnetic field for magnetic force-based isolation
- electric field for electric force-based isolation
- the isolation can be conducted in a chip format.
- the method can further comprise a step of recovering said isolated moiety from said bead, by any suitable methods, e.g., by optical, chemical or other cleavage methods.
- the present invention is directed to a method for manipulating a moiety, which method comprises: a) providing a bead comprising 1) a magnetizable substance, 2) an electrically conductive substance, and preferably 3) a binding partner that is capable of binding to a moiety to be manipulated; b) coupling said moiety to said bead provided in step a) via binding between said moiety and said bead and/or said binding partner to form a moiety-bead complex; and c) manipulating said moiety-bead complex with a dielectrophoresis, a traveling-wave dielectrophoresis and/or a magnetic force, in a chip or non-chip format, thereby said moiety is manipulated.
- the binding partner specifically binds to the moiety.
- the manipulation can be conducted in any suitable apparatus or device.
- the manipulation can be conducted in a liquid container such as a beaker, a flask, a cylinder, a test tube, a microcentrifuge tube, a centrifugation tube, a culture dish, a multiwell plate and a filter device or membrane.
- a liquid container such as a beaker, a flask, a cylinder, a test tube, a microcentrifuge tube, a centrifugation tube, a culture dish, a multiwell plate and a filter device or membrane.
- magnetic field for magnetic force-based manipulation
- electric field for electric force-based manipulation
- Electrodes such as conductive wires may be introduced into the liquid container to generate electric fields.
- the manipulation is effected through a combination of a structure that is external to the chip and a structure that is built-in in the chip.
- chips and structures internal and external to the chips that are disclosed in the co-pending U.S. patent application Ser. No. 09/636,104, filed Aug. 10, 2000 and 09/679,024, filed Oct. 4, 2000, the disclosures of which are incorporated by reference in its entirety, can be used in the present method.
- the methods can be used on silicon, silicon dioxide, silicon nitride, plastic, glass, ceramic, photoresist or rubber chips.
- the methods can be used on a chemchip, i.e., on which chemical reactions are carried out, a biochip, i.e., on which biological reactions are carried out, or a combination of a biochemchip.
- the physical forces used in the present methods are effected through a combination of the structure that is external to the chip and the structure that is built-in in the chip.
- the external structures are energy sources that can be connected to the built-in structures for energizing the built-in structures to generate a physical force such as dielectrophoresis force, magnetic force, acoustic force, electrostatic force, mechanical force or optical radiation force.
- the built-in structures comprise a single unit or a plurality of units. Each unit is, when energized and in combination with the external structure, capable of effecting the physical force on the moiety-bead complex. In the case of a plurality of units, the built-in structure may further comprise the means for selectively energizing any one of the plurality of units.
- the electromagnetic chip disclosed in the co-pending U.S. Pat. No. 6,355,491 when magnetic force is used to manipulate a complex of a moiety (e.g., DNA molecules) and a bead comprising its binding partner, the electromagnetic chip disclosed in the co-pending U.S. Pat. No. 6,355,491, which is incorporated by reference in its entirety, can be used in the methods.
- such electromagnetic chips with individually addressable micro-electromagnetic units comprise: a substrate; a plurality of micro-electromagnetic units on the substrate, each unit capable of inducing a magnetic field upon application electric current; a means for selectively energizing any one of a plurality of units to induce a magnetic field therein.
- the electromagnetic chips further comprise a functional layer coated on the surface of the chips for immobilizing certain types of molecules.
- microelectromagnetic units are the built-in structures internal to the chip and the electrical current source that is connected to the microelectromagnetic units is the structures external to the chip.
- the electric current from the external current source is applied to the microelectromagnetic units, magnetic fields will be generated in the regions around the microelectromagnetic units and magnetic forces will be produced on magnetic particles that are present in the region around the microelectromagnetic units.
- the built-in structures are electromagnetic units that are incorporated on the chip and the external structures are the electrical signal sources (e.g., current sources).
- the electrical signal sources e.g., current sources.
- magnetic fields are generated in the regions around the chip.
- the bead-binding partner-moiety complexes are subjected to such magnetic fields, magnetic forces are produced on them, and such forces are dependent on the magnetic field distribution, the magnetic properties of the beads or the binding partner or bead-binding partner-moiety complexes and the magnetic properties of the medium that surrounds the beads or bead-binding partner-moiety complexes.
- dielectrophoresis force and traveling-wave dielectrophoresis force are used to manipulate a complex of a moiety (e.g., protein molecules) and its binding partner coupled onto a bead (e.g., antibodies can be coupled onto beads' surfaces, allowing for binding of protein molecules), a spiral electrode array on a glass chip, together with a phase-quardrature AC electrical signal source, can be used in the method (see “Dielectrophoretic manipulation of cells using spiral electrodes by Wang, X-B. et al., in Biophys. J . Volume 72, pages 1887-1899, 1997”).
- a spiral electrode array is a built-in structure internal to the chip and the AC electrical signal source that is connected to the spiral electrodes is the structure external to the chip.
- AC electrical signals of appropriate phases from the external signal source are applied to the spiral electrode array, electrical fields will be generated in the regions around the spiral electrode array. Dielectrophoretic and traveling-wave dielectrophoretic forces will be produced on moiety-binding partner-bead complexes that are present in the region around the spiral electrode array.
- the built-in structures are the electrode elements and electrode arrays that are incorporated on a chip and the external structures are electrical signal sources.
- the appropriately designed electrode elements and electrode arrays are energized by the electrical signal sources, non-uniform electrical fields are generated in the regions around the chip.
- dielectrophoresis and/or traveling-wave dielectrophoresis forces acting on the beads or bead-binding partner-moiety complexes are produced. Such forces are dependent on the interaction between the electrical field distributions and field induced dielectric polarization in beads, bead-moiety complex, or bead-binding partner-moiety complex, etc.
- any moiety including the moieties disclosed in the above Section B can be manipulated by the present method.
- the moiety to be manipulated can be a cell, a cellular organelle, a virus, a molecule and an aggregate or complex thereof.
- the present method can be used for any type of suitable manipulation.
- exemplary manipulations include transportation, focusing, enrichment, concentration, aggregation, trapping, repulsion, levitation, separation, fractionation, isolation and linear or other directed motion of the moiety.
- the moiety is not directly manipulatable by a dielectrophoresis, a traveling-wave dielectrophoresis and/or a magnetic force.
- neither the moiety nor the binding partner is directly manipulatable by a dielectrophoresis, a traveling-wave dielectrophoresis and/or a magnetic force.
- the present method can be used to manipulate a single type of moiety, it is preferably to be used in a high throughput analysis and preferably a plurality types of moieties is manipulated.
- the plurality types of moieties is manipulated via a plurality types of corresponding beads.
- the plurality types of moieties can be manipulated sequentially or simultaneously.
- the present method can further comprise a step of recovering said manipulated moiety from said bead and/or said chip.
- the bead used in the present method comprises an optical labeling substance and the method further comprises a step of assessing the identity of the manipulated moiety by analyzing the optical labeling substance comprised in the bead.
- the optical labeling substance used in the present beads is a fluorescent substance, a scattered-light detectable particle (See e.g., U.S. Pat. No. 6,214,560) and a quantum dot (See e.g., U.S. Pat. No. 6,252,664). More preferably, the optical labeling substance is a quantum dot.
- the bead used in the present method comprises an optical labeling substance and the method further comprises a step of assessing the identity of the manipulated moiety by analyzing the optical labeling substance comprised in the bead. More preferably, the optical labeling substance is a quantum dot.
- the present invention is directed to a kit for manipulating a moiety, which kit comprises: a) a bead comprising 1) a magnetizable substance, 2) an electrically conductive substance or an optical labeling substance, and preferably 3) a binding partner that is capable of binding, or capable of specifically binding, to a moiety to be manipulated; and b) a means for generating a physical force for manipulating said moiety-bead complex.
- the bead comprises an optical labeling substance, e.g., a quantum dot.
- the means for generating a physical force for manipulating said moiety-bead complex refers to any substance, structure or a combination thereof that is capable of generating a desirable physical force for manipulating moiety-bead complex that is placed in a fluid or otherwise existed in a fluid.
- the fluid containing the moiety-bead complex is introduced or placed or is generally contained in a fluid container (e.g. a liquid container such as a beaker, an eppendorf tube, any plastic or glass tube).
- a fluid container e.g. a liquid container such as a beaker, an eppendorf tube, any plastic or glass tube.
- a fluid container e.g. a liquid container such as a beaker, an eppendorf tube, any plastic or glass tube.
- a fluid container e.g. a liquid container such as a beaker, an eppendorf tube, any plastic or glass tube.
- a fluid container e.g. a liquid container such as a bea
- the present invention is directed to a kit for manipulating a moiety
- kit comprises: a) a bead comprising 1) a magnetizable substance, 2) an electrically conductive substance or an optical labeling substance, and preferably 3) a binding partner that is capable of binding, or capable of specifically binding, to a moiety to be manipulated; and b) a chip on which a moiety-bead complex can be manipulated.
- the kit further comprises an instruction(s) for coupling the moiety to the bead and/or for manipulating the moiety-bead complex on the chip.
- the chip provided in the kit is in the form of a chamber that comprises a chip and that is capable of containing fluidic sample.
- a chamber can be of any size or dimensions, and preferably can contain a fluid sample of between 0.001 microliter and 50 milliliters, more preferably between about 1 microliters and about 20 milliliters, and most preferably between about 10 microliters and about 10 milliliters.
- a chamber comprises a chip.
- a chamber can comprise any suitable material, for example, silicon, glass, metal, ceramics, polymers, plastics, etc. and can be of a rigid or flexible material.
- Preferred materials for a chamber include materials that do not interfere with dielectrophoresis of moieties in a sample, for example, materials that do not bind charged or polarized molecules, such as silicon, certain plastics and polymers, for example, acrylic, or glass.
- Chambers used in the methods of the present invention or comprised in the kits of the present invention can comprise chips, where chips are solid supports on which one or more separations, assays, or capturing procedures can be performed.
- a chip can comprise one or more metals, ceramics, polymers, copolymers, plastics, rubber, silicon, gels, or glass.
- a chip can comprise one or more flexible materials, and can comprise one or more semi-solid layers.
- a chip can comprise porous or non-porous materials.
- the micro structures or micro-scale structures such as, channels and wells and electrode elements and electromagnetic units are incorporated into or fabricated on the substrate for facilitating physical, biophysical, biological, biochemical, chemical reactions or processes on the chip.
- a chip can have a small thickness in one dimension and can have large sizes in the other two dimensions.
- the size of the major surfaces of a chip can vary considerably and have an area from about 1 mm 2 to about 0.25 m 2 .
- the size of the major surface of the chips useable in the present methods is from about 4 mm 2 to about 25 cm 2 .
- the shape of the chips useable in the present methods can be regular shapes such as square, rectangular, circular, or oval, or can be irregularly shaped. Chip surfaces may be flat or may not be flat. Chips useable in the methods of the present invention can have one or more wells or one or more channels that can be etched or bored into a chip or built onto the surface of a chip.
- chips of special geometries and configurations may have been used.
- the chips may be fabricated on flexible materials so that the chips can be folded to form tube like chambers. Multiple chips may be configured into a same chamber.
- the electrode elements may have to have certain configurations so that effective dielectrophoretic forces may be generated in the region of the interest in the chamber.
- Electrodes on a chip can be of any shape, such as rectangular, castellated, triangular, circular, and the like. Electrodes can be arranged in various patterns, for example, spiral, parallel, interdigitated, polynomial, etc. Electrode arrays can be fabricated on a chip by microfabrication or micromachining methods known in the art, for example, electroplating, sputtering, photolithography or etching.
- Examples of a chip comprising electrodes include, but are not limited to, the dielectrophoresis electrode array on a glass substrate (e.g., Dielectrophoretic Manipulation of Particles by Wang et al., in IEEE Transaction on Industry Applications, Vol. 33, No. 3, May/June, 1997, pages 660-669), individually addressable electrode array on a microfabricated bioelectronic chip (e.g., Preparation and Hybridization Analysis of DNA/RNA from E. coli on Microfabricated Bioelectronic Chips by Cheng et al., Nature Biotechnology, Vol.
- the dielectrophoresis electrode array on a glass substrate e.g., Dielectrophoretic Manipulation of Particles by Wang et al., in IEEE Transaction on Industry Applications, Vol. 33, No. 3, May/June, 1997, pages 660-669
- individually addressable electrode array on a microfabricated bioelectronic chip e.g., Preparation and Hybridization Analysis
- a chamber that comprises a chip useable in the methods of the present invention can comprise one or more ports, or openings in the walls of a chamber.
- a port is of a shape and size that allows a conduit to engage a port for the dispensing of a sample into the chamber.
- a conduit can be any tube that allows for the entry of a fluid sample into the chamber.
- Preferred conduits for use in the present invention include tubing, for example, rubber or polymeric tubing, e.g., tygon or teflon or PEEK tubing.
- a port can provide an opening in a wall of a chamber for the dispensing of sample into the chamber by, for example, pipetting or injection.
- Conduits that engage one or more ports of the sample can introduce a sample by any means, including a pump (for example, a peristaltic pump or infusion pump), pressure source syringe, or gravity feed.
- a pump for example, a peristaltic pump or infusion pump
- One or more reagents, buffers, or solutions including, but not limited to, a solution that selectively modifies the dielelectric properties of one or more moieties in a sample, can be added to the chamber before, after, or concurrently with the addition of a sample to a chamber. It is also within the scope of the invention to mix the sample with a reagent, buffer, or solution, before adding the sample to the chamber. Such mixing can optionally occur in one or more conduits leading to a chamber, or in one or more reservoirs connected to conduits.
- the present invention is directed to a method for detecting a moiety, which method comprises: a) providing a bead comprising 1) a magnetizable substance, 2) an optical labeling substance, and preferably 3) a binding partner that is capable of binding to a moiety to be detected; b) contacting a sample containing or suspected of containing of said moiety with said bead provided in step a) under conditions allowing binding between said moiety and said bead and/or said binding partner; and c) detecting binding between said moiety and said bead and/or said binding partner, whereby the presence or amount of said moiety is assessed by analysis of binding between said moiety and said bead and/or said binding partner and the identity of said moiety is assessed by analyzing the optical labeling substance comprised in the bead.
- the binding partner specifically binds to the moiety.
- any suitable optical labeling substance including the ones described in the above Section B, can used in the present method.
- the optical labeling substance used in the present beads is a fluorescent substance, a scattered-light detectable particle (See e.g., U.S. Pat. No. 6,214,560) and a quantum dot (See e.g., U.S. Pat. No. 6,252,664).
- Any suitable quantum dot including the ones described in the above Section B, can used in the present method.
- any moiety including the moieties disclosed in the above Section B can be detected by the present method.
- the moiety to be detected can be a cell, a cellular organelle, a virus, a molecule and/or an aggregate or complex thereof.
- the present method can be used to detect a single type of moiety, it is preferably to be used in a high throughput analysis and preferably a plurality types of moieties is detected by using a plurality types of different types of beads, each type of the beads contains a binding partner that is capable of binding to a member of the plurality types of the moieties.
- the plurality types of moieties can be detected sequentially or simultaneously.
- the beads' optical encoding can correspond to the binding partner (and so moiety).
- each type of the beads has a unique optical encoding property and contains a specific binding partner that is capable of binding to a member of the plurality types of the moieties.
- the beads' dielectric property can correspond to the binding partner.
- each type of the beads has a unique dielectric property and can be manipulated or processed by an electric field of a specific condition (e.g., the bead exhibiting positive dielectrophoresis at a specific frequency).
- Each type of these beads can contain specific binding partners that is capable of binding to a member of the plurality types of the moieties.
- the detection can be conducted in any suitable apparatus or device.
- the detection can be conducted in a liquid container such as a beaker, a flask, a cylinder, a test tube, an enpindorf tube, a centrifugation tube, a culture dish, a multiwell plate and a filter device or membrane.
- the bead is placed or immobilized on a surface and the detection can be conducted in a chip format.
- a plurality of bead is placed or immobilized on a surface and the detection can be conducted in a chip format.
- a moiety in any suitable sample can be detected.
- the moiety to be detected is contained in a fluid sample.
- the binding between the moiety and the bead and/or binding partner can be detected by any suitable methods, devices or instruments.
- the moiety can be labeled, e.g., with fluorescent, radioactive, enzymatic or other chemical labels.
- the moiety can be labeled before its binding with the bead or binding partner or after its binding with the bead or binding partner.
- the absorbance or other optical properties of the moiety can be used in detecting its binding with the bead or binding partner.
- the molecular weight of the moiety can be used in detecting its binding with the bead or binding partner, e.g., by mass spectrometry such as MALDI-TOF.
- the detecting methods based on the labeling of the moiety can be conducted in a direct labeling method, i.e., the moiety to be detected is labeled, or in a competitive assay format, i.e., a labeled moiety or moiety analog is added to the sample containing a moiety to be detected.
- the moiety is cleaved off or recovered from, or isolated or purified from the moiety-bead (or binding partner) complex before the detection. Any suitable methods, e.g., HPLC, can be used to isolate or purify the moiety.
- the present invention is directed to an array for detecting, isolating or manipulating moieties, which array comprises a plurality of beads of the present invention positioned, deposited or immobilized on a surface, e.g., a chip, each of said beads comprising 1) a magnetizable substance, 2) an electrically conductive substance or an optical labeling substance, and preferably 3) a binding partner that is capable of binding, or capable of specifically binding, to a moiety to be detected, isolated or manipulated.
- the beads can be positioned, deposited or immobilized on the surface e.g., a chip surface, using any suitable methods such as being positioned on a surface by a magnetic force.
- the present methods can be used for analyzing, isolating, manipulating or detecting any types of moieties when the moieties are involved in certain processes, such as physical, chemical, biological, biophysical or biochemical processes, etc., in a chip format or non-chip format.
- Moieties can be cells, cellular organelles, viruses, molecules or an aggregate or complex thereof.
- Moieties can be pure substances or can exist in a mixture of substances wherein the target moiety is only one of the substances in the mixture. For example, cancer cells in the blood from leukemia patients, cancer cells in the solid tissues from patients with solid tumors and fetal cells in maternal blood from pregnant women can be the moieties to be isolated, manipulated or detected.
- various blood cells such as red and white blood cells in the blood can be the moieties to be isolated, manipulated or detected.
- DNA molecules, mRNA molecules, certain types of protein molecules, or all protein molecules from a cell lysate can be moieties to be isolated, manipulated or detected.
- Non-limiting examples of cells include animal cells, plant cells, fungi, bacteria, recombinant cells or cultured cells.
- Animal, plant cells, fungus, bacterium cells to be isolated, manipulated or detected can be derived from any genus or subgenus of the Animalia, Plantae, fungus or bacterium kingdom.
- Cells derived from any genus or subgenus of ciliates, cellular slime molds, flagellates and microsporidia can also be isolated, manipulated or detected.
- Cells derived from birds such as chickens, vertebrates such as fish and mammals such as mice, rats, rabbits, cats, dogs, pigs, cows, ox, sheep, goats, horses, monkeys and other non-human primates, and humans can be isolated, manipulated or detected by the present methods.
- cells derived from a particular tissue or organ can be isolated, manipulated or detected.
- connective, epithelium, muscle or nerve tissue cells can be isolated, manipulated or detected.
- cells derived from an accessory organ of the eye annulospiral organ, auditory organ, Chievitz organ, circumventricular organ, Corti organ, critical organ, enamel organ, end organ, external female genital organ, external male genital organ, floating organ, flower-spray organ of Ruffini, genital organ, Golgi tendon organ, gustatory organ, organ of hearing, internal female genital organ, internal male genital organ, intromittent organ, Jacobson organ, neurohemal organ, neurotendinous organ, olfactory organ, otolithic organ, ptotic organ, organ of Rosenmüller, sense organ, organ of smell, spiral organ, subcommissural organ, subformical organ, supernumerary organ, tactile organ, target organ, organ of taste, organ of touch, urinary organ, vascular organ of
- cells derived from an internal animal organ such as brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, gland, internal blood vessels, etc can be isolated, manipulated or detected.
- cells derived from any plants, fungi such as yeasts, bacteria such as eubacteria or archaebacteria can be isolated, manipulated or detected.
- Recombinant cells derived from any eucaryotic or prokaryotic sources such as animal, plant, fungus or bacterium cells can also be isolated, manipulated or detected.
- Cells from various types of body fluid such as blood, urine, saliva, bone marrow, sperm or other ascitic fluids, and subfractions thereof, e.g., serum or plasma, can also be isolated, manipulated or detected.
- Isolatable, manipulatable or detectable cellular organelles include nucleus, mitochondria, chloroplasts, ribosomes, ERs, Golgi apparatuses, lysosomes, proteasomes, secretory vesicles, vacuoles or microsomes.
- Isolatable, manipulatable or detectable viruses include intact viruses or any viral structures, e.g., viral particles, in the virus life cycle that can be derived from viruses such as Class I viruses, Class II viruses, Class III viruses, Class IV viruses, Class V viruses or Class VI viruses.
- Isolatable, manipulatable or detectable molecules can be inorganic molecules such as ions, organic molecules or a complex thereof.
- ions include sodium, potassium, magnesium, calcium, chlorine, iron, copper, zinc, manganese, cobalt, iodine, molybdenum, vanadium, nickel, chromium, fluorine, silicon, tin, boron or arsenic ions.
- organic molecules include amino acids, peptides, proteins, nucleosides, nucleotides, oligonucleotides, nucleic acids, vitamins, monosaccharides, oligosaccharides, carbohydrates, lipids or a complex thereof.
- Any amino acids can be isolated, manipulated or detected by the present methods.
- a D- and a L-amino-acid can be isolated, manipulated or detected.
- any building blocks of naturally occurring peptides and proteins including Ala (A), Arg (R), Asn (N), Asp (D), Cys (C), Gln (Q), Glu (E), Gly (G), His (H), Ile (I), Leu (L), Lys (K), Met (M), Phe (F), Pro (P) Ser (S), Thr (T), Trp (W), Tyr (Y) and Val (V) can be isolated, manipulated or detected.
- proteins or peptides can be isolated, manipulated or detected by the present methods.
- membrane proteins such as receptor proteins on cell membranes, enzymes, transport proteins such as ion channels and pumps, nutrient or storage proteins, contractile or motile proteins such as actins and myosins, structural proteins, defense protein or regulatory proteins such as antibodies, hormones and growth factors can be isolated, manipulated or detected.
- Proteineous or peptidic antigens can also be isolated, manipulated or detected.
- nucleic acids including single-, double and triple-stranded nucleic acids, can be isolated, manipulated or detected by the present methods.
- nucleic acids include DNA, such as A-, B- or Z-form DNA, and RNA such as mRNA, tRNA and rRNA.
- nucleosides can be isolated, manipulated or detected by the present methods.
- nucleo sides include adenosine, guano sine, cytidine, thymidine and uridine.
- Any nucleotides can be isolated, manipulated or detected by the present methods. Examples of such nucleotides include AMP, GMP, CMP, UMP, ADP, GDP, CDP, UDP, ATP, GTP, CTP, UTP, dAMP, dGMP, dCMP, dTMP, dADP, dGDP, dCDP, dTDP, dATP, dGTP, dCTP and dTTP.
- any vitamins can be isolated, manipulated or detected by the present methods.
- water-soluble vitamins such as thiamine, riboflavin, nicotinic acid, pantothenic acid, pyridoxine, biotin, folate, vitamin B 12 and ascorbic acid can be isolated, manipulated or detected.
- fat-soluble vitamins such as vitamin A, vitamin D, vitamin E, and vitamin K can be isolated, manipulated or detected.
- monosaccharides include triose such as glyceraldehyde, tetroses such as erythrose and threose, pentoses such as ribose, arabinose, xylose, lyxose and ribulose, hexoses such as allose, altrose, glucose, mannose, gulose, idose, galactose, talose and fructose and heptose such as sedoheptulose.
- triose such as glyceraldehyde
- tetroses such as erythrose and threose
- pentoses such as ribose, arabinose, xylose, lyxose and ribulose
- hexoses such as allose, altrose,
- lipids can be isolated, manipulated or detected by the present methods.
- lipids include triacylglycerols such as tristearin, tripalmitin and triolein, waxes, phosphoglycerides such as phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphatidylinositol and cardiolipin, sphingolipids such as sphingomyelin, cerebrosides and gangliosides, sterols such as cholesterol and stigmasterol and sterol fatty acid esters.
- the fatty acids can be saturated fatty acids such as lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid and lignoceric acid, or can be unsaturated fatty acids such as palmitoleic acid, oleic acid, linoleic acid, linolenic acid and arachidonic acid.
- the present invention is directed to a method for synthesizing a library, which method comprises: a) providing a plurality of beads, each of said beads comprises a magnetizable substance and an optical labeling substance that corresponds to an entity to be synthesized on said bead; and b) synthesizing said entities on said beads, wherein said beads are sorted after each synthesis cycle according to said optical labeling substances and are directed to appropriate next synthesis cycle, whereby a library is synthesized, wherein each of said beads contains an entity that corresponds to an optical labeling substance on said bead and the sum of said beads collectively contains a plurality of entities that is predetermined before the library synthesis.
- any suitable magnetizable substance including the ones described in the above Section B, can be used in the present method.
- paramagnetic substance comprising a metal oxide particle is used in the present method.
- any suitable optical labeling substance including the ones described in the above Section B, can be used in the present method.
- the optical labeling substance used in the present beads is a fluorescent substance, a scattered-light detectable particle (See e.g., U.S. Pat. No. 6,214,560) and a quantum dot (See e.g., U.S. Pat. No. 6,252,664).
- the optical labeling substance used in the present method is a quantum dot. Any suitable quantum dot, including the ones described in the above Section B, can be used in the present method.
- the bead used in the present method can further comprise an element that facilitates and/or enables manipulation of the bead and/or a moiety/bead complex (See e.g., U.S. Pat. No. 7,081,192; co-pending U.S. patent application Ser. Nos. 09/679,024, filed Oct. 4, 2000; and Ser. No. 09/924,428, filed Aug. 7, 2001, published as U.S. Patent Application No. 20020137059A1).
- Any suitable element can be used.
- the element can be a cell, a cellular organelle, a virus, a microparticle, an aggregate or complex of molecules and an aggregate or complex thereof.
- the element can facilitate and/or enable manipulation of the bead and/or a moiety/bead complex by any suitable physical force such as a dielectrophoresis, a traveling-wave dielectrophoresis, a magnetic, an acoustic, an electrostatic, a mechanical, an optical radiation and a thermal convection force.
- the element can be a conductive or insulating material for manipulation by a dielectrophoresis force, a material with high or low acoustic impedance for manipulation by a acoustic force or a charged material for manipulation by an electrostatic force.
- the bead used in the present method can comprise a single element, it can also be used in a high throughput analysis and can comprise a plurality of the elements, each of the elements facilitates and/or enables manipulation of the bead and/or the moiety/bead complex by a different physical force.
- Any number of suitable entity(ies) can be synthesized on a single bead.
- a single entity or a plurality of entities can be synthesized on a single bead.
- a single entity is synthesized on a single bead.
- the synthesized entities can be peptides, proteins, oligonucleotides, nucleic acids, vitamins, oligosaccharides, carbohydrates, lipids, small molecules, or a complex or combination thereof.
- the synthesized library comprises a defined set of entities that are involved in a biological pathway, belongs to a group of entities with identical or similar biological function, expressed in a stage of cell cycle, expressed in a cell type, expressed in a tissue type, expressed in an organ type, expressed in a developmental stage, entities whose expression and/or activity are altered in a disease or disorder type or stage, or entities whose expression and/or activity are altered by drug or other treatments.
- the synthesized library comprises a defined set of nucleic acid, e.g., DNA or RNA, fragments such as a defined set of nucleic acid fragments that cover an entire genome, e.g., the entire human genome sequence.
- each of the nucleic acid fragments in the synthesized library comprises at least 10, 15, 20, 25, 50, 75, 100, 200, or 500 nucleotides.
- the synthesized library comprises a defined set of protein or peptide fragments such as a defined set of protein or peptide fragments that cover protein or peptide sequences encoded by an entire genome, e.g., the entire human genome sequence.
- each of the protein or peptide fragments in the synthesized library comprises at least 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 300, 400 or 500 amino acid residues.
- a method for generating an antibody library comprises: a) contacting a library synthesized by the above-described method with a plurality of antibodies; and b) selecting and/or recovering the antibodies that specifically bind to the entities of the library synthesized according to the above-described method.
- Any suitable antibodies can be used in the present method.
- plurality of antibodies used in the present method is a phage display library (See U.S. Pat. Nos. 6,127,132 and 6,174,708).
- the present invention is directed to a method for synthesizing a library, which method comprises: a) providing a plurality of beads, each of said beads comprising a magnetizable substance, an electrically conductive substance and a unique optical labeling substance; and b) synthesizing an entity on said beads, wherein said beads are identified after each synthesis cycle according to said unique optical labeling substances, whereby a library is synthesized, wherein each of said beads contains an entity that can be identified according to said unique optical labeling substance on each of said beads.
- a library that is synthesized according to the above-described method is provided. In this method of library synthesis, no two beads would have same optical labeling substance. The synthesis cycle that each bead goes through during library synthesis has been identified and recorded based on the unique optical labeling substance on each bead. Thus, the entity on each bead can be identified.
- Lab-on-a-chip is a concept that revolutionizes the analytical process, featuring miniaturization, integration, and automation.
- Active chips such as AVIVA Biosciences' multiple force chips, make the integration of multiple tasks, such as sample preparation, reaction, and detection possible.
- These active chips can utilize numerous beads as molecular carriers in the analytical process or as additional means to process cells or other biological materials.
- the beads can be designed to be responsive to the forces generated by the chips.
- Magnetic force has been widely used for separation and analysis with magnetic beads.
- Magnetic beads are generally prepared by precipitation of FeCl 3 and FeCl 2 in basic solution such as NaOH or NH 4 OH.
- the formed Fe 3 O 4 particle is in the size range of about 10 nm to about 5 micrometer.
- These particles are coated with a layer of polymer on their surfaces, e.g., dextran.
- the coated polymer is further activated to bind other molecules.
- These particles can also be mixed with organic monomers (e.g. styrene) and initiators to formed larger-size particles after the polymerization of the monomer.
- organic monomers e.g. styrene
- initiators e.g. styrene
- Fe 3 O 4 particles are encapsulated in the organic polymer beads, e.g., polystyrene beads.
- the formed larger particles can be further coated and modified on the surface to bind other molecules. Modified magnetic particles can be used to
- Carbon particles are electrically conductive, and they have been shown to be responsive to dielectrophoretic forces and exhibit both positive and negative dielectrophoresis effects under appropriate electric field conditions. Also, the density of carbon particles is quite low, thereby making it easier to be manipulated on a flat surface. Carbon particles can be modified by oxidation and further chemical and biochemical reactions.
- Quantum dots have attracted a lot of attention recently for their use as fluorescence sensing of biomolecules. Quantum dots of different sizes fluoresce at different wavelengths. Therefore, beads containing various sized quantum dots can be used to encode the beads. Bead encoding allows high throughput analysis of a large number of molecules, such as DNA and proteins. Details of quantum dots and how they can be incorporated into microbeads may be found in the literatures, for example, in the articles by Chan and Nie, Science, 281:2016 (1998) and by Han et al., Nature Biotechnology, 19:631-635 (2001).
- composite beads comprising magnetic particles (Fe 3 O 4 ), carbon particles, and quantum dots are prepared.
- the composite beads are further modified for the conjugation of biomolecules and their use for high throughput analyses are illustrated.
- nanometer size (10 to 100 nm) magnetic particles are prepared by reaction of FeCl 3 and FeCl 2 with NaOH. These particles are added to the polymerization mixture of urea and formaldehyde solution at pH of about 2.0. As a result, spherical beads with about 5 micrometer size are obtained.
- carbon particles, polyaniline, quantum dots, and above magnetic beads are added to a new urea-formaldehyde polymerization mixture at pH of about 2.0. Uniform spherical composite beads with the size of about 6 micrometer are obtained.
- these new beads are coated with a crosslinked layer of functional group containing polymer, and these functional groups are useful for conjugating special molecules for further affinity bindings.
- the prepared beads possess multiple properties that can be used for many purposes, but in this specific embodiment, we emphasize their use with the multiple force chips for the separation and analysis of multiple analytes.
- the exemplary uses include cell separation, e.g., fetal and cancer cells separation, mRNA extraction, DNA extraction, protein extraction and separation, DNA analysis, protein analysis, drug discovery and screening and other bioassays.
- This suspension was shaken and the pH was adjusted to 1.9, then 3.5 g urea and 5.6 g formaldehyde were added, mixed well, let sit. After 30 minutes, the magnetic beads formed were separated from the liquid by a magnet. The beads were washed three times with H 2 O.
- the magnetic beads prepared above were dispersed in propanol, carbon colloidal was added to the suspension, and the mixture was vortexed for 3 minutes, then the particle was collected with a magnet and the liquid was decanted. The beads were washed with H 2 O. Finally, the beads were dispersed in DI H 2 O.
- FIG. 1 shows the random distribution of the microbeads on a microelectrode array.
- pk-to-pk an electric voltage of 5 V peak-to-peak
- the microbeads at these frequencies were less polarizable than that of the suspending medium, exhibiting a negative dielectrophoresis.
- an electric voltage of 5 V pk-to-pk at frequency of 500 kHz was applied to the electrodes, the microbeads moved towards the electrode edges where the electric field strength was maximum or strongest ( FIG. 3 ).
- the microbeads at these frequencies were more polarizable than that of the suspending medium, exhibiting a positive dielectrophoresis. As shown below, these microbeads can be further manipulated by a magnetic field.
- microbeads have unique compositions as well as unique properties so that they can be manipulated not only by magnetic field but also by AC electrical field to exhibit both positive dielectrophoresis (DEP) and negative DEP.
- DEP dielectrophoresis
- commercially available magnetic beads exhibit magnetic field responses with none or small negative dielectrophoresis behavior.
- FIG. 4 shows the random distribution of the microbeads on an electromagnetic chip.
- the chip used for beads-testing comprises both magnetic elements as well as microelectrode elements so that the microelectrode elements can be used for dielectrophoretic manipulation of the microbeads while the magnetic elements are used for magnetic manipulation of the microbeads.
- microbeads were produced with magnetizable properties.
- a 100 mL three neck flask was equipped with a mechanical stirrer, a condenser, a thermometer and an argon inlet.
- Ten mL of iron oxide colloid solution (see above) and 10 mL of DI water were added to the flask.
- the liquid was stirred under argon.
- Thirty mg of benzoyl peroxide (BPO) were dissolved in 1 mL of mixture of styrene and divinyl benzene (DVB) (9:1, V/V) to form monomer solution.
- BPO benzoyl peroxide
- DVB divinyl benzene
- the reaction mixture was filtered through two layers of cheese cloth, and the filtrate was magnetically decanted (2 minutes magnetic decantation).
- the magnetic particles were resuspended in DI water and magnetic decantation (1-2 minutes) was performed.
- the wash step was repeated until the decanted liquid became clear.
- Magnetic particles suspension (containing about 300 mg of particles) was added to a 100 mL flask, and the suspension was diluted with water to 50 mL volume. Thirty mg of sodium dodecyl sulfate (SDS) and 300 mg of potassium persulfate (KPS) were added to the particle suspension, shaken until SDS and KPS were completely dissolved.
- SDS sodium dodecyl sulfate
- KPS potassium persulfate
- a monomer solution was made by mixing 0.09 mL of styrene, 0.03 mL of DVB, and 0.06 mL of undecylenic acid in 0.6 mL of methanol.
- the monomer solution was added to the particle suspension, and the flask was sealed with rubber septa.
- the flask was evacuated with a vacuum pump for 10 minutes, and shaken (250 rps) at 55° C. for 5 hours.
- the reaction solution was magnetically decanted.
- the coated magnetic particles were resuspended in DI water and magnetic decantation was performed.
- streptavidin bonded magnetic microbeads were produced.
- Magnetic beads were dispersed in DI water (40 mL), 0.5 mL of 20% SDS solution was added to above beads solution, shaken with Vortex shaker for 10 seconds, sonicated for 2 min., and liquid was separated from beads using a 50 mL magnetic separator.
- the beads were dispersed in 2-(N-morpholino)-ethane sulfonic acid (MES) buffer (0.1 M, pH 4.7), and 0.1 g 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and 0.05 g Sulfo-NHS (N-hydroxysuccinimide 3-sulfonic acid) were added to this solution, shaken with Vortex shaker for 10 seconds, and shaken on a plate shaker for 2 hours. The beads were washed with MES buffer.
- MES 2-(N-morpholino)-ethane sulfonic acid
- EDC 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride
- Sulfo-NHS N-hydroxysuccinimide 3-sulfonic acid
- the beads were then dispersed in phosphate-buffered saline (PBS buffer), 0.5 mL of 2,2′-(ethylenedioxy)bis(ethylamine) was added to this solution, vortexed for 10 seconds and shaken on a plate shaker for 2 hours. After that, the beads were washed with PBS buffer. Again, the beads were dispersed in PBS buffer (35 mL), 0.5 mL of glutaric dialdehyde was added to the beads, shaken for 1 hour. The beads were washed with PBS buffer, and dispersed in PBS buffer.
- PBS buffer phosphate-buffered saline
- Streptavidin (2 mg in water) and 10 mg of sodium cyanoborohydride were added to the dispersed beads, shaken on a plate shaker for 2 hours. After that, 5 mg of sodium cyanoborohydride were added, shaken for another 1 hour. The beads were washed with PBS buffer. The beads were stored in PBS buffer containing 1% Tween 20, 0.5% bovine serum albumin (BSA) and 0.02% sodium azide.
- BSA bovine serum albumin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Electrochemistry (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
This invention relates generally to the field of moiety or molecule isolation, detection and manipulation and library synthesis. In particular, the invention provides a bead, which bead comprises: a) a magnetizable substance; and b) an electrically conductive substance or an optical labeling substance. Methods and kits for isolating, detecting and manipulating moieties and synthesizing libraries using the beads are also provided.
Description
- This application is a divisional of prior U.S. patent application Ser. No. 10/104,579, filed on Mar. 21, 2002, now allowed. The contents of that application are incorporated herein by reference in their entirety.
- This invention relates generally to the field of moiety or molecule isolation, detection and manipulation and library synthesis. In particular, the invention provides a bead, which bead comprises: a) a magnetizable substance; and b) an electrically conductive substance or an optical labeling substance. Methods and kits for isolating, detecting and manipulating moieties and synthesizing libraries using the beads are also provided.
- The preparation and use of magnetically responsive beads are known in the art. See. e.g., U.S. Pat. Nos. 4,285,819, 4,582,622, 4,795,698, 5,091,206, 5,795,470, 5,648,124, and 5,834,121. Carbon beads have been used as HPLC packing materials and coating filler. Quantum dots have found their applications in bioanalysis just recently. Quantum dot nanocrystals are nanometer scale particles that are neither small molecules nor bulk solids. Their composition and small size (a few hundred to a few thousand atoms) give these dots extraordinary optical properties, which can be readily customized by changing the size or composition of the dots. This property is the basis for encoding using quantum dots.
- Microarray, biochips, and high throughput bioassays have experienced rapid progress during last several years. There are two types of biochips: passive and active biochips. Passive biochips refer to those on which chemical or biochemical reactions are dependent on passive diffusion of sample molecules. Active biochips, on the other hand, allow versatile functions of molecular manipulation, interaction, hybridization reaction and separation by external forces through means such as microfluidic manipulation and electrical manipulation of molecules. When functional beads are used as molecular carrier, the beads are manipulated on the active chips.
- Although beads technology has found wide applications in separation and analysis, there is a limited supply of various beads, especially those suitable to be used with active biochips, e.g., multiple-forces chips. The present invention addresses this and other related needs in the art.
- In one aspect, the present invention is directed to a bead, which bead comprises: a) a magnetizable substance; and b) an electrically conductive substance or an optical labeling substance.
- In another aspect, the present invention is directed to a method for isolating a moiety, which method comprises: a) providing a bead comprising 1) a magnetizable substance, 2) an optical labeling substance, and preferably 3) a binding partner that is capable of binding to a moiety to be isolated; b) contacting a sample containing or suspected of containing of said moiety with said bead provided in step a) under conditions allowing binding between said moiety and said bead and/or binding partner; and c) recovering said bead from said sample, whereby the identity of said isolated moiety is assessed by analyzing said optical labeling substance comprised in said bead.
- In still another aspect, the present invention is directed to a method for manipulating a moiety, which method comprises: a) providing a bead comprising 1) a magnetizable substance, 2) an electrically conductive substance, and preferably 3) a binding partner that is capable of binding to a moiety to be manipulated; b) coupling said moiety to said bead provided in step a) via binding between said moiety and said binding partner to form a moiety-bead complex; and c) manipulating said moiety-bead complex with a dielectrophoresis, a traveling-wave dielectrophoresis and/or a magnetic force, preferably in a chip format, thereby said moiety is manipulated. The above method for manipulating a moiety can be readily extended to manipulating multiple moieties by using multiple types of beads, each type of which is targeted to one type of moieties to be manipulated.
- In yet another aspect, the present invention is directed to a kit for manipulating a moiety, which kit comprises: a) a bead comprising 1) a magnetizable substance, 2) an electrically conductive substance or an optical labeling substance, and preferably 3) a binding partner that is capable of binding, or capable of specifically binding, to a moiety to be manipulated; and b) a means for generating a physical force for manipulating said moiety-bead complex.
- In yet another aspect, the present invention is directed to a kit for manipulating a moiety in a chip format, which kit comprises: a) a bead comprising 1) a magnetizable substance, 2) an electrically conductive substance or an optical labeling substance, and preferably 3) a binding partner that is capable of binding, or capable of specifically binding, to a moiety to be manipulated; and b) a chip on which a moiety-bead complex can be manipulated.
- In yet another aspect, the present invention is directed to a method for detecting a moiety, which method comprises: a) providing a bead comprising 1) a magnetizable substance, 2) an optical labeling substance, and preferably 3) a binding partner that is capable of binding to a moiety to be detected; b) contacting a sample containing or suspected of containing of said moiety with said bead provided in step a) under conditions allowing binding between said moiety and said bead and/or said binding partner; and c) detecting binding between said moiety and said bead and/or said binding partner, whereby the presence or amount of said moiety is assessed by analysis of binding between said moiety and said bead and/or said binding partner and the identity of said moiety is assessed by analyzing the optical labeling substance comprised in the bead. The above method for detecting a moiety can be readily extended to detecting multiple moieties by using multiple types of beads, each type of which is targeted to one type of moieties to be detected and each of which has a unique optical labeling substance.
- In yet another aspect, the present invention is directed to a method for synthesizing a library, which method comprises: a) providing a plurality of beads of the present invention, each of said beads comprising a magnetizable substance and an optical labeling substance that corresponds to an entity to be synthesized on said bead; and b) synthesizing said entities on said beads, wherein said beads are sorted after each synthesis cycle according to said optical labeling substances and the sorted beads are then subjected to appropriate synthesis reaction in the next synthesis cycle according to said entities to be synthesized on said beads, whereby a library is synthesized, wherein each of said beads contains an entity that corresponds to an optical labeling substance on said bead and the sum of said beads collectively contains a plurality of entities that is predetermined before the library synthesis. A library that is synthesized according to the above method is also provided.
- In yet another aspect, the present invention is directed to a method for synthesizing a library, which method comprises: a) providing a plurality of beads, each of said beads comprising a magnetizable substance, an electrically conductive substance and a unique optical labeling substance, wherein said unique optical labeling substance on each of said beads corresponds to an entity to be synthesized on each of said beads; and b) synthesizing said entities on said beads, wherein said beads are identified after each synthesis cycle according to said unique optical labeling substances, whereby a library is synthesized, wherein each of said beads contains an entity that corresponds to said unique optical labeling substance on each of said beads.
- In yet another aspect, the present invention is directed to a method for generating an antibody library, which method comprises: a) contacting a library synthesized according to the above method with a plurality of antibodies; and b) selecting and/or recovering the antibodies that specifically bind to the entities of the above library.
-
FIG. 1 shows the random distribution of exemplary beads (or microbeads) of the present invention on a microelectrode array. These microbeads can exhibit magnetic field induced effects, and positive and negative dielectrophoresis effects. The microbeads are seen as black dots, the microelectrodes are seen as the light structure and the grey area represents the inter-microelectrode space. -
FIG. 2 shows the collection and aggregation of the microbeads at the interspaces between the neighboring electrodes under an electric voltage of 5 V peak-peak (pk-to-pk) at frequency of 50 kHz. The microbeads are seen as black dots, the microelectrodes are seen as the light structure and the grey area represents the inter-microelectrode space. -
FIG. 3 shows the collection and aggregation of the microbeads at the electrode edges between the neighboring electrodes under an electric voltage of 5 V pk-to-pk at frequency of 500 kHz. The microbeads are seen as black dots, the microelectrodes are seen as the light structure and the grey area represents the inter-microelectrode space. -
FIG. 4 shows the random distribution of the microbeads on an electromagnetic chip. The microbeads are seen as black dots, the dielectrophoretic force generating structures are seen as the light structures and the electromagnetic coil is seen as the dark structure underneath the dielectrophoretic force generating structures. -
FIG. 5 shows that the microbeads were attracted towards the poles of the electromagnetic units when a DC current of 200 mA was applied to an electromagnetic unit on the chip. The microbeads are seen as black dots, the dielectrophoretic force generating structures are seen as the light structures and the electromagnetic coil is seen as the dark structure underneath the dielectrophoretic force generating structures. -
FIG. 6 shows that the collection of the microbeads at the poles of the electromagnetic units after the DC current has been applied for over 2 minutes. The microbeads are seen as black dots, the dielectrophoretic force generating structures are seen as the light structures and the electromagnetic coil is seen as the dark structure underneath the dielectrophoretic force generating structures. - For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the subsections that follow.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this invention belongs. All patents, applications, published applications and other publications referred to herein are incorporated by reference in their entirety. If a definition set forth in this section is contrary to or otherwise inconsistent with a definition set forth in the patents, applications, published applications and other publications that are herein incorporated by reference, the definition set forth in this section prevails over the definition that is incorporated herein by reference.
- As used herein, “a” or “an” means “at least one” or “one or more.”
- As used herein, “magnetic substance” refers to any substance that has the properties of a magnet, pertaining to a magnet or to magnetism, producing, caused by, or operating by means of, magnetism.
- As used herein, “magnetizable substance” refers to any substance that has the property of being interacted with the field of a magnet, and hence, when suspended or placed freely in a magnetic field, of inducing magnetization and producing a magnetic moment. Examples of magnetizable substances include, but are not limited to, paramagnetic, ferromagnetic and ferrimagnetic substances.
- As used herein, “paramagnetic substance” refers to the substances where the individual atoms, ions or molecules possess a permanent magnetic dipole moment. In the absence of an external magnetic field, the atomic dipoles point in random directions and there is no resultant magnetization of the substances as a whole in any direction. This random orientation is the result of thermal agitation within the substance. When an external magnetic field is applied, the atomic dipoles tend to orient themselves parallel to the field, since this is the state of lower energy than antiparallel position. This gives a net magnetization parallel to the field and a positive contribution to the susceptibility. Further details on “paramagnetic substance” or “paramagnetism” can be found in various literatures, e.g., at Page 169-page 171, Chapter 6, in “Electricity and Magnetism” by B. I Bleaney and B. Bleaney, Oxford, 1975.
- As used herein, “ferromagnetic substance” refers to the substances that are distinguished by very large (positive) values of susceptibility, and are dependent on the applied magnetic field strength. In addition, ferromagnetic substances may possess a magnetic moment even in the absence of the applied magnetic field, and the retention of magnetization in zero field is known as “remanence”. Further details on “ferromagnetic substance” or “ferromagnetism” can be found in various literatures, e.g., at Page 171-page 174, Chapter 6, in “Electricity and Magnetism” by B. I Bleaney and B. Bleaney, Oxford, 1975.
- As used herein, “ferrimagnetic substance” refers to the substances that show spontaneous magnetization, remanence, and other properties similar to ordinary ferromagnetic materials, but the spontaneous moment does not correspond to the value expected for full parallel alignment of the (magnetic) dipoles in the substance. Further details on “ferrimagnetic substance” or “ferrimagnetism” can be found in various literatures, e.g., at Page 519-524, Chapter 16, in “Electricity and Magnetism” by B. I Bleaney and B. Bleaney, Oxford, 1975.
- As used herein, “metal oxide particle” refers to any oxide of a metal in a particle form. Certain metal oxide particles have paramagnetic or super-paramagnetic properties. “Paramagnetic particle” is defined as a particle which is susceptible to the application of external magnetic fields, yet is unable to maintain a permanent magnetic domain. In other words, “paramagnetic particle” may also be defined as a particle that is made from or made of “paramagnetic substances”. Non-limiting examples of paramagnetic particles include certain metal oxide particles, e.g., Fe3O4 particles, metal alloy particles, e.g., CoTaZr particles.
- As used herein, “electrically conductive substance” refers to any substance that is not electrically-insulating and can exhibit positive dielectrophoresis force under appropriate conditions. Under such conditions, “electrically conductive substance” has higher electrical conductivity and/or higher dielectric permittivity than those of the suspending media in which the “electrically conductive substance” is suspended, placed, or introduced.
- As used herein, “optical labeling substance” refers to any optically detectable substance that can be used to label the beads of the present invention to facilitate and/or enable detection and/or identification of the beads. Quantum-dot is an example of an optical labeling substance.
- As used herein, “scattered-light detectable particle” refers to any particle that can emit unique and identifiable scattered-light upon illumination with light under appropriate conditions. The nano-sized particles with certain “resonance light scattering (RLS)” properties are examples of one type of “scattered-light detectable particle.”
- As used herein, “quantum dot” refers to a fluorescent label comprising water-soluble semiconductor nanocrystal(s). One unique feature of a quantum dot is that its fluorescent spectrum is related to or determined by the diameter of its nanocrystals(s). “Water-soluble” is used herein to mean sufficiently soluble or suspendable in a aqueous-based solution, such as in water or water-based solutions or physiological solutions, including those used in the various fluorescence detection systems as known by those skilled in the art. Generally, quantum dots can be prepared which result in relative monodispersity; e.g., the diameter of the core varying approximately less than 10% between quantum dots in the preparation. Details of quantum dots and how they can be incorporated into microbeads may be found in the literatures, for example, in the articles by Chan and Nie, Science, 281:2016 (1998) and by Han et al., Nature Biotechnology, 19:631-635 (2001).
- As used herein, “chip” refers to a solid substrate with a plurality of one-, two- or three-dimensional micro structures or micro-scale structures on which certain processes, such as physical, chemical, biological, biophysical or biochemical processes, etc., can be carried out. The micro structures or micro-scale structures such as, channels and wells, electrode elements, electromagnetic elements, are incorporated into, fabricated on or otherwise attached to the substrate for facilitating physical, biophysical, biological, biochemical, chemical reactions or processes on the chip. The chip may be thin in one dimension and may have various shapes in other dimensions, for example, a rectangle, a circle, an ellipse, or other irregular shapes. The size of the major surface of chips of the present invention can vary considerably, e.g., from about 1 mm2 to about 0.25 m2. Preferably, the size of the chips is from about 4 mm2 to about 25 cm2 with a characteristic dimension from about 1 mm to about 5 cm. The chip surfaces may be flat, or not flat. The chips with non-flat surfaces may include channels or wells fabricated on the surfaces.
- As used herein, a “chamber” refers to a structure that comprises a chip and that is capable of containing a fluid sample. The chamber may have various dimensions and its volume may vary between 0.001 microliter and 50 milliliter. More detailed description of a chamber is given in Section C.
- As used herein, “a means for generating a physical force on said chip” refers to any substance, structure or a combination thereof that is capable of generating, in conjunction with an internal structure on a chip, to generate a desirable physical force on the chip.
- As used herein, “physical field,” e.g., used itself or used as “physical field in a region of space” or “physical field is generated in a region of space” means that the region of space has following characteristics. When a moiety, alone or bound to a bead via a binding partner, of appropriate properties is introduced into the region of space (i.e. into the physical field), forces are produced on the moiety, the bead or both, as a result of the interaction between the moiety and/or bead and the field. A moiety can be manipulated within a field via the physical forces exerted on the moiety by the field. Exemplary fields include electric, magnetic, acoustic, optical and velocity fields. In the present invention, physical field always exists in a medium in a region of space, and the moiety is suspended in, or is dissolved in, or more generally, is placed in the medium. Typically, the medium is a fluid such as aqueous or non-aqueous liquids, or a gas. Depending on the field configuration, an electric field may produce electrophoretic forces on charged moieties, or may produce conventional dielectrophoretic forces and/or traveling wave dielectrophoretic forces on charged and/or neutral moieties. Magnetic field may produce magnetic forces on magnetic moieties. Acoustic field may produce acoustic radiation forces on moieties. Optical field may produce optical radiation forces on moieties. Velocity field in the medium in a region of space refers to a velocity distribution of the medium that moves in the region of the space. Various mechanisms may be responsible for causing the medium to move and the medium at different positions may exhibit different velocities, thus generating a velocity field. Velocity field may exert mechanical forces on moieties in the medium.
- As used herein, “medium (or media)” refers to a fluidic carrier, e.g., liquid or gas, wherein a moiety, alone or bound to a bead via a binding partner, is dissolved, suspended or contained.
- As used herein, “microfluidic application” refers to the use of microscale devices, e.g., the characteristic dimension of basic structural elements is in the range between less than 1 micron to 1 cm scale, for manipulations and processes in a fluidic setting, typically for performing specific biological, biochemical or chemical reactions and procedures. The specific areas include, but are not limited to, biochips, i.e., chips for biologically related reactions and processes, chemchips, i.e., chips for chemical reactions, or a combination thereof. The characteristic dimensions of the basic elements refer to the single dimension sizes. For example, for the microscale devices having circular shape structures (e.g. round electrode pads), the characteristic dimension refers to the diameter of the round electrodes. For the devices having thin, rectangular lines as basic structures, the characteristic dimensions may refer to the width or length of these lines.
- As used herein, “built-in structures on said substrate of a chip” means that the structures are built into the substrate or the structures are located on the substrate or the structures are structurally linked to the substrate of the chip. In one embodiment, the built-in structures may be fabricated on the substrate. For example, as described in “Dielectrophoretic manipulation of cells using spiral electrodes by Wang et al., Biophys. J, 72:1887-1899 (1997)”, spiral electrodes are fabricated on a glass substrate. Here the spiral electrodes are “built-in” structures on the glass substrate. In another embodiment, the “built-in” structures may be first fabricated on one substrate and the structure-containing first substrate may then be attached or bound to a second substrate. Such structures are “built-in” structures not only on the first substrate but also on the second substrate. In still another embodiment, the built-in structures may be attached or bound to the substrate. For example, thin, electrically-conductive wires may be used as electrodes for producing electric field. These electric wires may be bound or attached to a glass substrate. In this case, the electrically-conductive wires are “built-in” structures on the glass substrate. Throughout this application, when it is described that “built-in” structures on the chip or on the substrate are capable of generating physical forces and/or physical fields or these structures generate physical forces and/or physical fields, these structures are used in combination with external signal sources or external energy sources.
- As used herein, “structures internal to said apparatus” means that the structures are integral parts of and structurally linked to other parts of the apparatus, or the structures are not separated or separable from other structural elements of the apparatus. For example, such internal structures can be microfabricated or otherwise attached to the substrate or other structural element(s) of the apparatus. Any “built-in structures on said substrates” described above are “structures internal to said apparatus” as long as the said apparatus comprise the substrates. Any built-in structures on a chip are “structures internal to said apparatus” as long as the said apparatus comprise the chip. Throughout this application, when it is described that “internal” structures of apparatus are capable of generating physical forces and/or physical fields or these structures generate physical forces and/or physical fields, these structures are used in combination with external signal sources or external energy sources.
- As used herein, “micro-scale structures” means that the scale of the internal structures of the apparatus for exerting desired physical forces must be compatible with and useable in microfluidic applications and have characteristic dimension of basic structural elements in the range from about 1 micron to about 20 mm scale.
- As used herein, “moiety” refers to any substance whose isolation, manipulation, measurement, quantification or detection using the present bead is desirable. Normally, the dimension (or the characteristic dimensions) of the moiety should not exceed 1 cm. For example, if the moiety is spherical or approximately spherical, the dimension of the moiety refers to the diameter of the sphere or an approximated sphere for the moiety. If the moiety is cubical or approximately cubical, then the dimension of the moiety refers to the side width of the cube or an approximated cube for the moiety. If the moiety has an irregular shape, the dimension of the moiety may refer to the average between its largest axis and smallest axis. Non-limiting examples of moieties include cells, cellular organelles, viruses, particles, molecules, e.g., proteins, DNAs and RNAs, or an aggregate or complex thereof.
- Moiety to be isolated, manipulated, measured, quantified or detected includes many types of particles—solid (e.g., glass beads, latex particles, magnetic beads), liquid (e.g., liquid droplets) or gaseous particles (e.g., gas bubble), dissolved particles (e.g., molecules, proteins, antibodies, antigens, lipids, DNAs, RNAs, molecule-complexes), suspended particles (e.g., glass beads, latex particles, polystyrene beads). Particles can be organic (e.g., mammalian cells or other cells, bacteria, virus, or other microorganisms) or inorganic (e.g., metal particles). Particles can be of different shapes (e.g., sphere, elliptical sphere, cubic, discoid, needle-type) and can be of different sizes (e.g., nano-meter-size gold sphere, to micrometer-size cells, to millimeter-size particle-aggregate). Examples of particles include, but not limited to, biomolecules such as DNA, RNA, chromosomes, protein molecules (e.g., antibodies), cells, colloid particles (e.g., polystyrene beads, magnetic beads), any biomolecules (e.g., enzyme, antigen, hormone etc). One specific type of particle refers to complexes formed between moieties and their binding partners, as described in a co-pending U.S. patent application entitled “METHODS FOR MANIPULATING MOIETIES IN MICROFLUIDIC SYSTEMS” (U.S. patent application Ser. No. 09/636,104, by Wang et al., filed on Aug. 10, 2000). The examples of such complexes include particle-particle complexes, particle-molecule complexes (e.g., cell-magnetic bead complexes formed by binding of the cells onto antibody-coated beads through the interaction between the antigens or protein molecules on cell surfaces and the antibody molecules immobilized on the magnetic bead surfaces; DNA molecule-magnetic bead complexes formed by immobilizing DNA molecules on magnetic bead surfaces, or protein molecule-polystyrene bead complexes formed by covering polystyrene bead surfaces with protein molecules). The methods disclosed in a co-pending U.S. patent application “METHODS FOR MANIPULATING MOIETIES IN MICROFLUIDIC SYSTEMS” (U.S. patent application Ser. No. 09/636,104, by Wang et al., filed on Aug. 10, 2000) may be used for manipulating moieties and/or binding partner-moiety complexes in the devices and apparatus in the present invention. The co-pending U.S. patent application “METHODS FOR MANIPULATING MOIETIES IN MICROFLUIDIC SYSTEMS” (U.S. patent application Ser. No. 09/636,104) by Wang et al., filed on Aug. 10, 2000 is incorporated by reference in their entirety. These moieties can be isolated, manipulated, measured, quantified or detected using a bead of the present application.
- As used herein, “plant” refers to any of various photosynthetic, eucaryotic multi-cellular organisms of the kingdom Plantae, characteristically producing embryos, containing chloroplasts, having cellulose cell walls and lacking locomotion.
- As used herein, “animal” refers to a multi-cellular organism of the kingdom of Animalia, characterized by a capacity for locomotion, nonphotosynthetic metabolism, pronounced response to stimuli, restricted growth and fixed bodily structure. Non-limiting examples of animals include birds such as chickens, vertebrates such fish and mammals such as mice, rats, rabbits, cats, dogs, pigs, cows, ox, sheep, goats, horses, monkeys and other non-human primates.
- As used herein, “bacteria” refers to small prokaryotic organisms (linear dimensions of around 1 micron) with non-compartmentalized circular DNA and ribosomes of about 70 S. Bacteria protein synthesis differs from that of eukaryotes. Many anti-bacterial antibiotics interfere with bacteria proteins synthesis but do not affect the infected host.
- As used herein, “eubacteria” refers to a major subdivision of the bacteria except the archaebacteria. Most Gram-positive bacteria, cyanobacteria, mycoplasmas, enterobacteria, pseudomonas and chloroplasts are eubacteria. The cytoplasmic membrane of eubacteria contains ester-linked lipids; there is peptidoglycan in the cell wall (if present); and no introns have been discovered in eubacteria.
- As used herein, “archaebacteria” refers to a major subdivision of the bacteria except the eubacteria. There are three main orders of archaebacteria: extreme halophiles, methanogens and sulphur-dependent extreme thermophiles. Archaebacteria differs from eubacteria in ribosomal structure, the possession (in some case) of introns, and other features including membrane composition.
- As used herein, “virus” refers to an obligate intracellular parasite of living but non-cellular nature, consisting of DNA or RNA and a protein coat. Viruses range in diameter from about 20 to about 300 nm. Class I viruses (Baltimore classification) have a double-stranded DNA as their genome; Class II viruses have a single-stranded DNA as their genome; Class III viruses have a double-stranded RNA as their genome; Class IV viruses have a positive single-stranded RNA as their genome, the genome itself acting as mRNA; Class V viruses have a negative single-stranded RNA as their genome used as a template for mRNA synthesis; and Class VI viruses have a positive single-stranded RNA genome but with a DNA intermediate not only in replication but also in mRNA synthesis. The majority of viruses are recognized by the diseases they cause in plants, animals and prokaryotes. Viruses of prokaryotes are known as bacteriophages.
- As used herein, “fungus” refers to a division of eucaryotic organisms that grow in irregular masses, without roots, stems, or leaves, and are devoid of chlorophyll or other pigments capable of photosynthesis. Each organism (thallus) is unicellular to filamentous, and possesses branched somatic structures (hyphae) surrounded by cell walls containing glucan or chitin or both, and containing true nuclei.
- As used herein, “binding partners” refers to any substances that bind to the moieties with desired affinity or specificity. Non-limiting examples of the binding partners include cells, cellular organelles, viruses, particles, microparticles or an aggregate or complex thereof, or an aggregate or complex of molecules, or specific molecules such as antibodies, single stranded DNAs. The binding partner can be a substance that is coated on the surface of a bead. Alternatively, the binding partner can be a substance that is incorporated, e.g., microfabricated, into the material composition of a bead. The material composition of a bead may possess binding affinity to certain moiety, and thus functioning a binding partner itself.
- As used herein, “an element that facilitates and/or enables manipulation of the bead and/or a moiety/bead complex” refers to any substance that is itself manipulatable or makes the moiety/bead complex manipulatable with the desired physical force(s). Non-limiting examples of the elements include cells, cellular organelles, viruses, particles, microparticles or an aggregate or complex thereof, or an aggregate or complex of molecules. Non-limiting examples of the elements may further include deposited or other-procedure-produced materials with specific physical or chemical properties. Various metal compositions such as Au, Cr, Ti, Pt etc are examples of the elements that can be incorporated into the beads and increase electrical conductivity of the beads. Other conductive materials such as carbon and/or conductive polymers can also be incorporated into the beads to increase electrical conductivity of the beads. Insulating materials such as polystyrene, paralene, or other plastic polymers are also examples of the elements that may be incorporated into the beads and reduce electrical conductivity of the beads.
- As used herein, “microparticles” refers to particles of any shape, any composition, any complex structures that are manipulatable by desired physical force(s) in microfluidic settings or applications. One example of microparticles is magnetic beads that are manipulatable by magnetic forces. Another example of microparticles is a cell that is manipulatable by an electric force such as a traveling-wave dielectrophoretic force. The microparticles used in the methods can have a dimension from about 0.01 micron to about ten centimeters. Preferably, the microparticles used in the methods have a dimension from about 0.01 micron to about several thousand microns. Examples of the microparticles include, but are not limited to, plastic particles, polystyrene microbeads, glass beads, magnetic beads, hollow glass spheres, particles of complex compositions, microfabricated free-standing microstructures, etc. Other particles include cells, cell organelles, large biomolecules such as DNA, RNA and proteins etc.
- As used herein, “manipulation” refers to moving or processing of the moieties and the beads disclosed in the present invention, which results in one-, two- or three-dimensional movement of the moiety (and the beads), in a chip format, whether within a single chip or between or among multiple chips, or on a substrate or among substrates of an apparatus. “Manipulation” of moieties and the beads can also be performed in a non-chip format, e.g., in liquid containers. Non-limiting examples of the manipulations include transportation, focusing, enrichment, concentration, aggregation, trapping, repulsion, levitation, separation, sorting, fractionation, isolation or linear or other directed motion of the moieties. For effective manipulation, the characteristics of the moiety (and the beads) to be manipulated and the physical force used for manipulation must be compatible. For example, the beads with certain magnetic properties can be used with magnetic force. Similarly, the beads with electric charge(s) can be used with electrostatic (i.e. electrophoretic) force. In the case of manipulating beads-binding partner-moiety complexes, the characteristics of the moiety, or its binding partner or the beads, and the physical force used for manipulation must be compatible. For example, moiety or its binding partner or the beads with certain dielectric properties to induce dielectric polarization in the moiety or its binding partner or the beads can be used with dielectrophoresis force.
- As used herein, “the moiety is not directly manipulatable” by a particular physical force means that no observable movement of the moiety can be detected when the moiety itself not coupled to a binding partner is acted upon by the particular physical force.
- As used herein, “physical force” refers to any force that moves the moieties or their binding partners or the corresponding beads without chemically or biologically reacting with the moieties and the binding partners, or with minimal chemical or biological reactions with the binding partners and the moieties so that the biological/chemical functions/properties of the binding partners and the moieties are not substantially altered as a result of such reactions. Throughout the application, the term of “forces” or “physical forces” always means the “forces” or “physical forces” exerted on a moiety or moieties, the binding partner(s) and/or the bead(s). The “forces” or “physical forces” are always generated through “fields” or “physical fields”. The forces exerted on moieties, the binding partner(s) and/or the bead(s) by the fields depend on the properties of the moieties, the binding partner(s) and/or the bead(s). Thus, for a given field or physical field to exert physical forces on a moiety, it is necessary for the moiety to have certain properties. While certain types of fields may be able to exert forces on different types of moieties having different properties, other types of fields may be able to exert forces on only limited type of moieties. For example, magnetic field can exert forces or magnetic forces only on magnetic particles or moieties having certain magnetic properties, but not on other particles, e.g., polystyrene beads. On the other hand, a non-uniform electric field can exert physical forces on many types of moieties such as polystyrene beads, cells, and also magnetic particles. It is not necessary for the physical field to be able to exert forces on different types of moieties or different moieties. But it is necessary for the physical field to be able to exert forces on at least one type of moiety or at least one moiety, the binding partner(s) and/or the bead(s).
- As used here in, “electric forces (or electrical forces)” are the forces exerted on moieties, the binding partner(s) and/or the bead(s) by an electric (or electrical) field.
- As used herein, “magnetic forces” are the forces exerted on moieties, the binding partner(s) and/or the bead(s) by a magnetic field.
- As used herein, “acoustic forces (or acoustic radiation forces)” are the forces exerted on moieties, the binding partner(s) and/or the bead(s) by an acoustic field.
- As used herein, “optical (or optical radiation) forces” are the forces exerted on moieties, the binding partner(s) and/or the bead(s) by an optical field.
- As used herein, “mechanical forces” are the forces exerted on moieties, the binding partner(s) and/or the bead(s) by a velocity field.
- As used herein, “the moiety to be manipulated is substantially coupled onto surface of the binding partner” means that a certain percentage, and preferably a majority, of the moiety to be manipulated is coupled onto surface of the binding partner and can be manipulated by a suitable physical force via manipulation of the binding partner in the microdevice. Ordinarily, at least 0.5% of the moiety to be manipulated is coupled onto surface of the binding partner. Preferably, at least 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of the moiety to be manipulated is coupled onto surface of the binding partner. The percentage of the coupled moiety includes the percentage of the moiety coupled onto surface of a particular type of binding partner or a plurality of binding partners. When a plurality of binding partners is used, the moiety can be coupled onto surface of the plurality of binding partners simultaneously or sequentially.
- As used herein, “the moiety to be manipulated is completely coupled onto surface of the binding partner” means that at least 90% of the moiety to be manipulated is coupled onto surface of the binding partner in the bead. Preferably, at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% of the moiety to be manipulated is coupled onto surface of the binding partner. The percentage of the coupled moiety includes the percentage of the moiety coupled onto surface of a particular type of binding partner or a plurality of binding partners. When a plurality of binding partners is used, the moiety can be coupled onto surface of the plurality of binding partners simultaneously or sequentially.
- As used herein, “a means for generating a physical force for manipulating a moiety-bead complex” refers to any substance, structure or a combination thereof that is capable of generating a desirable physical force for manipulating moiety-bead complex that is introduced or placed or suspended or dissolved in a fluid or otherwise existed in a fluid. The fluid containing the moiety-bead complex is introduced or placed or is generally contained in a fluid container (e.g. a liquid container such as a beaker, an eppendorf tube, any plastic or glass tube).
- As used herein, “intracellular moiety” refers to any moiety that resides or is otherwise located within a cell, i.e., located in the cytoplasm or matrix of cellular organelle, attached to any intracellular membrane, resides or is otherwise located within periplasma, if there is one, or resides or is otherwise located on cell surface, i.e., attached on the outer surface of cytoplasm membrane or cell wall, if there is one.
- As used herein, “an optical labeling substance that corresponds to an entity to be synthesized on said bead” means that the entity to be synthesized on a particular bead is predetermined according to the optical labeling substance on that bead.
- As used herein, “wherein said beads are sorted after each synthesis cycle according to said optical labeling substances” means that the synthetic steps or orders for making an entity on a particular bead are predetermined according to the optical labeling substance on that bead and after each synthesis cycle, the optical labeling substance on the bead is assessed for directing the next synthetic step or order.
- As used herein, “sample” refers to anything which may contain a moiety to be isolated, manipulated, measured, quantified or detected by the present beads and/or methods. The sample may be a biological sample, such as a biological fluid or a biological tissue. Examples of biological fluids include urine, blood, plasma, serum, saliva, semen, stool, sputum, cerebral spinal fluid, tears, mucus, amniotic fluid or the like. Biological tissues are aggregates of cells, usually of a particular kind together with their intercellular substance that form one of the structural materials of a human, animal, plant, bacterial, fungal or viral structure, including connective, epithelium, muscle and nerve tissues. Examples of biological tissues also include organs, tumors, lymph nodes, arteries and individual cell(s). The sample may also be a mixture of target analyte or enzyme containing molecules prepared in vitro.
- As used herein, a “liquid (fluid) sample” refers to a sample that naturally exists as a liquid or fluid, e.g., a biological fluid. A “liquid sample” also refers to a sample that naturally exists in a non-liquid status, e.g., solid or gas, but is prepared as a liquid, fluid, solution or suspension containing the solid or gas sample material. For example, a liquid sample can encompass a liquid, fluid, solution or suspension containing a biological tissue.
- As used herein the term “assessing (or assessed)” is intended to include quantitative and qualitative determination of the identity and/or amount of a moiety, e.g., a protein or nucleic acid, present in the sample or one bound to the beads or in whatever form or state. Assessment would involve obtaining an index, ratio, percentage, visual or other value indicative of the identity of a moiety in the sample and may further involve obtaining a number, an index, or other value indicative of the amount or quantity or the concentration of a moiety present in the sample or on the microdevice or in whatever form or state. Assessment may be direct or indirect and may be qualitative or quantitative.
- In one aspect, the present invention is directed to a bead, which bead comprises: a) a magnetizable substance; and b) an electrically conductive substance or an optical labeling substance.
- Any suitable magnetizable substance can be used in the present beads. No-limiting examples of the magnetizable substances include ferrimagnetic substance, ferromagnetic substance, paramagnetic substance or superparamagnetic substances. In a specific embodiment, the present bead comprises a paramagnetic substance, e.g., a paramagnetic metal oxide composition. Preferably, the paramagnetic metal oxide composition is a transition metal oxide or an alloy thereof. Any suitable transition metals can be used, such as iron, nickel, copper, cobalt, manganese, tantalum (Ta), zinc and zirconium (Zr). In a preferred embodiment, the metal oxide composition is Fe3O4 or Fe2O3. In another example, the magnetizable substance used in the beads of the present invention comprises a metal composition. Preferably, the metal composition is a transition metal composition or an alloy thereof such as iron, nickel, copper, cobalt, manganese, tantalum, zirconium and cobalt-tantalum-zirconium (CoTaZr) alloy.
- The beads of this invention may be prepared from the available primary beads, from raw materials or from metal oxides that are encapsulated by monomers which when crosslinked form rigid, polymeric coatings as disclosed in U.S. Pat. No. 5,834,121. As used herein, “rigid” refers to a polymeric coating that cross linked to the extent that the polymeric coating stabilizes the metal oxide particle within the coating (i.e. the coating essentially does not swell or dissolve) so that the particle remains enclosed therein. As used herein, “microporous” refers to a resinous polymeric matrix that swells or expands in polar organic solvent. As used herein, “load” is used to mean the capacity of the bead for attachment sites useful for functionalization or derivatization.
- Suitable substances which may be incorporated as magnetizable materials, for example, include iron oxides such as magnetite, ferrites of manganese, cobalt, and nickel, hematite and various alloys. Magnetite is the preferred metal oxide. Frequently, metal salts are taught to be converted to metal oxides then either coated with a polymer or adsorbed into a bead comprising a thermoplastic polymer resin having reducing groups thereon. When starting with metal oxide particles to obtain a hydrophobic primary bead, it is necessary to provide a rigid coating of a thermoplastic polymer derived from vinyl monomers, preferably a cross-linked polystyrene that is capable of binding or being bound by a microporous matrix. Magnetic particles may be formed by methods known in the art, e.g., procedures shown in Vandenberge et al., J. of Magnetism and Magnetic Materials, 15-18:1117-18 (1980); Matijevic, Acc. Chem. Res., 14:22-29 (1981); and U.S. Pat. Nos. 5,091,206; 4,774,265; 4,554,088; and 4,421,660. Examples of primary beads that may be used in this invention are shown in U.S. Pat. Nos. 5,395,688; 5,318,797; 5,283,079; 5,232,7892; 5,091,206; 4,965,007; 4,774,265; 4,654,267; 4,490,436; 4,336,173; and 4,421,660. Or, primary beads may be obtained commercially from available hydrophobic or hydrophilic beads that meet the starting requirements of size, sufficient stability of the polymeric coating to swelling in solvents to retain the paramagnetic particle, and ability to adsorb or absorb the vinyl monomer used to form the enmeshing matrix network. Preferably, the primary bead is a hydrophobic, polystyrene encapsulated, paramagnetic bead. Such polystyrene paramagnetic beads are available from Dynal, Inc. (Lake Success, N.Y.), Rhone Poulonc (France), and SINTEF (Trondheim, Norway). The use of toner particles or of magnetic particles having a first coating of an unstable polymer which are further encapsulated to produce an exterior rigid polymeric coating is also contemplated.
- Any suitable electrically conductive substance can be used in the present beads. In a specific embodiment, the electrically conductive substance used in the present beads is gold, silver or other metal compositions, carbon material or a conductive polymer, e.g., a polyaniline, a polypyrrole, or a polythiophene. Preferably, the electrically conductive substance allows the bead to exhibit positive dielectrophoresis force. Metal materials or compositions may be incorporated into the beads by, for example, sputtering or evaporating onto the beads. Conductive polymers may be incorporated onto the bead surfaces via chemical binding or polymerization. Carbon can be claded onto the surface of metal oxide to make it conductive.
- Any suitable optical labeling substance can be used in the present beads. In specific embodiments, the optical labeling substance used in the present beads is a fluorescent substance, a scattered-light detectable particle (See e.g., U.S. Pat. No. 6,214,560) and a quantum dot (See e.g., U.S. Pat. No. 6,252,664).
- Any suitable quantum dot can be used in the present beads. In a specific embodiment, the quantum dot used in the present beads comprises a Cd—X core, X being Se, S or Te. Preferably, the quantum dot can be passivated with an inorganic coating shell, e.g., a coating shell comprising Y-Z, Y being Cd or Zn, and Z being S or Se. Also preferably, the quantum dot can comprise a Cd—X core, X being Se, S or Te, a Y-Z shell, Y being Cd or Zn, and Z being S or Se, and the bead can further be overcoated with a trialkylphosphine oxide.
- Any suitable methods can be used to make the CdX core/YZ shell quantum dots water-soluble (See e.g., U.S. Pat. No. 6,252,664). One method to make the CdX core/YZ shell quantum dots water-soluble is to exchange this overcoating layer with a coating which will make the quantum dots water-soluble. For example, a mercaptocarboxylic acid may be used to exchange with the trialkylphosphine oxide coat. Exchange of the coating group is accomplished by treating the water-insoluble quantum dots with a large excess of neat mercaptocarboxylic acid. Alternatively, exchange of the coating group is accomplished by treating the water-insoluble quantum dots with a large excess of mercaptocarboxylic acid in CHCl3 solution (Chan and Nie, Science, 281:2016-2018 (1998)). The thiol group of the new coating molecule forms Cd (or Zn)—S bonds, creating a coating which is not easily displaced in solution. Another method to make the CdX core/YZ shell quantum dots water-soluble is by the formation of a coating of silica around the dots (Bruchez et al., Science, 281:2013-2015 (1998)). An extensively polymerized polysilane shell imparts water solubility to nanocrystalline materials, as well as allowing further chemical modifications of the silica surface. Generally, these “water-soluble” quantum dots require further functionalization to make them sufficiently stable in an aqueous solution for practical use in a fluorescence detection system (See e.g., U.S. Pat. No. 6,114,038), particularly when exposed to air (oxygen) and/or light. Water-soluble functionalized nanocrystals are extremely sensitive in terms of detection, because of their fluorescent properties (e.g., including, but not limited to, high quantum efficiency, resistance to photobleaching, and stability in complex aqueous environments); and comprise a class of semiconductor nanocrystals that may be excited with a single peak wavelength of light resulting in detectable fluorescence emissions of high quantum yield and with discrete fluorescence peaks (e.g., having a narrow spectral band ranging between about 10 nm to about 60 nm).
- The quantum dot used in the present bead can have any suitable size. For example, the quantum dot can have a size ranging from about 1 nm to about 100 nm.
- The bead of the present invention can comprise a single quantum dot. Alternatively, the bead of the present invention can comprise a plurality of quantum dots. Preferably, the bead of the present invention comprises at least two quantum dots that have different sizes and/or different colors. Details of quantum dots and how they can be incorporated into microbeads may be found in the literatures, for example, in the articles by Chan and Nie, Science, 281:2016 (1998) and by Han et al., Nature Biotechnology, 19:631-635 (2001).
- The bead of the present invention can comprise a single optical labeling substance. Alternatively, the bead of the present invention can comprise a plurality of optical labeling substances. Preferably, the bead of the present invention comprises at least two different types of optical labeling substances.
- In a specific embodiment, the bead of the present invention comprises a magnetizable substance and an electrically conductive substance. In another specific embodiment, the bead of the present invention comprises a magnetizable substance and an optical labeling substance.
- The bead of the present invention can further comprise a binding partner that is capable of binding to a moiety to be isolated, manipulated or detected. Preferably, the binding partner specifically binds to the moiety. Any suitable binding partner can be used in the present bead, e.g., a cell, a cellular organelle, a virus, a molecule and an aggregate or complex thereof.
- In a preferred embodiment, the bead of the present invention comprises a magnetizable substance, an electrically conductive substance and an optical labeling substance. The magnetizable substance in this preferred embodiment may be selected from groups of ferrimagnetic, ferromagnetic and paramagnetic substances. In another preferred embodiment, the bead of the present invention comprises a ferrimagentic, ferromagnetic or paramagnetic substance, an electrically conductive substance and a quantum dot. This preferred bead can further comprise a binding partner that is capable of binding to a moiety to be isolated, manipulated or detected. Preferably, the binding partner specifically binds to the moiety. Any suitable binding partner can be used in the present bead, e.g., a cell, a cellular organelle, a virus, a molecule and an aggregate or complex thereof. In still another preferred embodiment, the bead of the present invention comprises a magnetic or paramagnetic core coated with an electrically conductive substance, a quantum dot and binding partner that is capable of binding to a moiety to be isolated, manipulated or detected.
- The bead of the present invention can have any suitable size. In a specific embodiment, bead of the present invention has a size ranging from about 0.02 μm to about 500 μm. Preferably, bead of the present invention has a size ranging from 0.1 μm to about 100 μm. Still preferably, bead of the present invention has a size ranging from 0.3 μm to about 20 μm.
- The bead of the present invention can have any suitable shape. In a specific embodiment, the bead of the present invention has a spherical, a elliptical-sphere, cubical or other regular or irregular shape.
- In another aspect, the present invention is directed to a method for isolating a moiety, which method comprises: a) providing a bead comprising 1) a magnetizable substance, 2) an optical labeling substance, and preferably 3) a binding partner that is capable of binding to a moiety to be isolated; b) contacting a sample containing or suspected of containing of said moiety with said bead provided in step a) under conditions allowing binding between said moiety and said bead or binding partner; and c) recovering said bead from said sample, whereby the identity of said isolated moiety is assessed by analyzing said optical labeling substance comprised in said bead. Preferably, the binding partner specifically binds to the moiety. The present method can further comprise a step of assessing or confirming whether a moiety has been isolated and bound to the bead by analyzing a property of the moiety. For example, if the moiety to be isolated is a biological cell, the step of assessing or confirming whether a cell has been isolated and bound to the bead may comprise examining the presence of a cell on the bead with various methods, for example, optical microscopy analysis. In another example, the moiety to be isolated is a molecule that may be labeled, for example, by a fluorescent molecule. In this example, the step of assessing or confirming whether a molecule has been isolated and bound to the bead may comprise examining the presence of certain fluorescent signals on the bead with various methods, for example, by fluorescent microscopy analysis.
- The above isolation methods may further comprise a step of recovering said isolated moiety from said bead by certain cleavage methods. For example, depending on the nature of binding between said moiety and said beads or binding partner, optical or chemical, or thermal cleavage methods may be utilized.
- Any suitable optical labeling substance can be used in the present method. In a specific embodiment, the optical labeling substance used in the present method is a fluorescent substance, a scattered-light detectable particle (See e.g., U.S. Pat. No. 6,214,560) and a quantum dot (See e.g., U.S. Pat. No. 6,252,664). Preferably, the optical labeling substance used in the present method is a quantum dot. Any suitable quantum dot, including the quantum dot described in the above Section B can be used.
- Any moiety can be isolated by the present method. For example, the moiety to be isolated can be a cell, a cellular organelle, a virus, a molecule and an aggregate or complex there of.
- The bead can be recovered from the sample by any suitable methods, e.g., by a magnetic field/force using, for example, a permanent magnet or an electromagnetic chip centrifugation, dielectrophoresis collection on a dielectrophoresis chip or filtration.
- Although the present method can be used to isolate a single type of moiety, it is preferably to be used in high throughput analysis and preferably a plurality of types of moieties are isolated by using a plurality of types of beads, each type of the beads is capable of binding to a member of said plurality of types of the moieties or each type of the beads contains a binding partner that is capable of binding to a member of said plurality of types of the moieties.
- A moiety in any suitable sample can be isolated. Preferably, the moiety to be isolated is contained in a fluid sample.
- The isolation can be conducted in any suitable apparatus or device. For example, the isolation can be conducted in a liquid container such as a beaker, a flask, a cylinder, a test tube, a microcentrifuge tube, a centrifugation tube, a culture dish, a multiwell plate and a filter device or membrane. In these non-chip formats of moiety isolation, magnetic field (for magnetic force-based isolation) and/or electric field (for electric force-based isolation) is generated in the liquid container via various means. For example, permanent magnet may be applied to the liquid container to induce magnetic field. Electrodes such as conductive wires may be introduced into the liquid container to generate electric fields. Alternatively, the isolation can be conducted in a chip format.
- The method can further comprise a step of recovering said isolated moiety from said bead, by any suitable methods, e.g., by optical, chemical or other cleavage methods.
- In still another aspect, the present invention is directed to a method for manipulating a moiety, which method comprises: a) providing a bead comprising 1) a magnetizable substance, 2) an electrically conductive substance, and preferably 3) a binding partner that is capable of binding to a moiety to be manipulated; b) coupling said moiety to said bead provided in step a) via binding between said moiety and said bead and/or said binding partner to form a moiety-bead complex; and c) manipulating said moiety-bead complex with a dielectrophoresis, a traveling-wave dielectrophoresis and/or a magnetic force, in a chip or non-chip format, thereby said moiety is manipulated. Preferably, the binding partner specifically binds to the moiety.
- When conducted in a non-chip format, the manipulation can be conducted in any suitable apparatus or device. For example, the manipulation can be conducted in a liquid container such as a beaker, a flask, a cylinder, a test tube, a microcentrifuge tube, a centrifugation tube, a culture dish, a multiwell plate and a filter device or membrane. In these non-chip formats of moiety manipulation, magnetic field (for magnetic force-based manipulation) and/or electric field (for electric force-based manipulation) is generated in the liquid container via various means. For example, permanent magnet may be applied to the liquid container to induce magnetic field. Electrodes such as conductive wires may be introduced into the liquid container to generate electric fields.
- When conducted in a chip format, the manipulation is effected through a combination of a structure that is external to the chip and a structure that is built-in in the chip. For example, chips and structures internal and external to the chips that are disclosed in the co-pending U.S. patent application Ser. No. 09/636,104, filed Aug. 10, 2000 and 09/679,024, filed Oct. 4, 2000, the disclosures of which are incorporated by reference in its entirety, can be used in the present method. For example, the methods can be used on silicon, silicon dioxide, silicon nitride, plastic, glass, ceramic, photoresist or rubber chips. In addition, the methods can be used on a chemchip, i.e., on which chemical reactions are carried out, a biochip, i.e., on which biological reactions are carried out, or a combination of a biochemchip.
- The physical forces used in the present methods are effected through a combination of the structure that is external to the chip and the structure that is built-in in the chip. The external structures are energy sources that can be connected to the built-in structures for energizing the built-in structures to generate a physical force such as dielectrophoresis force, magnetic force, acoustic force, electrostatic force, mechanical force or optical radiation force. The built-in structures comprise a single unit or a plurality of units. Each unit is, when energized and in combination with the external structure, capable of effecting the physical force on the moiety-bead complex. In the case of a plurality of units, the built-in structure may further comprise the means for selectively energizing any one of the plurality of units.
- In one example, when magnetic force is used to manipulate a complex of a moiety (e.g., DNA molecules) and a bead comprising its binding partner, the electromagnetic chip disclosed in the co-pending U.S. Pat. No. 6,355,491, which is incorporated by reference in its entirety, can be used in the methods. Typically, such electromagnetic chips with individually addressable micro-electromagnetic units comprise: a substrate; a plurality of micro-electromagnetic units on the substrate, each unit capable of inducing a magnetic field upon application electric current; a means for selectively energizing any one of a plurality of units to induce a magnetic field therein. Preferably, the electromagnetic chips further comprise a functional layer coated on the surface of the chips for immobilizing certain types of molecules. In this example of magnetic manipulation of moiety-binding partner-bead complexes, microelectromagnetic units are the built-in structures internal to the chip and the electrical current source that is connected to the microelectromagnetic units is the structures external to the chip. When the electric current from the external current source is applied to the microelectromagnetic units, magnetic fields will be generated in the regions around the microelectromagnetic units and magnetic forces will be produced on magnetic particles that are present in the region around the microelectromagnetic units. Typically, for the case of the manipulation force being magnetic force, the built-in structures are electromagnetic units that are incorporated on the chip and the external structures are the electrical signal sources (e.g., current sources). When the appropriately designed and fabricated electromagnetic units are energized by the electrical signal sources, magnetic fields are generated in the regions around the chip. When the bead-binding partner-moiety complexes are subjected to such magnetic fields, magnetic forces are produced on them, and such forces are dependent on the magnetic field distribution, the magnetic properties of the beads or the binding partner or bead-binding partner-moiety complexes and the magnetic properties of the medium that surrounds the beads or bead-binding partner-moiety complexes.
- In another example, when dielectrophoresis force and traveling-wave dielectrophoresis force are used to manipulate a complex of a moiety (e.g., protein molecules) and its binding partner coupled onto a bead (e.g., antibodies can be coupled onto beads' surfaces, allowing for binding of protein molecules), a spiral electrode array on a glass chip, together with a phase-quardrature AC electrical signal source, can be used in the method (see “Dielectrophoretic manipulation of cells using spiral electrodes by Wang, X-B. et al., in Biophys. J. Volume 72, pages 1887-1899, 1997”). In this example of dielectrophoretic manipulation of moiety-binding partner-bead complexes, a spiral electrode array is a built-in structure internal to the chip and the AC electrical signal source that is connected to the spiral electrodes is the structure external to the chip. When AC electrical signals of appropriate phases from the external signal source are applied to the spiral electrode array, electrical fields will be generated in the regions around the spiral electrode array. Dielectrophoretic and traveling-wave dielectrophoretic forces will be produced on moiety-binding partner-bead complexes that are present in the region around the spiral electrode array. Typically, for the case of the manipulation force being dielectrophoresis and/or dielectrophoresis force, the built-in structures are the electrode elements and electrode arrays that are incorporated on a chip and the external structures are electrical signal sources. When the appropriately designed electrode elements and electrode arrays are energized by the electrical signal sources, non-uniform electrical fields are generated in the regions around the chip. When the bead or bead-binding partner-moiety complexes are subjected to such non-uniform electrical fields, dielectrophoresis and/or traveling-wave dielectrophoresis forces acting on the beads or bead-binding partner-moiety complexes are produced. Such forces are dependent on the interaction between the electrical field distributions and field induced dielectric polarization in beads, bead-moiety complex, or bead-binding partner-moiety complex, etc.
- Any moiety including the moieties disclosed in the above Section B can be manipulated by the present method. For example, the moiety to be manipulated can be a cell, a cellular organelle, a virus, a molecule and an aggregate or complex thereof.
- The present method can be used for any type of suitable manipulation. Exemplary manipulations include transportation, focusing, enrichment, concentration, aggregation, trapping, repulsion, levitation, separation, fractionation, isolation and linear or other directed motion of the moiety.
- In a preferred embodiment, the moiety is not directly manipulatable by a dielectrophoresis, a traveling-wave dielectrophoresis and/or a magnetic force. In another preferred embodiment, neither the moiety nor the binding partner is directly manipulatable by a dielectrophoresis, a traveling-wave dielectrophoresis and/or a magnetic force.
- Although the present method can be used to manipulate a single type of moiety, it is preferably to be used in a high throughput analysis and preferably a plurality types of moieties is manipulated. Preferably, the plurality types of moieties is manipulated via a plurality types of corresponding beads. The plurality types of moieties can be manipulated sequentially or simultaneously.
- The present method can further comprise a step of recovering said manipulated moiety from said bead and/or said chip.
- In a preferred embodiment, the bead used in the present method comprises an optical labeling substance and the method further comprises a step of assessing the identity of the manipulated moiety by analyzing the optical labeling substance comprised in the bead. In specific embodiments, the optical labeling substance used in the present beads is a fluorescent substance, a scattered-light detectable particle (See e.g., U.S. Pat. No. 6,214,560) and a quantum dot (See e.g., U.S. Pat. No. 6,252,664). More preferably, the optical labeling substance is a quantum dot.
- In another preferred embodiment, the bead used in the present method comprises an optical labeling substance and the method further comprises a step of assessing the identity of the manipulated moiety by analyzing the optical labeling substance comprised in the bead. More preferably, the optical labeling substance is a quantum dot.
- In yet another aspect, the present invention is directed to a kit for manipulating a moiety, which kit comprises: a) a bead comprising 1) a magnetizable substance, 2) an electrically conductive substance or an optical labeling substance, and preferably 3) a binding partner that is capable of binding, or capable of specifically binding, to a moiety to be manipulated; and b) a means for generating a physical force for manipulating said moiety-bead complex. Preferably, the bead comprises an optical labeling substance, e.g., a quantum dot.
- In the above-mentioned kit, the means for generating a physical force for manipulating said moiety-bead complex refers to any substance, structure or a combination thereof that is capable of generating a desirable physical force for manipulating moiety-bead complex that is placed in a fluid or otherwise existed in a fluid. The fluid containing the moiety-bead complex is introduced or placed or is generally contained in a fluid container (e.g. a liquid container such as a beaker, an eppendorf tube, any plastic or glass tube). For example, when the physical force for manipulation is a magnetic force, a permanent magnet in suitable form may be part of the kit for generating magnetic field in a liquid container. In another example, when the physical force for manipulation is an electrical force, electrodes in suitable configuration may be part of the kits for generating electric field in a liquid container.
- In yet another aspect, the present invention is directed to a kit for manipulating a moiety, which kit comprises: a) a bead comprising 1) a magnetizable substance, 2) an electrically conductive substance or an optical labeling substance, and preferably 3) a binding partner that is capable of binding, or capable of specifically binding, to a moiety to be manipulated; and b) a chip on which a moiety-bead complex can be manipulated. Preferably, the kit further comprises an instruction(s) for coupling the moiety to the bead and/or for manipulating the moiety-bead complex on the chip. Also preferably, the chip provided in the kit is in the form of a chamber that comprises a chip and that is capable of containing fluidic sample.
- A chamber can be of any size or dimensions, and preferably can contain a fluid sample of between 0.001 microliter and 50 milliliters, more preferably between about 1 microliters and about 20 milliliters, and most preferably between about 10 microliters and about 10 milliliters. Preferably, a chamber comprises a chip. A chamber can comprise any suitable material, for example, silicon, glass, metal, ceramics, polymers, plastics, etc. and can be of a rigid or flexible material. Preferred materials for a chamber include materials that do not interfere with dielectrophoresis of moieties in a sample, for example, materials that do not bind charged or polarized molecules, such as silicon, certain plastics and polymers, for example, acrylic, or glass.
- Chambers used in the methods of the present invention or comprised in the kits of the present invention can comprise chips, where chips are solid supports on which one or more separations, assays, or capturing procedures can be performed. A chip can comprise one or more metals, ceramics, polymers, copolymers, plastics, rubber, silicon, gels, or glass. A chip can comprise one or more flexible materials, and can comprise one or more semi-solid layers. A chip can comprise porous or non-porous materials. The micro structures or micro-scale structures such as, channels and wells and electrode elements and electromagnetic units are incorporated into or fabricated on the substrate for facilitating physical, biophysical, biological, biochemical, chemical reactions or processes on the chip. A chip can have a small thickness in one dimension and can have large sizes in the other two dimensions. The size of the major surfaces of a chip can vary considerably and have an area from about 1 mm2 to about 0.25 m2. Preferably, the size of the major surface of the chips useable in the present methods is from about 4 mm2 to about 25 cm2. The shape of the chips useable in the present methods can be regular shapes such as square, rectangular, circular, or oval, or can be irregularly shaped. Chip surfaces may be flat or may not be flat. Chips useable in the methods of the present invention can have one or more wells or one or more channels that can be etched or bored into a chip or built onto the surface of a chip.
- For chambers with large volumes (up to 50 mL), chips of special geometries and configurations may have been used. The chips may be fabricated on flexible materials so that the chips can be folded to form tube like chambers. Multiple chips may be configured into a same chamber. The electrode elements may have to have certain configurations so that effective dielectrophoretic forces may be generated in the region of the interest in the chamber.
- Preferably, in embodiments where the chamber comprises electrodes, they will be incorporated onto or within the chip, but this is not a requirement of the present invention. Electrodes on a chip can be of any shape, such as rectangular, castellated, triangular, circular, and the like. Electrodes can be arranged in various patterns, for example, spiral, parallel, interdigitated, polynomial, etc. Electrode arrays can be fabricated on a chip by microfabrication or micromachining methods known in the art, for example, electroplating, sputtering, photolithography or etching. Examples of a chip comprising electrodes include, but are not limited to, the dielectrophoresis electrode array on a glass substrate (e.g., Dielectrophoretic Manipulation of Particles by Wang et al., in IEEE Transaction on Industry Applications, Vol. 33, No. 3, May/June, 1997, pages 660-669), individually addressable electrode array on a microfabricated bioelectronic chip (e.g., Preparation and Hybridization Analysis of DNA/RNA from E. coli on Microfabricated Bioelectronic Chips by Cheng et al., Nature Biotechnology, Vol. 16, 1998, pages 541-546), and the capillary electrophoresis chip (e.g., Combination of Sample-Preconcentration and Capillary Electrophoresis On-Chip by Lichtenberg, et al., in Micro Total Analysis Systems 2000 edited by A. van den Berg et al., pages 307-310).
- A chamber that comprises a chip useable in the methods of the present invention can comprise one or more ports, or openings in the walls of a chamber. Preferably, a port is of a shape and size that allows a conduit to engage a port for the dispensing of a sample into the chamber. A conduit can be any tube that allows for the entry of a fluid sample into the chamber. Preferred conduits for use in the present invention include tubing, for example, rubber or polymeric tubing, e.g., tygon or teflon or PEEK tubing. Alternatively, a port can provide an opening in a wall of a chamber for the dispensing of sample into the chamber by, for example, pipetting or injection.
- Conduits that engage one or more ports of the sample can introduce a sample by any means, including a pump (for example, a peristaltic pump or infusion pump), pressure source syringe, or gravity feed. One or more reagents, buffers, or solutions, including, but not limited to, a solution that selectively modifies the dielelectric properties of one or more moieties in a sample, can be added to the chamber before, after, or concurrently with the addition of a sample to a chamber. It is also within the scope of the invention to mix the sample with a reagent, buffer, or solution, before adding the sample to the chamber. Such mixing can optionally occur in one or more conduits leading to a chamber, or in one or more reservoirs connected to conduits.
- In yet another aspect, the present invention is directed to a method for detecting a moiety, which method comprises: a) providing a bead comprising 1) a magnetizable substance, 2) an optical labeling substance, and preferably 3) a binding partner that is capable of binding to a moiety to be detected; b) contacting a sample containing or suspected of containing of said moiety with said bead provided in step a) under conditions allowing binding between said moiety and said bead and/or said binding partner; and c) detecting binding between said moiety and said bead and/or said binding partner, whereby the presence or amount of said moiety is assessed by analysis of binding between said moiety and said bead and/or said binding partner and the identity of said moiety is assessed by analyzing the optical labeling substance comprised in the bead. Preferably, the binding partner specifically binds to the moiety.
- Any suitable optical labeling substance, including the ones described in the above Section B, can used in the present method. In specific embodiments, the optical labeling substance used in the present beads is a fluorescent substance, a scattered-light detectable particle (See e.g., U.S. Pat. No. 6,214,560) and a quantum dot (See e.g., U.S. Pat. No. 6,252,664). Any suitable quantum dot, including the ones described in the above Section B, can used in the present method.
- Any moiety including the moieties disclosed in the above Section B can be detected by the present method. For example, the moiety to be detected can be a cell, a cellular organelle, a virus, a molecule and/or an aggregate or complex thereof.
- Although the present method can be used to detect a single type of moiety, it is preferably to be used in a high throughput analysis and preferably a plurality types of moieties is detected by using a plurality types of different types of beads, each type of the beads contains a binding partner that is capable of binding to a member of the plurality types of the moieties. The plurality types of moieties can be detected sequentially or simultaneously. To be used in the assay, the beads' optical encoding can correspond to the binding partner (and so moiety). Thus, each type of the beads has a unique optical encoding property and contains a specific binding partner that is capable of binding to a member of the plurality types of the moieties. Alternatively, the beads' dielectric property can correspond to the binding partner. Thus, each type of the beads has a unique dielectric property and can be manipulated or processed by an electric field of a specific condition (e.g., the bead exhibiting positive dielectrophoresis at a specific frequency). Each type of these beads can contain specific binding partners that is capable of binding to a member of the plurality types of the moieties.
- The detection can be conducted in any suitable apparatus or device. For example, the detection can be conducted in a liquid container such as a beaker, a flask, a cylinder, a test tube, an enpindorf tube, a centrifugation tube, a culture dish, a multiwell plate and a filter device or membrane. Alternatively, the bead is placed or immobilized on a surface and the detection can be conducted in a chip format. Preferably, a plurality of bead is placed or immobilized on a surface and the detection can be conducted in a chip format.
- A moiety in any suitable sample can be detected. Preferably, the moiety to be detected is contained in a fluid sample.
- The binding between the moiety and the bead and/or binding partner can be detected by any suitable methods, devices or instruments. For example, the moiety can be labeled, e.g., with fluorescent, radioactive, enzymatic or other chemical labels. The moiety can be labeled before its binding with the bead or binding partner or after its binding with the bead or binding partner. In another example, the absorbance or other optical properties of the moiety can be used in detecting its binding with the bead or binding partner. In still another example, the molecular weight of the moiety can be used in detecting its binding with the bead or binding partner, e.g., by mass spectrometry such as MALDI-TOF. The detecting methods based on the labeling of the moiety can be conducted in a direct labeling method, i.e., the moiety to be detected is labeled, or in a competitive assay format, i.e., a labeled moiety or moiety analog is added to the sample containing a moiety to be detected. In yet another example, the moiety is cleaved off or recovered from, or isolated or purified from the moiety-bead (or binding partner) complex before the detection. Any suitable methods, e.g., HPLC, can be used to isolate or purify the moiety.
- In yet another aspect, the present invention is directed to an array for detecting, isolating or manipulating moieties, which array comprises a plurality of beads of the present invention positioned, deposited or immobilized on a surface, e.g., a chip, each of said beads comprising 1) a magnetizable substance, 2) an electrically conductive substance or an optical labeling substance, and preferably 3) a binding partner that is capable of binding, or capable of specifically binding, to a moiety to be detected, isolated or manipulated. The beads can be positioned, deposited or immobilized on the surface e.g., a chip surface, using any suitable methods such as being positioned on a surface by a magnetic force.
- The present methods can be used for analyzing, isolating, manipulating or detecting any types of moieties when the moieties are involved in certain processes, such as physical, chemical, biological, biophysical or biochemical processes, etc., in a chip format or non-chip format. Moieties can be cells, cellular organelles, viruses, molecules or an aggregate or complex thereof. Moieties can be pure substances or can exist in a mixture of substances wherein the target moiety is only one of the substances in the mixture. For example, cancer cells in the blood from leukemia patients, cancer cells in the solid tissues from patients with solid tumors and fetal cells in maternal blood from pregnant women can be the moieties to be isolated, manipulated or detected. Similarly, various blood cells such as red and white blood cells in the blood can be the moieties to be isolated, manipulated or detected. DNA molecules, mRNA molecules, certain types of protein molecules, or all protein molecules from a cell lysate can be moieties to be isolated, manipulated or detected.
- Non-limiting examples of cells include animal cells, plant cells, fungi, bacteria, recombinant cells or cultured cells. Animal, plant cells, fungus, bacterium cells to be isolated, manipulated or detected can be derived from any genus or subgenus of the Animalia, Plantae, fungus or bacterium kingdom. Cells derived from any genus or subgenus of ciliates, cellular slime molds, flagellates and microsporidia can also be isolated, manipulated or detected. Cells derived from birds such as chickens, vertebrates such as fish and mammals such as mice, rats, rabbits, cats, dogs, pigs, cows, ox, sheep, goats, horses, monkeys and other non-human primates, and humans can be isolated, manipulated or detected by the present methods.
- For animal cells, cells derived from a particular tissue or organ can be isolated, manipulated or detected. For example, connective, epithelium, muscle or nerve tissue cells can be isolated, manipulated or detected. Similarly, cells derived from an accessory organ of the eye, annulospiral organ, auditory organ, Chievitz organ, circumventricular organ, Corti organ, critical organ, enamel organ, end organ, external female genital organ, external male genital organ, floating organ, flower-spray organ of Ruffini, genital organ, Golgi tendon organ, gustatory organ, organ of hearing, internal female genital organ, internal male genital organ, intromittent organ, Jacobson organ, neurohemal organ, neurotendinous organ, olfactory organ, otolithic organ, ptotic organ, organ of Rosenmüller, sense organ, organ of smell, spiral organ, subcommissural organ, subformical organ, supernumerary organ, tactile organ, target organ, organ of taste, organ of touch, urinary organ, vascular organ of lamina terminalis, vestibular organ, vestibulocochlear organ, vestigial organ, organ of vision, visual organ, vomeronasal organ, wandering organ, Weber organ and organ of Zuckerkandl can be isolated, manipulated or detected. Preferably, cells derived from an internal animal organ such as brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, gland, internal blood vessels, etc can be isolated, manipulated or detected. Further, cells derived from any plants, fungi such as yeasts, bacteria such as eubacteria or archaebacteria can be isolated, manipulated or detected. Recombinant cells derived from any eucaryotic or prokaryotic sources such as animal, plant, fungus or bacterium cells can also be isolated, manipulated or detected. Cells from various types of body fluid such as blood, urine, saliva, bone marrow, sperm or other ascitic fluids, and subfractions thereof, e.g., serum or plasma, can also be isolated, manipulated or detected.
- Isolatable, manipulatable or detectable cellular organelles include nucleus, mitochondria, chloroplasts, ribosomes, ERs, Golgi apparatuses, lysosomes, proteasomes, secretory vesicles, vacuoles or microsomes. Isolatable, manipulatable or detectable viruses include intact viruses or any viral structures, e.g., viral particles, in the virus life cycle that can be derived from viruses such as Class I viruses, Class II viruses, Class III viruses, Class IV viruses, Class V viruses or Class VI viruses.
- Isolatable, manipulatable or detectable molecules can be inorganic molecules such as ions, organic molecules or a complex thereof. Non-limiting examples of ions include sodium, potassium, magnesium, calcium, chlorine, iron, copper, zinc, manganese, cobalt, iodine, molybdenum, vanadium, nickel, chromium, fluorine, silicon, tin, boron or arsenic ions. Non-limiting examples of organic molecules include amino acids, peptides, proteins, nucleosides, nucleotides, oligonucleotides, nucleic acids, vitamins, monosaccharides, oligosaccharides, carbohydrates, lipids or a complex thereof.
- Any amino acids can be isolated, manipulated or detected by the present methods. For example, a D- and a L-amino-acid can be isolated, manipulated or detected. In addition, any building blocks of naturally occurring peptides and proteins including Ala (A), Arg (R), Asn (N), Asp (D), Cys (C), Gln (Q), Glu (E), Gly (G), His (H), Ile (I), Leu (L), Lys (K), Met (M), Phe (F), Pro (P) Ser (S), Thr (T), Trp (W), Tyr (Y) and Val (V) can be isolated, manipulated or detected.
- Any proteins or peptides can be isolated, manipulated or detected by the present methods. For example, membrane proteins such as receptor proteins on cell membranes, enzymes, transport proteins such as ion channels and pumps, nutrient or storage proteins, contractile or motile proteins such as actins and myosins, structural proteins, defense protein or regulatory proteins such as antibodies, hormones and growth factors can be isolated, manipulated or detected. Proteineous or peptidic antigens can also be isolated, manipulated or detected.
- Any nucleic acids, including single-, double and triple-stranded nucleic acids, can be isolated, manipulated or detected by the present methods. Examples of such nucleic acids include DNA, such as A-, B- or Z-form DNA, and RNA such as mRNA, tRNA and rRNA.
- Any nucleosides can be isolated, manipulated or detected by the present methods. Examples of such nucleo sides include adenosine, guano sine, cytidine, thymidine and uridine. Any nucleotides can be isolated, manipulated or detected by the present methods. Examples of such nucleotides include AMP, GMP, CMP, UMP, ADP, GDP, CDP, UDP, ATP, GTP, CTP, UTP, dAMP, dGMP, dCMP, dTMP, dADP, dGDP, dCDP, dTDP, dATP, dGTP, dCTP and dTTP.
- Any vitamins can be isolated, manipulated or detected by the present methods. For example, water-soluble vitamins such as thiamine, riboflavin, nicotinic acid, pantothenic acid, pyridoxine, biotin, folate, vitamin B12 and ascorbic acid can be isolated, manipulated or detected. Similarly, fat-soluble vitamins such as vitamin A, vitamin D, vitamin E, and vitamin K can be isolated, manipulated or detected.
- Any monosaccharides, whether D- or L-monosaccharides and whether aldoses or ketoses, can be isolated, manipulated or detected by the present methods. Examples of monosaccharides include triose such as glyceraldehyde, tetroses such as erythrose and threose, pentoses such as ribose, arabinose, xylose, lyxose and ribulose, hexoses such as allose, altrose, glucose, mannose, gulose, idose, galactose, talose and fructose and heptose such as sedoheptulose.
- Any lipids can be isolated, manipulated or detected by the present methods. Examples of lipids include triacylglycerols such as tristearin, tripalmitin and triolein, waxes, phosphoglycerides such as phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphatidylinositol and cardiolipin, sphingolipids such as sphingomyelin, cerebrosides and gangliosides, sterols such as cholesterol and stigmasterol and sterol fatty acid esters. The fatty acids can be saturated fatty acids such as lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid and lignoceric acid, or can be unsaturated fatty acids such as palmitoleic acid, oleic acid, linoleic acid, linolenic acid and arachidonic acid.
- In yet another aspect, the present invention is directed to a method for synthesizing a library, which method comprises: a) providing a plurality of beads, each of said beads comprises a magnetizable substance and an optical labeling substance that corresponds to an entity to be synthesized on said bead; and b) synthesizing said entities on said beads, wherein said beads are sorted after each synthesis cycle according to said optical labeling substances and are directed to appropriate next synthesis cycle, whereby a library is synthesized, wherein each of said beads contains an entity that corresponds to an optical labeling substance on said bead and the sum of said beads collectively contains a plurality of entities that is predetermined before the library synthesis. In this method of library synthesis, it is possible to have multiple individual beads to have same optical encoding substance. These beads having same optical encoding substance will go through same synthesis cycle and same entity will be synthesized on these beads. Furthermore, if desired, it is even possible for the beads having different encoding substance to go through same synthesis cycle and to have same synthesized entity on them.
- Any suitable magnetizable substance, including the ones described in the above Section B, can be used in the present method. Preferably, paramagnetic substance comprising a metal oxide particle is used in the present method.
- Any suitable optical labeling substance, including the ones described in the above Section B, can be used in the present method. In specific embodiments, the optical labeling substance used in the present beads is a fluorescent substance, a scattered-light detectable particle (See e.g., U.S. Pat. No. 6,214,560) and a quantum dot (See e.g., U.S. Pat. No. 6,252,664). Preferably, the optical labeling substance used in the present method is a quantum dot. Any suitable quantum dot, including the ones described in the above Section B, can be used in the present method.
- The bead used in the present method can further comprise an element that facilitates and/or enables manipulation of the bead and/or a moiety/bead complex (See e.g., U.S. Pat. No. 7,081,192; co-pending U.S. patent application Ser. Nos. 09/679,024, filed Oct. 4, 2000; and Ser. No. 09/924,428, filed Aug. 7, 2001, published as U.S. Patent Application No. 20020137059A1). Any suitable element can be used. For example, the element can be a cell, a cellular organelle, a virus, a microparticle, an aggregate or complex of molecules and an aggregate or complex thereof. The element can facilitate and/or enable manipulation of the bead and/or a moiety/bead complex by any suitable physical force such as a dielectrophoresis, a traveling-wave dielectrophoresis, a magnetic, an acoustic, an electrostatic, a mechanical, an optical radiation and a thermal convection force. For example, the element can be a conductive or insulating material for manipulation by a dielectrophoresis force, a material with high or low acoustic impedance for manipulation by a acoustic force or a charged material for manipulation by an electrostatic force.
- Although the bead used in the present method can comprise a single element, it can also be used in a high throughput analysis and can comprise a plurality of the elements, each of the elements facilitates and/or enables manipulation of the bead and/or the moiety/bead complex by a different physical force.
- Any number of suitable entity(ies) can be synthesized on a single bead. For example, a single entity or a plurality of entities can be synthesized on a single bead. Preferably, a single entity is synthesized on a single bead.
- The present method can be used to synthesize any kind of library. For example, the synthesized entities can be peptides, proteins, oligonucleotides, nucleic acids, vitamins, oligosaccharides, carbohydrates, lipids, small molecules, or a complex or combination thereof. Preferably, the synthesized library comprises a defined set of entities that are involved in a biological pathway, belongs to a group of entities with identical or similar biological function, expressed in a stage of cell cycle, expressed in a cell type, expressed in a tissue type, expressed in an organ type, expressed in a developmental stage, entities whose expression and/or activity are altered in a disease or disorder type or stage, or entities whose expression and/or activity are altered by drug or other treatments.
- In a specific embodiment, the synthesized library comprises a defined set of nucleic acid, e.g., DNA or RNA, fragments such as a defined set of nucleic acid fragments that cover an entire genome, e.g., the entire human genome sequence. Preferably, each of the nucleic acid fragments in the synthesized library comprises at least 10, 15, 20, 25, 50, 75, 100, 200, or 500 nucleotides.
- In another specific embodiment, the synthesized library comprises a defined set of protein or peptide fragments such as a defined set of protein or peptide fragments that cover protein or peptide sequences encoded by an entire genome, e.g., the entire human genome sequence. Preferably, each of the protein or peptide fragments in the synthesized library comprises at least 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 300, 400 or 500 amino acid residues.
- In still another specific embodiment, a library that is synthesized according to the above-described method is provided.
- In yet another specific embodiment, a method for generating an antibody library is provided, which method comprises: a) contacting a library synthesized by the above-described method with a plurality of antibodies; and b) selecting and/or recovering the antibodies that specifically bind to the entities of the library synthesized according to the above-described method. Any suitable antibodies can be used in the present method. For example, plurality of antibodies used in the present method is a phage display library (See U.S. Pat. Nos. 6,127,132 and 6,174,708).
- In yet another aspect, the present invention is directed to a method for synthesizing a library, which method comprises: a) providing a plurality of beads, each of said beads comprising a magnetizable substance, an electrically conductive substance and a unique optical labeling substance; and b) synthesizing an entity on said beads, wherein said beads are identified after each synthesis cycle according to said unique optical labeling substances, whereby a library is synthesized, wherein each of said beads contains an entity that can be identified according to said unique optical labeling substance on each of said beads. A library that is synthesized according to the above-described method is provided. In this method of library synthesis, no two beads would have same optical labeling substance. The synthesis cycle that each bead goes through during library synthesis has been identified and recorded based on the unique optical labeling substance on each bead. Thus, the entity on each bead can be identified.
- Lab-on-a-chip is a concept that revolutionizes the analytical process, featuring miniaturization, integration, and automation. Active chips, such as AVIVA Biosciences' multiple force chips, make the integration of multiple tasks, such as sample preparation, reaction, and detection possible. These active chips can utilize numerous beads as molecular carriers in the analytical process or as additional means to process cells or other biological materials. The beads can be designed to be responsive to the forces generated by the chips.
- Magnetic force has been widely used for separation and analysis with magnetic beads. Magnetic beads are generally prepared by precipitation of FeCl3 and FeCl2 in basic solution such as NaOH or NH4OH. The formed Fe3O4 particle is in the size range of about 10 nm to about 5 micrometer. These particles are coated with a layer of polymer on their surfaces, e.g., dextran. The coated polymer is further activated to bind other molecules. These particles can also be mixed with organic monomers (e.g. styrene) and initiators to formed larger-size particles after the polymerization of the monomer. In this way, Fe3O4 particles are encapsulated in the organic polymer beads, e.g., polystyrene beads. The formed larger particles can be further coated and modified on the surface to bind other molecules. Modified magnetic particles can be used to bind interested moieties and conveniently separate them from sample matrix using a magnet. This method has been used for the separation of cells, DNA, and proteins.
- Carbon particles are electrically conductive, and they have been shown to be responsive to dielectrophoretic forces and exhibit both positive and negative dielectrophoresis effects under appropriate electric field conditions. Also, the density of carbon particles is quite low, thereby making it easier to be manipulated on a flat surface. Carbon particles can be modified by oxidation and further chemical and biochemical reactions.
- Quantum dots have attracted a lot of attention recently for their use as fluorescence sensing of biomolecules. Quantum dots of different sizes fluoresce at different wavelengths. Therefore, beads containing various sized quantum dots can be used to encode the beads. Bead encoding allows high throughput analysis of a large number of molecules, such as DNA and proteins. Details of quantum dots and how they can be incorporated into microbeads may be found in the literatures, for example, in the articles by Chan and Nie, Science, 281:2016 (1998) and by Han et al., Nature Biotechnology, 19:631-635 (2001).
- In a preferred embodiment, composite beads comprising magnetic particles (Fe3O4), carbon particles, and quantum dots are prepared. The composite beads are further modified for the conjugation of biomolecules and their use for high throughput analyses are illustrated.
- First, nanometer size (10 to 100 nm) magnetic particles are prepared by reaction of FeCl3 and FeCl2 with NaOH. These particles are added to the polymerization mixture of urea and formaldehyde solution at pH of about 2.0. As a result, spherical beads with about 5 micrometer size are obtained. Second, carbon particles, polyaniline, quantum dots, and above magnetic beads are added to a new urea-formaldehyde polymerization mixture at pH of about 2.0. Uniform spherical composite beads with the size of about 6 micrometer are obtained. Third, these new beads are coated with a crosslinked layer of functional group containing polymer, and these functional groups are useful for conjugating special molecules for further affinity bindings.
- The prepared beads possess multiple properties that can be used for many purposes, but in this specific embodiment, we emphasize their use with the multiple force chips for the separation and analysis of multiple analytes. The exemplary uses include cell separation, e.g., fetal and cancer cells separation, mRNA extraction, DNA extraction, protein extraction and separation, DNA analysis, protein analysis, drug discovery and screening and other bioassays.
- In the first example, multiple property beads with both magnetizable property and electronic conductive properties were produced.
- Fifteen grams FeSO4.7H2O and 60 g Fe2(SO4)3.XH2O were added to 250 mL de-ionized (DI) H2O in a flask, the mixture was heated to 90° C. with stirring, then 220 mL of 6 N NaOH were added to the flask, while keep stirring for 45 minutes. After the mixture was cooled down, the mixture was centrifuged at 2,500 RPM for 15 minutes. The supernatant was removed and the pellet was re-suspended in DI H2O. This centrifuge step was repeated for three times. The pellet was collected in the final wash and was dispersed into 250 mL of 10% perchloric acid. This suspension was shaken and the pH was adjusted to 1.9, then 3.5 g urea and 5.6 g formaldehyde were added, mixed well, let sit. After 30 minutes, the magnetic beads formed were separated from the liquid by a magnet. The beads were washed three times with H2O.
- The magnetic beads prepared above were dispersed in propanol, carbon colloidal was added to the suspension, and the mixture was vortexed for 3 minutes, then the particle was collected with a magnet and the liquid was decanted. The beads were washed with H2O. Finally, the beads were dispersed in DI H2O.
- The microbeads prepared above were tested for their dielectric and magnetic properties. To investigate their dielectric properties, the beads were suspended in an aqueous solution having an electric conductivity of ˜10 μS/cm. The microbeads were then tested for their dielectrophoretic responses.
FIG. 1 shows the random distribution of the microbeads on a microelectrode array. When an electric voltage of 5 V peak-to-peak (pk-to-pk) at frequency of 50 kHz was applied to the electrodes, the microbeads moved towards the interspaces between the neighboring electrodes where the electric field strength was minimum or weak (FIG. 2 ). The microbeads at these frequencies were less polarizable than that of the suspending medium, exhibiting a negative dielectrophoresis. On the other hand, when an electric voltage of 5 V pk-to-pk at frequency of 500 kHz was applied to the electrodes, the microbeads moved towards the electrode edges where the electric field strength was maximum or strongest (FIG. 3 ). The microbeads at these frequencies were more polarizable than that of the suspending medium, exhibiting a positive dielectrophoresis. As shown below, these microbeads can be further manipulated by a magnetic field. Clearly, these microbeads have unique compositions as well as unique properties so that they can be manipulated not only by magnetic field but also by AC electrical field to exhibit both positive dielectrophoresis (DEP) and negative DEP. Typically, commercially available magnetic beads exhibit magnetic field responses with none or small negative dielectrophoresis behavior. - In another test, the microbead suspension was introduced over an electrical magnetic chip on which the multiple electromagnetic coil/units are incorporated.
FIG. 4 shows the random distribution of the microbeads on an electromagnetic chip. In this example, the chip used for beads-testing comprises both magnetic elements as well as microelectrode elements so that the microelectrode elements can be used for dielectrophoretic manipulation of the microbeads while the magnetic elements are used for magnetic manipulation of the microbeads. - When a DC current of 200 mA was applied to an electromagnetic unit on the chip, the microbeads at its neighborhood were attracted towards the poles of the electromagnetic units (
FIG. 5 ). The applied DC current resulted in a magnetic field generated around this unit. The microbeads, because of their magnetic particles incorporated inside, responded to the magnetic field and were caused to move towards the poles of the magnetic units where the magnetic field was strongest. With time during the process of magnetic collection/manipulation, more and more magnetic microbeads were collected at the poles of the electromagnetic units. Such collection of the microbeads at the poles of the electromagnetic units (FIG. 6 ) clearly demonstrates that the microbeads possess magnetic materials or magnetizable materials so that the microbeads can interact with and be manipulated and/or processed by magnetic field. - In this example, microbeads were produced with magnetizable properties.
- A 100 mL three neck flask was equipped with a mechanical stirrer, a condenser, a thermometer and an argon inlet. Ten mL of iron oxide colloid solution (see above) and 10 mL of DI water were added to the flask. The liquid was stirred under argon. Thirty mg of benzoyl peroxide (BPO) were dissolved in 1 mL of mixture of styrene and divinyl benzene (DVB) (9:1, V/V) to form monomer solution. The monomer mixture was added to the colloid solution, stirred at room temperature under argon for 20 minutes, and then stirred under argon atmosphere at 55° C. for 16-20 hours. The reaction mixture was filtered through two layers of cheese cloth, and the filtrate was magnetically decanted (2 minutes magnetic decantation). The magnetic particles were resuspended in DI water and magnetic decantation (1-2 minutes) was performed. The wash step was repeated until the decanted liquid became clear.
- Magnetic particles suspension (containing about 300 mg of particles) was added to a 100 mL flask, and the suspension was diluted with water to 50 mL volume. Thirty mg of sodium dodecyl sulfate (SDS) and 300 mg of potassium persulfate (KPS) were added to the particle suspension, shaken until SDS and KPS were completely dissolved.
- A monomer solution was made by mixing 0.09 mL of styrene, 0.03 mL of DVB, and 0.06 mL of undecylenic acid in 0.6 mL of methanol. The monomer solution was added to the particle suspension, and the flask was sealed with rubber septa. The flask was evacuated with a vacuum pump for 10 minutes, and shaken (250 rps) at 55° C. for 5 hours. The reaction solution was magnetically decanted. The coated magnetic particles were resuspended in DI water and magnetic decantation was performed.
- In this example, streptavidin bonded magnetic microbeads were produced.
- Magnetic beads were dispersed in DI water (40 mL), 0.5 mL of 20% SDS solution was added to above beads solution, shaken with Vortex shaker for 10 seconds, sonicated for 2 min., and liquid was separated from beads using a 50 mL magnetic separator. The beads were dispersed in 2-(N-morpholino)-ethane sulfonic acid (MES) buffer (0.1 M, pH 4.7), and 0.1 g 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and 0.05 g Sulfo-NHS (N-hydroxysuccinimide 3-sulfonic acid) were added to this solution, shaken with Vortex shaker for 10 seconds, and shaken on a plate shaker for 2 hours. The beads were washed with MES buffer. The beads were then dispersed in phosphate-buffered saline (PBS buffer), 0.5 mL of 2,2′-(ethylenedioxy)bis(ethylamine) was added to this solution, vortexed for 10 seconds and shaken on a plate shaker for 2 hours. After that, the beads were washed with PBS buffer. Again, the beads were dispersed in PBS buffer (35 mL), 0.5 mL of glutaric dialdehyde was added to the beads, shaken for 1 hour. The beads were washed with PBS buffer, and dispersed in PBS buffer. Streptavidin (2 mg in water) and 10 mg of sodium cyanoborohydride were added to the dispersed beads, shaken on a plate shaker for 2 hours. After that, 5 mg of sodium cyanoborohydride were added, shaken for another 1 hour. The beads were washed with PBS buffer. The beads were stored in PBS buffer containing 1% Tween 20, 0.5% bovine serum albumin (BSA) and 0.02% sodium azide.
- The above examples are included for illustrative purposes only and are not intended to limit the scope of the invention. Many variations to those described above are possible. Since modifications and variations to the examples described above will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims.
Claims (53)
1-32. (canceled)
33. A method for isolating a moiety, which method comprises:
a) providing a bead, which bead comprises a magnetizable substance, an optical labeling substance and a binding partner that is capable of binding to a moiety to be isolated;
b) contacting a sample containing or suspected of containing of said moiety with said bead provided in step a) under conditions allowing binding between said moiety and said binding partner; and
c) recovering said bead from said sample,
whereby the identity of said isolated moiety is assessed by analyzing said optical labeling substance comprised in said bead.
34. The method of claim 33 , wherein the optical labeling substance is a quantum dot.
35. The method of claim 33 , wherein the moiety is a cell, a cellular organelle, a virus, a molecule and an aggregate or complex thereof.
36. The method of claim 33 , wherein the bead is recovered from the sample by a magnetic field, centrifugation or filtration.
37. The method of claim 33 , wherein a plurality types of moieties are isolated by using a plurality types of beads, each type of the beads contains a binding partner that is capable of binding to a member of the plurality types of the moieties.
38. The method of claim 33 , wherein the sample is a fluid sample.
39. The method of claim 33 , wherein the isolation is conducted in a liquid container selected from the group consisting of a beaker, a flask, a cylinder, a test tube, an enpindorf tube, a centrifugation tube, a culture dish, a multiwell plate and a filter membrane.
40. The method of claim 33 , further comprising a step of recovering said isolated moiety from said bead.
41. The method of claim 33 , wherein the binding partner specifically binds to the moiety.
42. A method for manipulating a moiety, which method comprises:
a) providing a bead, which bead comprises (a) a magnetizable substance, and (b) an electrically conductive substance or an optical labeling substance, and which further comprises a binding partner that is capable of binding to a moiety to be manipulated;
b) coupling said moiety to said bead provided in step a) via binding between said moiety and said binding partner to form a moiety-bead complex; and
c) manipulating said moiety-bead complex with a dielectrophoresis, a traveling-wave dielectrophoresis and/or a magnetic force,
thereby said moiety is manipulated.
43. The method of claim 42 , wherein the moiety-bead complex is manipulated in a chip format and the manipulation is effected through a combination of a structure that is external to the chip and a structure that is built-in in the chip.
44. The method of claim 42 , wherein the moiety to be manipulated is selected from the group consisting of a cell, a cellular organelle, a virus, a molecule and an aggregate or complex thereof.
45. The method of claim 42 , wherein the manipulation is selected from the group consisting of transportation, focusing, enrichment, concentration, aggregation, trapping, repulsion, levitation, separation, fractionation, isolation and linear or other directed motion of the moiety.
46. The method of claim 42 , wherein the moiety is not directly manipulatable by a dielectrophoresis, a traveling-wave dielectrophoresis and/or a magnetic force.
47. The method of claim 42 , wherein neither the moiety nor the binding partner is directly manipulatable by a dielectrophoresis, a traveling-wave dielectrophoresis and/or a magnetic force.
48. The method of claim 42 , wherein at least two types of moieties are manipulated.
49. The method of claim 48 , wherein the moieties are manipulated via a plurality of types of corresponding beads.
50. The method of claim 48 , wherein the moieties are manipulated sequentially or simultaneously.
51. The method of claim 42 , further comprising a step of recovering said isolated moiety from said bead.
52. The method of claim 42 , wherein the bead comprises an optical labeling substance and the method further comprises a step of assessing the identity of the manipulated moiety by analyzing the optical labeling substance comprised in the bead.
53. The method of claim 52 , wherein the optical labeling substance is a quantum dot.
54. The method of claim 51 , wherein the bead comprises an optical labeling substance and the method further comprises a step of assessing the identity of the isolated moiety by analyzing the optical labeling substance comprised in the bead.
55. The method of claim 54 , wherein the optical labeling substance is a quantum dot.
56. The method of claim 42 , wherein the binding partner specifically binds to the moiety.
57-59. (canceled)
60. A method for detecting a moiety, which method comprises:
a) providing a bead, which bead comprises a magnetizable substance, an optical labeling substance and a binding partner that is capable of binding to a moiety to be detected;
b) contacting a sample containing or suspected of containing of said moiety with said bead provided in step a) under conditions allowing binding between said moiety and said binding partner; and
c) detecting binding between said moiety and said binding partner,
whereby the presence or amount of said moiety is assessed by analysis of binding between said moiety and said binding partner and the identity of said moiety is assessed by analyzing the optical labeling substance comprised in the bead.
61. The method of claim 60 , wherein the optical labeling substance is a quantum dot.
62. The method of claim 60 , wherein the moiety is a cell, a cellular organelle, a virus, a molecule and an aggregate or complex thereof.
63. The method of claim 60 , wherein a plurality of moieties is detected by using a plurality of beads, each of the beads contains a binding partner that is capable of binding to a member of the plurality of the moieties.
64. The method of claim 63 , wherein the presence, amount or identity of said moieties are detected simultaneously.
65. The method of claim 60 , wherein the sample is a fluid sample.
66. The method of claim 60 , wherein the sample is contacted with the bead in a liquid container selected from the group consisting of a beaker, a flask, a cylinder, a test tube, an enpindorf tube, a centrifugation tube, a culture dish, a multiwell plate and a filter membrane.
67. The method of claim 60 , wherein the binding partner specifically binds to the moiety.
68. A method for synthesizing a library, which method comprises:
a) providing a plurality of beads, wherein each of said beads comprises an optical labeling substance that corresponds to an entity to be synthesized on said bead and a magnetizable substance; and
b) synthesizing said entities on said beads, wherein said beads are sorted after each synthesis cycle according to said optical labeling substances,
whereby a library is synthesized, wherein each of said beads contains an entity that corresponds to an optical labeling substance on said bead and the sum of said beads collectively contains a plurality of entities that is predetermined before the library synthesis.
69. The method of claim 68 , wherein the optical labeling substance is a quantum dot.
70. The method of claim 68 , wherein the beads further comprises an element that facilitates and/or enables manipulation of the beads and/or the bead/synthesized entity complexes.
71. The method of claim 70 , wherein the element is selected from the group consisting of a cell, a cellular organelle, a virus, a microparticle, an aggregate or complex of molecules and an aggregate or complex thereof.
72. The method of claim 68 , wherein the beads further comprise a molecular tag.
73. The method of claim 72 , wherein the molecular tag is a DNA sequence or an antibody.
74. The method of claim 68 , wherein each of the beads contains a single synthesized entity.
75. The method of claim 68 , wherein the synthesized entities are selected from group consisting of peptides, proteins, oligonucleotides, nucleic acids, vitamins, oligosaccharides, carbohydrates, lipids, small molecules, or a complex or combination thereof.
76. The method of claim 68 , wherein the synthesized library comprises a defined set of entities that are involved in a biological pathway, belongs to a group of entities with identical or similar biological function, expressed in a stage of cell cycle, expressed in a cell type, expressed in a tissue type, expressed in an organ type, expressed in a developmental stage, entities whose expression and/or activity are altered in a disease or disorder type or stage, or entities whose expression and/or activity are altered by drug or other treatments.
77. The method of claim 68 , wherein the synthesized library comprises a defined set of DNA fragments.
78. The method of claim 77 , wherein each of the DNA fragments in the synthesized library comprises at least 10, 15, 20, 25, 50, 75, 100, 200 or 500 nucleotides.
79. The method of claim 68 , wherein the synthesized library comprises a defined set of protein or peptide fragments.
80. The method of claim 79 , wherein each of the protein or peptide fragments in the synthesized library comprises at least 10, 15, 20, 25, 50, 75, 100, 200 or 500 amino acids.
81. A library that is synthesized according to the method of claim 68 .
82. A method for generating an antibody library, which method comprises:
a) contacting the library of claim 81 with a plurality of antibodies;
b) selecting and/or recovering the antibodies that specifically bind to the entities of the library of claim 81 .
83. The method of claim 82 , wherein the plurality of antibodies is derived from a phage display library.
84. A method for synthesizing a library, which method comprises:
a) providing a plurality of beads, each of said beads comprising a magnetizable substance, an electrically conductive substance and a unique optical labeling substance; and
b) synthesizing an entity on said beads, wherein said beads are identified after each synthesis cycle according to said unique optical labeling substances,
whereby a library is synthesized, wherein each of said beads contains an entity that can be identified according to said unique optical labeling substance on each of said beads.
85. A library that is synthesized according to the method of claim 84 .
86-88. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/714,954 US20070160984A1 (en) | 2002-03-21 | 2007-03-06 | Multiple-property composite beads and preparation and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/104,579 US7214427B2 (en) | 2002-03-21 | 2002-03-21 | Composite beads comprising magnetizable substance and electro-conductive substance |
US11/714,954 US20070160984A1 (en) | 2002-03-21 | 2007-03-06 | Multiple-property composite beads and preparation and use thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/104,579 Division US7214427B2 (en) | 2002-03-21 | 2002-03-21 | Composite beads comprising magnetizable substance and electro-conductive substance |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070160984A1 true US20070160984A1 (en) | 2007-07-12 |
Family
ID=28040636
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/104,579 Expired - Fee Related US7214427B2 (en) | 2002-03-21 | 2002-03-21 | Composite beads comprising magnetizable substance and electro-conductive substance |
US11/714,954 Abandoned US20070160984A1 (en) | 2002-03-21 | 2007-03-06 | Multiple-property composite beads and preparation and use thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/104,579 Expired - Fee Related US7214427B2 (en) | 2002-03-21 | 2002-03-21 | Composite beads comprising magnetizable substance and electro-conductive substance |
Country Status (5)
Country | Link |
---|---|
US (2) | US7214427B2 (en) |
EP (1) | EP1490213A4 (en) |
AU (1) | AU2003213835A1 (en) |
CA (1) | CA2480781A1 (en) |
WO (1) | WO2003080327A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100041061A1 (en) * | 2008-08-18 | 2010-02-18 | BioDtech, Inc. | Enhancing Endotoxin Detection |
US20110014630A1 (en) * | 2005-10-27 | 2011-01-20 | Clemson University | Fluorescent Carbon Nanoparticles |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US8168389B2 (en) | 2006-06-14 | 2012-05-01 | The General Hospital Corporation | Fetal cell analysis using sample splitting |
US8195415B2 (en) | 2008-09-20 | 2012-06-05 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US8921063B2 (en) | 2011-02-28 | 2014-12-30 | BioDtech, Inc. | Enhancing endotoxin detection |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
CN108896756A (en) * | 2018-07-17 | 2018-11-27 | 广东工业大学 | A kind of colloid gold nano-polyaniline-gold nano complex microsphere and its preparation method and application |
CN109726417A (en) * | 2018-07-17 | 2019-05-07 | 中国科学院力学研究所 | Method for Determining Step Length and Envelope of Cylinder Array Wave Force Amplitude Curve |
US10591391B2 (en) | 2006-06-14 | 2020-03-17 | Verinata Health, Inc. | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US10704090B2 (en) | 2006-06-14 | 2020-07-07 | Verinata Health, Inc. | Fetal aneuploidy detection by sequencing |
US10798438B2 (en) | 2011-12-09 | 2020-10-06 | Microsoft Technology Licensing, Llc | Determining audience state or interest using passive sensor data |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040166502A1 (en) * | 2001-03-13 | 2004-08-26 | Yaming Lai | Microelectromagnetic dispenser heads and uses thereof |
US8367013B2 (en) | 2001-12-24 | 2013-02-05 | Kimberly-Clark Worldwide, Inc. | Reading device, method, and system for conducting lateral flow assays |
US20030119203A1 (en) | 2001-12-24 | 2003-06-26 | Kimberly-Clark Worldwide, Inc. | Lateral flow assay devices and methods for conducting assays |
US7285424B2 (en) | 2002-08-27 | 2007-10-23 | Kimberly-Clark Worldwide, Inc. | Membrane-based assay devices |
US7314763B2 (en) | 2002-08-27 | 2008-01-01 | Kimberly-Clark Worldwide, Inc. | Fluidics-based assay devices |
US7432105B2 (en) | 2002-08-27 | 2008-10-07 | Kimberly-Clark Worldwide, Inc. | Self-calibration system for a magnetic binding assay |
US7781172B2 (en) | 2003-11-21 | 2010-08-24 | Kimberly-Clark Worldwide, Inc. | Method for extending the dynamic detection range of assay devices |
US7247500B2 (en) | 2002-12-19 | 2007-07-24 | Kimberly-Clark Worldwide, Inc. | Reduction of the hook effect in membrane-based assay devices |
KR20040069476A (en) * | 2003-01-29 | 2004-08-06 | 엘지전자 주식회사 | A heat-exchanger for direct-type refrigerator |
US7601491B2 (en) * | 2003-02-06 | 2009-10-13 | Becton, Dickinson And Company | Pretreatment method for extraction of nucleic acid from biological samples and kits therefor |
US20040197819A1 (en) * | 2003-04-03 | 2004-10-07 | Kimberly-Clark Worldwide, Inc. | Assay devices that utilize hollow particles |
US7851209B2 (en) | 2003-04-03 | 2010-12-14 | Kimberly-Clark Worldwide, Inc. | Reduction of the hook effect in assay devices |
US7713748B2 (en) | 2003-11-21 | 2010-05-11 | Kimberly-Clark Worldwide, Inc. | Method of reducing the sensitivity of assay devices |
US7943395B2 (en) | 2003-11-21 | 2011-05-17 | Kimberly-Clark Worldwide, Inc. | Extension of the dynamic detection range of assay devices |
US20050112703A1 (en) | 2003-11-21 | 2005-05-26 | Kimberly-Clark Worldwide, Inc. | Membrane-based lateral flow assay devices that utilize phosphorescent detection |
US7943089B2 (en) | 2003-12-19 | 2011-05-17 | Kimberly-Clark Worldwide, Inc. | Laminated assay devices |
JP2005265654A (en) * | 2004-03-19 | 2005-09-29 | Hitachi Maxell Ltd | Composite particles |
US7745001B2 (en) * | 2004-03-23 | 2010-06-29 | University Of New Orleans Research And Technology Foundation, Inc. | Synthesis of nanoassemblies containing luminescent quantum dots and magnetic nanoparticles |
US7405002B2 (en) * | 2004-08-04 | 2008-07-29 | Agency For Science, Technology And Research | Coated water-soluble nanoparticles comprising semiconductor core and silica coating |
US7534489B2 (en) | 2004-09-24 | 2009-05-19 | Agency For Science, Technology And Research | Coated composites of magnetic material and quantum dots |
US20060177815A1 (en) * | 2004-11-29 | 2006-08-10 | The Regents Of The University Of California | Dielectrophoretic particle sorter |
US8198075B2 (en) * | 2005-08-31 | 2012-06-12 | Ut-Battelle, Llc | Method and apparatus for enhanced detection of toxic agents |
US8158377B2 (en) | 2005-08-31 | 2012-04-17 | Ut-Battelle, Llc | Biosensor method and system based on feature vector extraction |
US8182669B2 (en) * | 2005-11-18 | 2012-05-22 | The Regents Of The University Of California | Dynamic equilibrium separation, concentration, and mixing apparatus and methods |
EP1957982A2 (en) * | 2005-12-05 | 2008-08-20 | Guava Technologies, Inc. | Particle-based analyte characterization |
US20080314749A1 (en) * | 2006-01-04 | 2008-12-25 | Koninklijke Philips Electronics N.V. | Microelectronic Device with Magnetic Excitation Wires |
WO2007115815A1 (en) * | 2006-04-07 | 2007-10-18 | Pauwels, Rudi | Method and apparatus for labelling, reading and sorting of microcarriers |
JP4415980B2 (en) * | 2006-08-30 | 2010-02-17 | 株式会社日立製作所 | High resistance magnet and motor using the same |
ITTO20070307A1 (en) * | 2007-05-04 | 2008-11-05 | Silicon Biosystems Spa | METHOD AND DEVICE FOR NON-INVASIVE PRENATAL DIAGNOSIS |
US8287810B2 (en) * | 2007-06-20 | 2012-10-16 | Board Of Trustees Of Michigan State University | Electrically-active ferromagnetic particle conductimetric biosensor test kit |
WO2010012002A1 (en) * | 2008-07-25 | 2010-01-28 | Saryna Medical Corporation | Methods and systems for genetic analysis of fetal nucleated red blood cells |
US20110171749A1 (en) * | 2009-03-02 | 2011-07-14 | Board Of Trustees Of Michigan State University | Nanoparticle tracer-based electrochemical dna sensor for detection of pathogens-amplification by a universal nano-tracer (aunt) |
US8845812B2 (en) * | 2009-06-12 | 2014-09-30 | Micron Technology, Inc. | Method for contamination removal using magnetic particles |
US8774488B2 (en) | 2010-03-11 | 2014-07-08 | Cellscape Corporation | Method and device for identification of nucleated red blood cells from a maternal blood sample |
KR101067695B1 (en) * | 2010-03-25 | 2011-09-27 | 충남대학교산학협력단 | Molecular Transport System Using Soft Magnetic Microstructures |
CN102219997B (en) * | 2011-04-29 | 2013-06-26 | 南京理工大学 | A method of preparing polypyrrole-coated bacterial cellulose nano-conductive composite material using bacterial cellulose as a template |
US8859297B2 (en) | 2011-05-23 | 2014-10-14 | Board Of Trustees Of Michigan State University | Detection of conductive polymer-labeled analytes |
US10739337B2 (en) * | 2011-08-30 | 2020-08-11 | Board Of Trustees Of Michigan State University | Extraction and detection of pathogens using carbohydrate-functionalized biosensors |
US9296771B2 (en) | 2013-03-15 | 2016-03-29 | The United States Of America, As Represented By The Secretary Of The Navy | Large scale preparation method for functionalizing the surface of magnetic microparticles with an inorganic phosphorous dendrimer |
EP2957912A1 (en) * | 2014-06-17 | 2015-12-23 | University College Dublin | A method of labelling a target molecule forming part of a corona of molecules on a surface of a nanosized object |
DE102014112685B4 (en) * | 2014-09-03 | 2021-02-04 | Dechema Forschungsinstitut Stiftung Bürgerlichen Rechts | Process for the microbiological-electrochemical synthesis of chemical substances by electroactive microorganisms |
US9390847B1 (en) | 2015-02-19 | 2016-07-12 | The United States Of America As Represented By The Secretary Of The Navy | System and method for electromagnetic-based propulsion |
CN108452793B (en) * | 2017-02-17 | 2020-08-28 | 中国科学院宁波材料技术与工程研究所 | A kind of monosaccharide epimerization catalyst |
CN111983221B (en) * | 2020-08-19 | 2024-04-09 | 深圳市卓润生物科技有限公司 | Surface-modified magnetic bead and preparation method and application thereof |
Citations (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4010242A (en) * | 1972-04-07 | 1977-03-01 | E. I. Dupont De Nemours And Company | Uniform oxide microspheres and a process for their manufacture |
US4285819A (en) * | 1980-01-28 | 1981-08-25 | California Institute Of Technology | Functional magnetic microspheres |
US4336173A (en) * | 1978-02-21 | 1982-06-22 | Sintef | Process for preparing an aqueous emulsion or dispersion of a partly water-soluble material, and optionally further conversion of the prepared dispersion or emulsion to a polymer dispersion when the partly water-soluble material is a polymerizable monomer |
US4421660A (en) * | 1980-12-15 | 1983-12-20 | The Dow Chemical Company | Colloidal size hydrophobic polymers particulate having discrete particles of an inorganic material dispersed therein |
US4490436A (en) * | 1981-10-30 | 1984-12-25 | Japan Synthetic Rubber Co., Ltd. | Polymer filler particles with filler free coating |
US4554088A (en) * | 1983-05-12 | 1985-11-19 | Advanced Magnetics Inc. | Magnetic particles for use in separations |
US4582622A (en) * | 1984-10-12 | 1986-04-15 | Fujirebio Kabushiki Kaisha | Magnetic particulate for immobilization of biological protein and process of producing the same |
US4654267A (en) * | 1982-04-23 | 1987-03-31 | Sintef | Magnetic polymer particles and process for the preparation thereof |
US4795698A (en) * | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
US4965007A (en) * | 1988-05-10 | 1990-10-23 | Eastman Kodak Company | Encapsulated superparamagnetic particles |
US5091206A (en) * | 1987-10-26 | 1992-02-25 | Baxter Diagnostics Inc. | Process for producing magnetically responsive polymer particles and application thereof |
US5232789A (en) * | 1989-03-09 | 1993-08-03 | Mtu Motoren- Und Turbinen-Union Muenchen Gmbh | Structural component with a protective coating having a nickel or cobalt basis and method for making such a coating |
US5295688A (en) * | 1992-04-23 | 1994-03-22 | Robert Montgomery | Golf club grip positioning device |
US5318797A (en) * | 1990-06-20 | 1994-06-07 | Clarkson University | Coated particles, hollow particles, and process for manufacturing the same |
US5346791A (en) * | 1991-11-29 | 1994-09-13 | Kyocera Corporation | Electroconductive magnetic carrier, developer using the same and image formation method |
US5648124A (en) * | 1993-07-09 | 1997-07-15 | Seradyn, Inc. | Process for preparing magnetically responsive microparticles |
US5744367A (en) * | 1994-11-10 | 1998-04-28 | Igen International, Inc. | Magnetic particle based electrochemiluminescent detection apparatus and method |
US5785913A (en) * | 1996-05-30 | 1998-07-28 | Westinghouse Electric Corporation | Method of magnetically forming a particle filled polymer having enhanced material characteristics |
US5795470A (en) * | 1991-03-25 | 1998-08-18 | Immunivest Corporation | Magnetic separation apparatus |
US5834121A (en) * | 1996-01-16 | 1998-11-10 | Solid Phase Sciences Corp. | Composite magnetic beads |
US6114038A (en) * | 1998-11-10 | 2000-09-05 | Biocrystal Ltd. | Functionalized nanocrystals and their use in detection systems |
US6127132A (en) * | 1991-07-08 | 2000-10-03 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Phagemid library for antibody screening |
US6134413A (en) * | 1995-01-20 | 2000-10-17 | Hitachi Metals, Ltd. | Carrier for magnetic developer and method of electrophotographically forming visual image |
US6174708B1 (en) * | 1995-12-04 | 2001-01-16 | Pasteur Merieux Serums & Vaccins | Preparation of a multicombinatorial library of antibody gene expression vectors |
US6214560B1 (en) * | 1996-04-25 | 2001-04-10 | Genicon Sciences Corporation | Analyte assay using particulate labels |
US6252664B1 (en) * | 1999-10-15 | 2001-06-26 | Biocrystal Ltd. | Fluorescence filter cube for fluorescence detection and imaging |
US6268222B1 (en) * | 1998-01-22 | 2001-07-31 | Luminex Corporation | Microparticles attached to nanoparticles labeled with flourescent dye |
US6284470B1 (en) * | 1998-04-22 | 2001-09-04 | Promega Corporation | Kits for cell concentration and lysate clearance using paramagnetic particles |
US6306310B1 (en) * | 1996-07-31 | 2001-10-23 | The F. B. Leopold Company, Inc. | Apparatus for distributing gas and liquid during concurrent gas/liquid backwash in filter underdrain flumes |
US6368800B1 (en) * | 1997-01-21 | 2002-04-09 | Promega Corporation | Kits for isolating biological target materials using silica magnetic particles |
US20020137059A1 (en) * | 2001-01-26 | 2002-09-26 | Lei Wu | Microdevice containing photorecognizable coding patterns and methods of using and producing the same thereof |
US20020164271A1 (en) * | 2001-05-02 | 2002-11-07 | Ho Winston Z. | Wavelength-coded bead for bioassay and signature recogniton |
US6548171B1 (en) * | 1998-11-10 | 2003-04-15 | Emilio Barbera-Guillem | Fluorescent nanocrystal-embedded microspheres for fluorescence analyses |
US6773812B2 (en) * | 2000-04-06 | 2004-08-10 | Luminex Corporation | Magnetically-responsive microspheres |
US6806050B2 (en) * | 1999-03-15 | 2004-10-19 | Aviva Biosciences | Individually addressable micro-electromagnetic unit array chips |
US7081192B1 (en) * | 2000-08-08 | 2006-07-25 | Aviva Biosciences Corporation | Methods for manipulating moieties in microfluidic systems |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US490436A (en) * | 1893-01-24 | Glove-fastener | ||
US5395688A (en) * | 1987-10-26 | 1995-03-07 | Baxter Diagnostics Inc. | Magnetically responsive fluorescent polymer particles |
JP3482420B2 (en) | 1995-11-27 | 2003-12-22 | 独立行政法人産業技術総合研究所 | Graphite-coated metal particles and method for producing the same |
JP3545524B2 (en) | 1995-12-28 | 2004-07-21 | ロッシュ ディアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Conductive magnetic beads with immobilized physiologically active substances |
US6306610B1 (en) * | 1998-09-18 | 2001-10-23 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
-
2002
- 2002-03-21 US US10/104,579 patent/US7214427B2/en not_active Expired - Fee Related
-
2003
- 2003-03-11 WO PCT/US2003/007423 patent/WO2003080327A1/en not_active Application Discontinuation
- 2003-03-11 CA CA002480781A patent/CA2480781A1/en not_active Abandoned
- 2003-03-11 AU AU2003213835A patent/AU2003213835A1/en not_active Abandoned
- 2003-03-11 EP EP03711528A patent/EP1490213A4/en not_active Withdrawn
-
2007
- 2007-03-06 US US11/714,954 patent/US20070160984A1/en not_active Abandoned
Patent Citations (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4010242A (en) * | 1972-04-07 | 1977-03-01 | E. I. Dupont De Nemours And Company | Uniform oxide microspheres and a process for their manufacture |
US4336173A (en) * | 1978-02-21 | 1982-06-22 | Sintef | Process for preparing an aqueous emulsion or dispersion of a partly water-soluble material, and optionally further conversion of the prepared dispersion or emulsion to a polymer dispersion when the partly water-soluble material is a polymerizable monomer |
US4285819A (en) * | 1980-01-28 | 1981-08-25 | California Institute Of Technology | Functional magnetic microspheres |
US4421660A (en) * | 1980-12-15 | 1983-12-20 | The Dow Chemical Company | Colloidal size hydrophobic polymers particulate having discrete particles of an inorganic material dispersed therein |
US4490436A (en) * | 1981-10-30 | 1984-12-25 | Japan Synthetic Rubber Co., Ltd. | Polymer filler particles with filler free coating |
US4654267A (en) * | 1982-04-23 | 1987-03-31 | Sintef | Magnetic polymer particles and process for the preparation thereof |
US4774265A (en) * | 1982-04-23 | 1988-09-27 | Sintef | Process for preparing magnetic polymer particles |
US4554088A (en) * | 1983-05-12 | 1985-11-19 | Advanced Magnetics Inc. | Magnetic particles for use in separations |
US4582622A (en) * | 1984-10-12 | 1986-04-15 | Fujirebio Kabushiki Kaisha | Magnetic particulate for immobilization of biological protein and process of producing the same |
US4795698A (en) * | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
US5283079A (en) * | 1987-10-26 | 1994-02-01 | Baxter Diagnostics Inc. | Process to make magnetically responsive fluorescent polymer particles |
US5091206A (en) * | 1987-10-26 | 1992-02-25 | Baxter Diagnostics Inc. | Process for producing magnetically responsive polymer particles and application thereof |
US4965007A (en) * | 1988-05-10 | 1990-10-23 | Eastman Kodak Company | Encapsulated superparamagnetic particles |
US5232789A (en) * | 1989-03-09 | 1993-08-03 | Mtu Motoren- Und Turbinen-Union Muenchen Gmbh | Structural component with a protective coating having a nickel or cobalt basis and method for making such a coating |
US5318797A (en) * | 1990-06-20 | 1994-06-07 | Clarkson University | Coated particles, hollow particles, and process for manufacturing the same |
US5795470A (en) * | 1991-03-25 | 1998-08-18 | Immunivest Corporation | Magnetic separation apparatus |
US6127132A (en) * | 1991-07-08 | 2000-10-03 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Phagemid library for antibody screening |
US5346791A (en) * | 1991-11-29 | 1994-09-13 | Kyocera Corporation | Electroconductive magnetic carrier, developer using the same and image formation method |
US5295688A (en) * | 1992-04-23 | 1994-03-22 | Robert Montgomery | Golf club grip positioning device |
US5648124A (en) * | 1993-07-09 | 1997-07-15 | Seradyn, Inc. | Process for preparing magnetically responsive microparticles |
US5744367A (en) * | 1994-11-10 | 1998-04-28 | Igen International, Inc. | Magnetic particle based electrochemiluminescent detection apparatus and method |
US6134413A (en) * | 1995-01-20 | 2000-10-17 | Hitachi Metals, Ltd. | Carrier for magnetic developer and method of electrophotographically forming visual image |
US6174708B1 (en) * | 1995-12-04 | 2001-01-16 | Pasteur Merieux Serums & Vaccins | Preparation of a multicombinatorial library of antibody gene expression vectors |
US5834121A (en) * | 1996-01-16 | 1998-11-10 | Solid Phase Sciences Corp. | Composite magnetic beads |
US6214560B1 (en) * | 1996-04-25 | 2001-04-10 | Genicon Sciences Corporation | Analyte assay using particulate labels |
US5785913A (en) * | 1996-05-30 | 1998-07-28 | Westinghouse Electric Corporation | Method of magnetically forming a particle filled polymer having enhanced material characteristics |
US6306310B1 (en) * | 1996-07-31 | 2001-10-23 | The F. B. Leopold Company, Inc. | Apparatus for distributing gas and liquid during concurrent gas/liquid backwash in filter underdrain flumes |
US6368800B1 (en) * | 1997-01-21 | 2002-04-09 | Promega Corporation | Kits for isolating biological target materials using silica magnetic particles |
US6268222B1 (en) * | 1998-01-22 | 2001-07-31 | Luminex Corporation | Microparticles attached to nanoparticles labeled with flourescent dye |
US6284470B1 (en) * | 1998-04-22 | 2001-09-04 | Promega Corporation | Kits for cell concentration and lysate clearance using paramagnetic particles |
US6114038A (en) * | 1998-11-10 | 2000-09-05 | Biocrystal Ltd. | Functionalized nanocrystals and their use in detection systems |
US6548171B1 (en) * | 1998-11-10 | 2003-04-15 | Emilio Barbera-Guillem | Fluorescent nanocrystal-embedded microspheres for fluorescence analyses |
US6806050B2 (en) * | 1999-03-15 | 2004-10-19 | Aviva Biosciences | Individually addressable micro-electromagnetic unit array chips |
US6252664B1 (en) * | 1999-10-15 | 2001-06-26 | Biocrystal Ltd. | Fluorescence filter cube for fluorescence detection and imaging |
US6773812B2 (en) * | 2000-04-06 | 2004-08-10 | Luminex Corporation | Magnetically-responsive microspheres |
US7081192B1 (en) * | 2000-08-08 | 2006-07-25 | Aviva Biosciences Corporation | Methods for manipulating moieties in microfluidic systems |
US20020137059A1 (en) * | 2001-01-26 | 2002-09-26 | Lei Wu | Microdevice containing photorecognizable coding patterns and methods of using and producing the same thereof |
US20020164271A1 (en) * | 2001-05-02 | 2002-11-07 | Ho Winston Z. | Wavelength-coded bead for bioassay and signature recogniton |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US8932877B2 (en) * | 2005-10-27 | 2015-01-13 | Clemson University Research Foundation | Fluorescent carbon nanoparticles |
US20110014630A1 (en) * | 2005-10-27 | 2011-01-20 | Clemson University | Fluorescent Carbon Nanoparticles |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US9017942B2 (en) | 2006-06-14 | 2015-04-28 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US8168389B2 (en) | 2006-06-14 | 2012-05-01 | The General Hospital Corporation | Fetal cell analysis using sample splitting |
US11781187B2 (en) | 2006-06-14 | 2023-10-10 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US10155984B2 (en) | 2006-06-14 | 2018-12-18 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US10591391B2 (en) | 2006-06-14 | 2020-03-17 | Verinata Health, Inc. | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US11674176B2 (en) | 2006-06-14 | 2023-06-13 | Verinata Health, Inc | Fetal aneuploidy detection by sequencing |
US10704090B2 (en) | 2006-06-14 | 2020-07-07 | Verinata Health, Inc. | Fetal aneuploidy detection by sequencing |
US9347100B2 (en) | 2006-06-14 | 2016-05-24 | Gpb Scientific, Llc | Rare cell analysis using sample splitting and DNA tags |
US9273355B2 (en) | 2006-06-14 | 2016-03-01 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US20100041061A1 (en) * | 2008-08-18 | 2010-02-18 | BioDtech, Inc. | Enhancing Endotoxin Detection |
US7846678B2 (en) * | 2008-08-18 | 2010-12-07 | BioDtech, Inc. | Enhancing endotoxin detection |
US20110020854A1 (en) * | 2008-08-18 | 2011-01-27 | BioDtech, Inc. | Enhancing Endotoxin Detection |
US8349570B2 (en) | 2008-08-18 | 2013-01-08 | BioDtech, Inc. | Enhancing endotoxin detection |
US8296076B2 (en) | 2008-09-20 | 2012-10-23 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuoploidy by sequencing |
US9404157B2 (en) | 2008-09-20 | 2016-08-02 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US9353414B2 (en) | 2008-09-20 | 2016-05-31 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US10669585B2 (en) | 2008-09-20 | 2020-06-02 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US8682594B2 (en) | 2008-09-20 | 2014-03-25 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US8195415B2 (en) | 2008-09-20 | 2012-06-05 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US12054777B2 (en) | 2008-09-20 | 2024-08-06 | The Board Of Trustees Of The Leland Standford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US8921063B2 (en) | 2011-02-28 | 2014-12-30 | BioDtech, Inc. | Enhancing endotoxin detection |
US10798438B2 (en) | 2011-12-09 | 2020-10-06 | Microsoft Technology Licensing, Llc | Determining audience state or interest using passive sensor data |
CN108896756A (en) * | 2018-07-17 | 2018-11-27 | 广东工业大学 | A kind of colloid gold nano-polyaniline-gold nano complex microsphere and its preparation method and application |
CN109726417A (en) * | 2018-07-17 | 2019-05-07 | 中国科学院力学研究所 | Method for Determining Step Length and Envelope of Cylinder Array Wave Force Amplitude Curve |
Also Published As
Publication number | Publication date |
---|---|
CA2480781A1 (en) | 2003-10-02 |
EP1490213A4 (en) | 2008-11-26 |
US20030178309A1 (en) | 2003-09-25 |
WO2003080327A1 (en) | 2003-10-02 |
AU2003213835A1 (en) | 2003-10-08 |
EP1490213A1 (en) | 2004-12-29 |
US7214427B2 (en) | 2007-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7214427B2 (en) | Composite beads comprising magnetizable substance and electro-conductive substance | |
US7015047B2 (en) | Microdevices having a preferential axis of magnetization and uses thereof | |
EP1381861B1 (en) | Processes for producing coated magnetic microparticles and uses thereof | |
US7081192B1 (en) | Methods for manipulating moieties in microfluidic systems | |
US7811768B2 (en) | Microdevice containing photorecognizable coding patterns and methods of using and producing the same | |
Verpoorte | Focusbeads and chips: New recipes for analysis | |
US20060228749A1 (en) | Methods for manipulating moieties in microfluidic systems | |
Gijs et al. | Microfluidic applications of magnetic particles for biological analysis and catalysis | |
CN1829916B (en) | Use of magnetic particles for determining binding between biologically active molecules | |
JP4711687B2 (en) | Microparticle-based biochip system and use thereof | |
WO2002073159A2 (en) | Microelectromagnetic dispenser heads and uses thereof | |
CN100417936C (en) | Micro-device with magnetization axis and its method of use and application | |
US20040166502A1 (en) | Microelectromagnetic dispenser heads and uses thereof | |
Gijs | Magnetic Beads in Microfluidic Systems–Towards New Analytical Applications | |
Tabnaoui | Magnetic fluidized bed for sample preconcentration and immunoextraction in microfluidic systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AVIVA BIOSCIENCES CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HUANG, MINGXIAN;WU, LEI;WANG, XIAOBO;AND OTHERS;REEL/FRAME:019218/0570;SIGNING DATES FROM 20020525 TO 20020606 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |